WO2013130824A1 - Methods and compositions for treating huntington's disease - Google Patents

Methods and compositions for treating huntington's disease Download PDF

Info

Publication number
WO2013130824A1
WO2013130824A1 PCT/US2013/028348 US2013028348W WO2013130824A1 WO 2013130824 A1 WO2013130824 A1 WO 2013130824A1 US 2013028348 W US2013028348 W US 2013028348W WO 2013130824 A1 WO2013130824 A1 WO 2013130824A1
Authority
WO
WIPO (PCT)
Prior art keywords
seq
htt
zinc finger
zfp
domain
Prior art date
Application number
PCT/US2013/028348
Other languages
French (fr)
Inventor
Jeffrey C. Miller
Edward J. Rebar
H. Steve Zhang
Original Assignee
Sangamo Biosciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP13755872.2A priority Critical patent/EP2820159B1/en
Application filed by Sangamo Biosciences, Inc. filed Critical Sangamo Biosciences, Inc.
Priority to CA2865011A priority patent/CA2865011C/en
Priority to NZ629427A priority patent/NZ629427A/en
Priority to CN201380016072.9A priority patent/CN104204225A/en
Priority to AU2013225950A priority patent/AU2013225950B2/en
Priority to MX2014010455A priority patent/MX359327B/en
Priority to KR1020147026364A priority patent/KR102084539B1/en
Priority to BR112014021104-3A priority patent/BR112014021104B1/en
Priority to RU2014138989A priority patent/RU2639277C2/en
Priority to JP2014560044A priority patent/JP6490426B2/en
Publication of WO2013130824A1 publication Critical patent/WO2013130824A1/en
Priority to ZA2014/06209A priority patent/ZA201406209B/en
Priority to HK15103974.7A priority patent/HK1203566A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/71—Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C07K2319/81—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor containing a Zn-finger domain for DNA binding

Definitions

  • the present disclosure is in the fields of gene expression and genome editing.
  • Huntington's Disease also known as Huntington's Chorea
  • the mean age of onset for this disease is age 35-44 years, although in about 10% of cases, onset occurs prior to age 21, and the average lifespan post-diagnosis of the disease is 15-18 years.
  • Prevalence is about 3 to 7 among 100,000 people of western European descent.
  • Trinucleotide repeat expansion disorders were first characterized in the early 1990s ⁇ see Di Prospero and Fischbeck (2005) Nature Reviews Genetics 6:756-765). These disorders involve the localized expansion of unstable repeats of sets of three nucleotides and can result in loss of function of the gene in which the expanded repeat resides, a gain of toxic function, or both. Trinucleotide repeats can be located in any part of the gene, including non- coding and coding gene regions. Repeats located within the coding regions typically involve either a repeated glutamine encoding triplet (CAG) or an alanine encoding triplet (CGA).
  • CAG repeated glutamine encoding triplet
  • CGA alanine encoding triplet
  • Expanded repeat regions within non-coding sequences can lead to aberrant expression of the gene while expanded repeats within coding regions (also known as codon reiteration disorders) may cause mis-folding and protein aggregation. The exact cause of the pathophysiology associated with the aberrant proteins is often not known.
  • these regions typically contain a variable number of repeat sequences in the normal population, but in the afflicted populations, the number of repeats can increase from a doubling to a log order increase in the number of repeats.
  • repeats are inserted within the N terminal coding region of the large cytosolic protein Huntingtin (Htt).
  • Normal Htt alleles contain 15-20 CAG repeats, while alleles containing 35 or more repeats can be considered potentially HD causing alleles and confer risk for developing the disease. Alleles containing 36-39 repeats are considered incompletely penetrant, and those individuals harboring those alleles may or may not develop the disease (or may develop symptoms later in life) while alleles containing 40 repeats or more are considered completely penetrant. In fact, no asymptomatic persons containing HD alleles with this many repeats have been reported. Those individuals with juvenile onset HD ( ⁇ 21 years of age) are often found to have 60 or more CAG repeats.
  • HD can involve +1 and +2 frameshifts within the repeat sequences such that the region will encode a poly-serine polypeptide (encoded by AGC repeats in the case of a +1 frameshift) track rather than poly-glutamine (Davies and Rubinsztein (2006) Journal of Medical Genetics : 893-896).
  • the mutant Htt allele is usually inherited from one parent as a dominant trait. Any child born of a HD patient has a 50% chance of developing the disease if the other parent was not afflicted with the disorder. In some cases, a parent may have an intermediate HD allele and be asymptomatic while, due to repeat expansion, the child manifests the disease. In addition, the HD allele can also display a phenomenon known as anticipation wherein increasing severity or decreasing age of onset is observed over several generations due to the unstable nature of the repeat region during spermatogenesis.
  • Htt leads to neuronal loss in the medium spiny gamma-aminobutyric acid (GAB A) projection neurons in the striatum, with neuronal loss also occurring in the neocortex.
  • GAB A medium spiny gamma-aminobutyric acid
  • brain areas greatly affected in people with Huntington's disease include the substantia nigra, cortical layers 3, 5, and 6, the CA1 region of the hippocampus, the angular gyrus in the parietal lobe, Purkinje cells of the cerebellum, lateral tuberal nuclei of the hypothalamus, and the centromedialparafascicular complex of the thalamus (Walker (2007) Lancet 369:218-228).
  • Htt brain-derived neurotrophic factor
  • Treatment options for HD are currently very limited. Some potential methodologies designed to prevent the toxicities associated with protein aggregation that occurs through the extended poly-glutamine tract such as overexpression of chaperonins or induction of the heat shock response with the compound geldanamycin have shown a reduction in these toxicities in in vitro models. Other treatments target the role of apoptosis in the clinical manifestations of the disease. For example, slowing of disease symptoms has been shown via blockage of caspase activity in animal models in the offspring of a pairing of mice where one parent contained a HD allele and the other parent had a dominant negative allele for caspase 1. Additionally, cleavage of mutant HD Htt by caspase may play a role in the pathogenicity of the disease.
  • Huntington's Disease In particular, provided herein are methods and compositions for modifying (e.g., modulating expression of) an HD Htt allele so as to treat Huntington Disease. Also provided are methods and compositions for generating animal models of Huntington' s Disease.
  • engineered DNA binding domains e.g., zinc finger proteins or TAL effector (TALE) proteins
  • TALE TAL effector
  • Engineered zinc finger proteins or TALEs are non- naturally occurring zinc finger or TALE proteins whose DNA binding domains (e.g., recognition helices or RVDs) have been altered (e.g., by selection and/or rational design) to bind to a pre-selected target site.
  • any of the zinc finger proteins described herein may include 1 , 2, 3, 4, 5, 6 or more zinc fingers, each zinc finger having a recognition helix that binds to a target subsite in the selected sequence(s) (e.g., gene(s)).
  • any of the TALE proteins described herein may include any number of TALE RVDs.
  • at least one RVD has non-specific DNA binding.
  • at least one recognition helix (or RVD) is non- naturally occurring.
  • the zinc finger proteins have the recognition helices shown in Tables 1 A and I B. In other embodiments, the zinc finger proteins bind to the target sequences shown in Tables 2 A and 2B.
  • the zinc finger proteins comprise the recognition helices in Table 2C. In certain embodiments, the zinc finger proteins are formulated into a pharmaceutical composition, for example, for administration to a subject.
  • repressors ZFP-TFs or TALE-TFs
  • ZFP or TALE repressors ZFP-TFs or TALE-TFs
  • ZFP-TFs or TALE-TFs ZFP-TFs or TALE-TFs
  • these ZFP-TFs or TALE-TFs preferentially bind to expanded trinucleotide tracts relative to repeat tracts of a wild-type length, thereby achieving preferential repression of the expanded allele.
  • these ZFP-TFs or TALE-TFs include protein interaction domains (or "dimerization domains") that allow multimerization when bound to DNA.
  • these ZFP-TFs or TALE TFs achieve cooperative DNA binding to the repeat sequence so that the expanded allele is bound more efficiently by a larger number of ZFPs or TALE proteins than the wild-type allele, allowing preferential repression of the mutant allele.
  • ZFP-TFs or TALE TFs may or may not further contain protein interaction domains that allow multimerization when bound to DNA.
  • ZFP TFs or TALE TFs form a stable complex of multimers of a given size, and thus are capable of preferentially interacting with a CAG tract above a certain minimum size, wherein that minimum size is greater than the length of a wild-type CAG tract.
  • the ZFPs or TALE proteins as described herein preferentially modify expression of a mutant Htt allele.
  • the ZFP or TALE binds specifically to mutant Htt alleles wherein the expanded tract encodes poly-glutamine, while in other embodiments, the ZFP or TALE binds specifically to a mutant Htt allele wherein the expansion tract encodes poly-serine.
  • the ZFP-TF or TALE-TF modulates both the wild type and mutant forms of the Htt allele.
  • the ZFP or TALE modulates only the wild type Htt allele. In other embodiments, the ZFP or TALE modulates only the mutant form of Htt.
  • repressing ZFP-TFs or TALE-TFs are provided which preferentially bind to known SNPs associated with the expanded HD Htt alleles.
  • the ZFP-TFs or TALE-TFs are specific for mutant Htt alleles which contain the SNP, allowing for specific repression of the mutant Htt allele.
  • ZFP-TFs or TALE-TFs that specifically activate the wild-type Htt allele by interacting with SNPs associated with wild-type alleles are provided. In this way, only the wild-type Htt allele is activated.
  • the zinc finger proteins (ZFPs) or TALE proteins as described herein can be placed in operative linkage with a regulatory domain (or functional domain) as part of a fusion protein.
  • the functional domain can be, for example, a transcriptional activation domain, a transcriptional repression domain and/or a nuclease (cleavage) domain.
  • a fusion protein comprising a ZFP or TALE targeted to a mutant Htt as described herein fused to a transcriptional repression domain that can be used to down-regulate mutant Htt expression is provided.
  • a fusion protein comprising a ZFP or TALE targeted to a wild-type Htt allele fused to a transcription activation domain that can up-regulate the wild type Htt allele is provided.
  • the activity of the regulatory domain is regulated by an exogenous small molecule or ligand such that interaction with the cell's transcription machinery will not take place in the absence of the exogenous ligand.
  • the regulatory domain(s) may be operatively linked to any portion(s) of one or more of the ZFPs or TALEs, including between one or more ZFPs or TALEs, exterior to one or more ZFPs or TALEs and any combination thereof. Any of the fusion proteins described herein may be formulated into a pharmaceutical composition.
  • the engineered DNA binding domains as described herein can be placed in operative linkage with nuclease (cleavage) domains as part of a fusion protein.
  • nuclease systems such as the CRISPR/Cas system may be utilized with a specific single guide RNA to target the nuclease to a target location in the DNA.
  • such nucleases and nuclease fusions may be utilized for targeting mutant Htt alleles in stem cells such as induced pluripotent stem cells (iPSC), human embryonic stem cells (hESC), mesenchymal stem cells (MSC) or neuronal stem cells wherein the activity of the nuclease fusion will result in an Htt allele containing a wild type number of CAG repeats.
  • stem cells such as induced pluripotent stem cells (iPSC), human embryonic stem cells (hESC), mesenchymal stem cells (MSC) or neuronal stem cells wherein the activity of the nuclease fusion will result in an Htt allele containing a wild type number of CAG repeats.
  • iPSC induced pluripotent stem cells
  • hESC human embryonic stem cells
  • MSC mesenchymal stem cells
  • neuronal stem cells wherein the activity of the nuclease fusion will result in an Htt allele containing a wild
  • a polynucleotide encoding any of the DNA binding proteins described herein is provided.
  • polynucleotides encoding a CRIPSR/Cas nuclease and a single guide RHA are provided. Such polynucleotides can be administered to a subject in which it is desirable to treat Huntington's Disease.
  • the invention provides methods and
  • the model systems comprise in vitro cell lines, while in other embodiments, the model systems comprise transgenic animals.
  • the animal may be, for example, a rodent (e.g., Tat, mouse), a primate (e.g., non-human primate) or a rabbit.
  • a gene delivery vector comprising any of the polynucleotides described herein.
  • the vector is an adenovirus vector (e.g., an Ad5/F35 vector), a lentiviral vector (LV) including integration competent or integration-defective lentiviral vectors, or an adenovirus associated viral vector (AAV).
  • Ad adenovirus
  • LV lentiviral vector
  • AAV adenovirus associated viral vector
  • the Ad vector is a chimeric Ad vector, for example an Ad5/F35 vector.
  • the lentiviral vector is an integrase-defective lentiviral vector (IDLV) or an integration competent lentiviral vector.
  • IDLV integrase-defective lentiviral vector
  • the vector is pseudo-typed with a VSV-G envelope, or with other envelopes.
  • model systems are provided for Huntington's disease wherein the target alleles (e.g., mutant Htt) are tagged with expression markers.
  • the mutant alleles e.g., mutant Htt
  • the wild type allele e.g., wild-type Htt
  • both wild type and mutant alleles are tagged with separate expression markers.
  • the model systems comprise in vitro cell lines, while in other embodiments, the model systems comprise transgenic animals.
  • compositions comprising the nucleic acids and/or proteins (e.g., ZFPs or TALEs or fusion proteins comprising the ZFPs or TALEs) are also provided.
  • certain compositions include a nucleic acid comprising a sequence that encodes one of the ZFPs or TALEs described herein operably linked to a regulatory sequence, combined with a pharmaceutically acceptable carrier or diluent, wherein the regulatory sequence allows for expression of the nucleic acid in a cell.
  • the ZFPs or TALEs encoded are specific for a HD Htt allele.
  • compositions comprise ZFPs or TALEs that modulate a HD Htt allele and ZFPs or TALEs that modulate a neurotrophic factor.
  • Protein based compositions include one of more ZFPs or TALEs as disclosed herein and a pharmaceutically acceptable carrier or diluent.
  • an isolated cell comprising any of the proteins, polynucleotides and/or compositions as described herein.
  • compositions for treating and/or preventing Huntington's Disease using the methods and compositions described herein.
  • the methods involve compositions where the polynucleotides and/or proteins may be delivered using a viral vector, a non- viral vector (e.g., plasmid) and/or combinations thereof.
  • the methods involve compositions comprising stem cell populations comprising a ZFP or TALE, or altered with the ZFNs, TALENs or the CRISPPJCas nuclease system of the invention.
  • FIG. 1 panels A to E, are schematics depicting wild type and mutant
  • FIG. 1 A shows ZFP designs that bind outside of the CAG repeat, and therefore are predicted to bind equally to the wild type allele and the mutant (HD) allele.
  • KRAB refers to the KRAB repression domain from the KOX1 gene and "ZFP” refers to the zinc finger DNA binding protein.
  • Standard ZFP TF is a ZFP transcription factor fusion protein in which the zinc finger DNA binding domains are linked to the KRAB repression domain.
  • Figure IB shows ZFP-TFs designed to bind within the CAG region.
  • Figure 1 C depicts a "two-handed ZFP TF," which is a ZFP transcription factor in which two clusters of zinc finger domains are separated by a rigid protein sequences.
  • the functional (repression) domain is depicted exterior to one ZFP in this Figure, but it will be apparent that the functional domain may be between the ZFPs or exterior to the ZFPs on either end of the protein.
  • Figure ID depicts a "multimerizing ZFP TF,” which is a ZFP TF that is capable of
  • Figure IE depicts a ZFP-ZFP- RAB configuration where two zinc finger DNA binding domains are linked by a flexible linker and are also fused to a KRAB domain. It will be apparent to the skilled artisan that in all fusion proteins, the functional domain can be on either end of the DNA binding domain, and that the DNA binding domain may comprise a wide number range of zinc fingers. Also depicted in Figure 1 as a box with black diamonds is a functional domain (e.g., activation, repression, cleavage domain). It will be apparent to the skilled artisan that the exemplary models presented in the Figures may apply to TALE TFs as well.
  • FIG. 1 A depicts repression of the human Htt alleles in HEK293 cells using ZFPs targeted to five loci in the human gene.
  • a diagram of the human Htt gene is shown and the locations of ZFP binding sites are shown. For each ZFP group, each bar represents an independent transfection.
  • Figure 2B depicts a Western blot showing Htt protein levels in HEK293 cells transfected with the GFP control or the 18856 ZFP TF repressor (comprising the KRAB repression domain of KOX1), where the NFKB p65 levels ("p65") were used to confirm equal protein loading.
  • the Western blot confirms the repression of Htt expression by the ZFP-TF.
  • Figure 2C depicts a similar set of data as Figure 2A for the mouse Htt specific ZFP in Neuro2A cells. As in Figure 2 A, a diagram of the mouse Htt gene is shown and the locations of ZFP binding sites are indicated.
  • Figure 2D and 2E demonstrate the repression of mouse Htt gene expression (RNA) in immortalized striatal cells, where different doses of ZFP-TF mRNA were used for transfection.
  • Htt mRNA levels were measured by real-time RT-PCR and normalized to those of Actin mRNA.
  • FIG 3 panels A to G, depict selective repression of mutant Htt by using ZFPs binding within the CAG repeat region, as illustrated in Figure IB.
  • This model illustrates that the longer CAG repeat region in the mutant allele allows for increased binding of CAG-targeted ZFP repressor molecules.
  • Figure 3A depicts different repressor activities on the endogenous Htt gene (with normal CAG repeat length) by CAG-targeted ZFPs in HEI 293 cells.
  • Figure 3B shows repression of luciferase reporters controlled by Htt promo ter/exonl fragments containing CAG repeats of varying lengths, ranging from 10 to 47 CAG repeats.
  • CAG10 shows results with 10 CAG repeats
  • CAG17 shows results with 17 CAG repeats
  • CAG23 shows results with 23 CAG repeats
  • CAG47 shows results with 47 CAG repeats.
  • the schematic above the graph depicts the arrangement of the Htt promoter, exon 1, the CAG repeats and the reporter luciferase gene used in this system. The data demonstrate that increasing the number of CAGs leads to a decreased expression from the Htt promoter by a CAG-targeted ZFP.
  • Figure 3C demonstrates that, while a relatively weak CAG-targeted ZFP does not repress the luciferase reporter that contains a normal-length CAG repeat as well as a strong CAG repressor, it drives similar repression of a luciferase reporter that contains an expanded CAG repeat as the strong CAG-targeted ZFP.at all doses tested.
  • "pRL-Htt-CAG23-intron 1" corresponds to expression from the wild type allele while "pRL- HttCAG47-intron 1" (right bar of each pair) correlates with expression from the mutant expanded Htt allele (containing 47 CAG repeats).
  • Figure 3D is a graph depicting repression of mutant Htt (1 11 CAG) by CAG-targeted ZFPs in
  • FIG. 3E depicts mutant Htt repression by CAG-targeted ZFPs in a HD patient derived fibroblast line (CAG15/70).
  • the wild type Htt allele comprises 15 CAG repeats ("099T(CAG15)" 5 middle bar of each indicated condition) and the mutant expanded Htt allele comprises 70 CAG repeats
  • Figure 3F shows selective repression of mutant Htt expression in 4 different HD patient derived fibroblast cell lines.
  • the numbers above each grouping indicate the number of CAG repeats on the wildtype Htt allele (e.g. 15 or 18) and on the mutant allele (e.g. 70, 67, 45 and 44); where two different doses of ZFP mRNA were tested.
  • the left-bar of each pair shows wild-type Htt expression and the right bar of each shows expression of mutant Htt.
  • Figure 3G depicts Htt expression in HD derived patient fibroblasts as assayed by Western blot analysis in the presence of the ZFP-TFs 30640, 32528 and 30657.
  • the slower migrating protein bands are those produced by the expanded mutant Htt alleles. 32528 binds to the transcription start site of Htt (TSS) and thus inhibits expression from both alleles, while 30640 and 30657 bind to the CAG repeats (CAG).
  • TSS transcription start site of Htt
  • CAG CAG repeats
  • FIG. 4 panels A and B, depict repression of the mutant Htt in a HD patient derived fibroblast line by a panel of ZFPs targeted to the CAG repeat.
  • a range of RNA concentrations were used from 0.1 ng to 3 ⁇ g.
  • the left bar of each indicated conditions shows total Htt expression
  • the middle bar shows expression of Htt in fibroblasts in which the Htt allele comprises 18 CAG repeats ("099T(CAG18)"
  • the mutant expanded Htt allele comprises 45 CAG repeats 099T (CAG45
  • Figure 5 shows the effect of CAG-targeted ZFP repressors on the expression of Htt and other C AG-containing genes in HD patient-derived fibroblasts.
  • the left bar under each indicated condition shows results with 30640; the middle bar under each indicated condition shows results with 30675; and the right bar shows mock transfections.
  • Figure 6 panels A and B depicts an experiment that examines the genome-wide specificity of three CAG-targeted ZFPs.
  • Figure 6A depicts qPCR analysis of Htt repression performed on six biological replicates (six separate transfections) of HD fibroblasts (CAG18 (middle bars)/ CAG45, right bars) using 30640, 30645, or 33074. The four most similar replicates by qPCR were then selected for microarray analysis, and the data is presented in Figure 6B.
  • Figure 7 depicts Htt repression in C AG 1 7/69 neuronal stem cells
  • NSC neurotrophic factor
  • Figure 8 depicts Htt expression in neurons differentiated from HD embryonic stem cells (ESC) (CAG 17/48) treated with ZFP TFs. The cells were transfected with ZFP mR A at indicated doses.
  • ESC HD embryonic stem cells
  • Figure 9 depicts repression of a mutant Htt transgene expression in
  • Figure 10A depicts ZFPs with multimerization domains that specifically targets expanded CAG repeats, as illustrated in Figure ID.
  • Figure 10A shows a single ZFP that have four components: (i) a KOX repressor domain (oval labeled “repressor”); (ii) an array of 2-6 fingers (two shown, small ovals marked “Z") that binds to (CAG)N or a permutation of this sequence; and (iii) two dimerization domains (rectangles labeled "dl” and "d2”) that interact in an antiparallel configuration. These domains allow the ZFP to polymerize within the major groove of a CAG tract.
  • Figure 10B shows a sketch of the binding event with a multimer of 3 ZFPs. It will be apparent that any number of multimers can be used and that the functional domain may be positioned anywhere on one or more of the individual ZFPs and that these diagrams are applicable to TALE-TFs as well.
  • Figure IOC shows protein sequences of the four ZFP monomer scaffolds that are designed to multimerize via interactions between dimerizing zinc fingers (DZ). Scaffolds are named DZ1 (SEQ ID NO: 180), DZ2 (SEQ ID NO: 181), DZ3 (SEQ ID NO: 182) and DZ4 (SEQ ID NO: 183).
  • FIG. 10D shows protein sequences of the seven ZFP monomer scaffolds that are designed to multimerize via interactions between coiled- coils (CC). Scaffolds are named CC1 (SEQ ID NO: 184), CC2 (SEQ ID NO: 185), CC3 (SEQ ID NO: 186), CC4 (SEQ ID NO: 187), CC5 (SEQ ID NO: 188), CC6 (SEQ ID NO: 189) and CC7 (SEQ ID NO:190).
  • pRL-Htt CAG 17 (left bar of each pair) stands for renilla luciferase reporter controlled by human Htt promoter/exonl fragment with 17 CAG; pGL3-Htt-CAG47 (right bar of each pair) stands for firefly luciferase reporter controlled by human Htt promoter/exonl fragment with 47 CAG repeats. See text in Example 10 for description of the various dimerization domains.
  • Figure 1 IB ZFPs with the dimerizing zinc finger "DZ" domains were tested with the same luciferase reporters, and demonstrates increased repression with some ZFP-TF dimerization domains.
  • the left bar in each doublet indicates the expression from the 17CAG repeat Htt allele while the right bar indicates expression from 47 CAG repeat Htt allele.
  • FIG. 12 panels A and B, depict repression of Htt by ZFP-ZFP-
  • Figure 12A depicts Htt repression by the single 33088 and 33084 ZFP-TFs, and repression by the 33088-33088 and 33088-33084 ZFP-ZFP-KOX proteins in wild-type (left bar), CAG18 (middle bar) and CAG45 (right bar) ( Figure 12A) HD fibroblasts;
  • Figure 12B depicts Htt repression by 33088-33088 and 33088- 33084 ZFP-ZFP-KOX in wild type (left bar), CAG 20 (middle bar) and CAG41 (left bar) HD fibroblasts.
  • Figure 13A depicts activation of mouse Htt.
  • Figure 13A demonstrates ZFP-TF-driven up-regulation of the mouse Htt genes at the RNA level in Neuro2A cells using a ZFP fused to the p65 activation domain. Double bars indicate duplicate transfections.
  • Figure 13B depicts a Western blot demonstrating increased Htt protein production driven by the ZFP.
  • Figure 13C depicts a wild type mouse Htt allele and a "knock in" Htt allele where mouse sequence (most of exonl and part of intron 1, line above wild-type allele schematic) has been replaced with corresponding human sequence with CAG expansion (line over knock-in allele schematic).
  • Figure 13D depicts the alignment between mouse sequence (SEQ ID NO: 191) that was replaced with the corresponding human sequence (SEQ ID NO: 191) that was replaced with the corresponding human sequence (SEQ ID NO: 191) that was replaced with the corresponding human sequence (SEQ ID NO: 191) that was replaced with the corresponding human sequence (
  • FIG. 13E depicts specific activation of the wild type mouse Htt allele in
  • FIG 14, panels A and B depicts the results of Cel-I mismatch assays (SurveyorTM, Transgenomics) following treatment of K562 cells with Htt specific ZFN pairs.
  • the percent NHEJ activity (in-del) for an active ZFN is shown at the bottom of the corresponding lane.
  • "GFP" indicates cells that have been transfected with a GFP encoding plasmid.
  • Figure 14A depicts results from ZFNs that cleave early Htt exons while Figure 14B depicts results from ZFNs that cleave near the stop codon. Inactive ZFN pairs were also observed (lanes not annotated with in- del percentages).
  • FIG. 15 depicts graphs of the Htt repression results for several candidate TALE-TF proteins.
  • the TALE-TFs were tested in HD patient derived fibroblasts (CAG 20/41). The results demonstrate that some of the TALE TFs were active in repressing overall Htt expression, while others exhibited mutant Htt- preferential repression.
  • compositions and methods for treating are compositions and methods for treating
  • Htt-modulating transcription factors comprising zinc finger proteins (ZFP TFs) or TALEs (TALE-TF) and methods utilizing such proteins are provided for use in treating or preventing Huntington's disease.
  • ZFP TFs zinc finger proteins
  • TALE-TF TALE-TF
  • ZFP-TFs or TALE-TFs which repress expression of a mutant Htt allele or activate expression of a wild-type Htt allele are provided.
  • ZFNs zinc finger nucleases
  • TALENs TALE nucleases
  • CRISPR/Cas nuclease systems that modify the genomic structure of the genes associated with HD are provided.
  • ZFNs, TALENs or CRISPR/Cas nuclease systems that are able to specifically alter portions of a mutant form of Htt are provided.
  • These include compositions and methods using engineered zinc finger proteins or engineered TALE proteins, i. e., non-naturally occurring proteins which bind to a predetermined nucleic acid target sequence.
  • the methods and compositions described herein provide methods for treatment and prevention of Huntington's Disease, and these methods and compositions can comprise zinc finger transcription factors or TALE transcription factors that are capable of modulating target genes as well as engineered zinc finger and TALE nucleases and CRISPRVCas nuclease systems capable of modifying or editing Htt.
  • compositions disclosed herein employ, unless otherwise indicated, conventional techniques in molecular biology, biochemistry, chromatin structure and analysis, computational chemistry, cell culture, recombinant DNA and related fields as are within the skill of the art. These techniques are fully explained in the literature. See, for example, Sambrook et al. MOLECULAR CLONING: A LABORATORY MANUAL,
  • nucleic acid refers to a deoxynbonucleotide or ribonucleotide polymer, in linear or circular conformation, and in either single- or double-stranded form.
  • polynucleotide refers to a deoxynbonucleotide or ribonucleotide polymer, in linear or circular conformation, and in either single- or double-stranded form.
  • these terms are not to be construed as limiting with respect to the length of a polymer.
  • the terms can encompass known analogues of natural nucleotides, as well as nucleotides that are modified in the base, sugar and/or phosphate moieties (e.g. , phosphorothioate backbones).
  • an analogue of a particular nucleotide has the same base-pairing specificity; i.e. , an analogue of A will base-pair with T.
  • polypeptide refers to a polymer of amino acid residues.
  • peptide refers to a polymer of amino acid residues.
  • protein refers to amino acid polymers in which one or more amino acids are chemical analogues or modified derivatives of a corresponding naturally-occurring amino acids.
  • Binding refers to a sequence-specific, non-covalent interaction between macromolecules (e.g. , between a protein and a nucleic acid). Not all
  • binding interaction components of a binding interaction need be sequence-specific (e.g. , contacts with phosphate residues in a DNA backbone), as long as the interaction as a whole is sequence-specific. Such interactions are generally characterized by a dissociation constant (3 ⁇ 4) of 10 "6 M " 1 or lower. "Affinity" refers to the strength of binding:
  • a "binding protein” is a protein that is able to bind non-covalently to another molecule.
  • a binding protein can bind to, for example, a DNA molecule (a DNA- binding protein), an RNA molecule (an RNA-binding protein) and/or a protein molecule (a protein-binding protein).
  • a protein-binding protein it can bind to itself (to form homodimers, homotrimers, etc.) and/or it can bind to one or more molecules of a different protein or proteins.
  • a binding protein can have more than one type of binding activity. For example, zinc finger proteins have DNA-binding, RNA-binding and protein- binding activity.
  • a "zinc finger DNA binding protein” (or binding domain) is a protein, or a domain within a larger protein, that binds DNA in a sequence-specific manner through one or more zinc fingers, which are regions of amino acid sequence within the binding domain whose structure is stabilized through coordination of a zinc ion.
  • the term zinc finger DNA binding protein is often abbreviated as zinc finger protein or ZFP.
  • a "TALE DNA binding domain” or “TALE” is a polypeptide comprising one or more TALE repeat domains/units. The repeat domains are involved in binding of the TALE to its cognate target DNA sequence.
  • a single “repeat unit” (also referred to as a “repeat”) is typically 33-35 amino acids in length and exhibits at least some sequence homology with other TALE repeat sequences within a naturally occurring TALE protein.
  • Zinc finger binding domains or TALE DNA binding domains can be any organic or organic
  • engineered zinc finger proteins or TALEs are proteins that are non-naturally occurring.
  • methods for engineering zinc finger proteins or TALEs are design and selection.
  • a designed zinc finger protein or TALE is a protein not occurring in nature whose design/composition results principally from rational criteria. Rational criteria for design include application of substitution rules and computerized algorithms for processing information in a database storing information of existing ZFP designs and binding data. See, for example, US Patents 6,140,081 ; 6,453,242; and 6,534,261 ; see also WO 98/53058; WO 98/53059; WO 98/53060; WO 02/016536 and WO 03/016496 and U.S.
  • a "selected" zinc finger protein or TALE is a protein not found in nature whose production results primarily from an empirical process such as phage display, interaction trap or hybrid selection. See e.g. , US 5,789,538; US 5,925,523;
  • WO 98/53057 WO 98/5431 1 ; WO 00/27878; WO 01/60970 WO 01/88197, WO 02/099084 and WO 201 1/146121 (U.S. Patent Publication No. 201 10301073).
  • homologous recombination refers to the specialized form of such exchange that takes place, for example, during repair of double-strand breaks in cells via homology-directed repair mechanisms. This process requires nucleotide sequence homology, uses a "donor” molecule to template repair of a "target” molecule (i.e. , the one that experienced the double-strand break), and is variously known as “non- crossover gene conversion” or “short tract gene conversion,” because it leads to the transfer of genetic information from the donor to the target.
  • such transfer can involve mismatch correction of heteroduplex DNA that forms between the broken target and the donor, and/or "synthesis-dependent strand annealing," in which the donor is used to resynthesize genetic information that will become part of the target, and/or related processes.
  • Such specialized HR often results in an alteration of the sequence of the target molecule such that part or all of the sequence of the donor polynucleotide is incorporated into the target polynucleotide.
  • one or more targeted nucleases as described herein create a double-stranded break in the target sequence (e.g., cellular chromatin) at a predetermined site, and a "donor" polynucleotide, having homology to the nucleotide sequence in the region of the break, can be introduced into the cell.
  • a "donor" polynucleotide having homology to the nucleotide sequence in the region of the break
  • the presence of the double-stranded break has been shown to facilitate integration of the donor sequence.
  • the donor sequence may be physically integrated or, alternatively, the donor polynucleotide is used as a template for repair of the break via homologous recombination, resulting in the introduction of all or part of the nucleotide sequence as in the donor into the cellular chromatin.
  • a first sequence in cellular chromatin can be altered and, in certain embodiments, can be converted into a sequence present in a donor polynucleotide.
  • replacement or replacement can be understood to represent replacement of one nucleotide sequence by another, (i. e. , replacement of a sequence in the informational sense), and does not necessarily require physical or chemical replacement of one polynucleotide by another.
  • additional pairs of zinc-finger or TALE proteins can be used for additional double-stranded cleavage of additional target sites within the cell.
  • a chromosomal sequence is altered by homologous recombination with an exogenous "donor" nucleotide sequence.
  • homologous recombination is stimulated by the presence of a double-stranded break in cellular chromatin, if sequences homologous to the region of the break are present.
  • the donor sequence can contain sequences that are homologous, but not identical, to genomic sequences in the region of interest, thereby stimulating homologous recombination to insert a non-identical sequence in the region of interest.
  • portions of the donor sequence that are homologous to sequences in the region of interest exhibit between about 80 to 99% (or any integer therebetween) sequence identity to the genomic sequence that is replaced.
  • the homology between the donor and genomic sequence is higher than 99%, for example if only 1 nucleotide differs as between donor and genomic sequences of over 100 contiguous base pairs.
  • a non-homologous portion of the donor sequence can contain sequences not present in the region of interest, such that new sequences are introduced into the region of interest.
  • the non-homologous sequence is generally flanked by sequences of 50- 1,000 base pairs (or any integral value therebetween) or any number of base pairs greater than 1,000, that are homologous or identical to sequences in the region of interest.
  • the donor sequence is non-homologous to the first sequence, and is inserted into the genome by non-homologous recombination
  • exogenous nucleic acid sequence can comprise, for example, one or more genes or cDNA
  • RNA molecules or any type of coding or noncoding sequence, as well as one or more control elements (e.g., promoters).
  • the exogenous nucleic acid sequence may produce one or more RNA molecules (e.g., small hairpin RNAs (shRNAs), inhibitory RNAs (RNAis), microRNAs (miRNAs), etc.).
  • shRNAs small hairpin RNAs
  • RNAis inhibitory RNAs
  • miRNAs microRNAs
  • Cleavage refers to the breakage of the covalent backbone of a DNA molecule. Cleavage can be initiated by a variety of methods including, but not limited to, enzymatic or chemical hydrolysis of a phosphodiester bond. Both single-stranded cleavage and double-stranded cleavage are possible, and double-stranded cleavage can occur as a result of two distinct single-stranded cleavage events. DNA cleavage can result in the production of either blunt ends or staggered ends. In certain embodiments, fusion polypeptides are used for targeted double-stranded DNA cleavage.
  • a "cleavage half-domain” is a polypeptide sequence which, in
  • first and second cleavage half-domains; "+ and - cleavage half-domains” and “right and left cleavage half-domains” are used interchangeably to refer to pairs of cleavage half- domains that dimerize.
  • An "engineered cleavage half-domain” is a cleavage half-domain that has been modified so as to form obligate heterodimers with another cleavage half- domain (e.g., another engineered cleavage half-domain). See, also, U.S. Patent
  • sequence refers to a nucleotide sequence of any length, which can be DNA or RNA; can be linear, circular or branched and can be either single-stranded or double stranded.
  • donor sequence refers to a nucleotide sequence that is inserted into a genome.
  • a donor sequence can be of any length, for example between 2 and 10,000 nucleotides in length (or any integer value
  • nucleotides in length preferably between about 100 and 1,000 nucleotides in length (or any integer therebetween), more preferably between about 200 and 500 nucleotides in length.
  • Chromatin is the nucleoprotein structure comprising the cellular genome.
  • Cellular chromatin comprises nucleic acid, primarily DNA, and protein, including histones and non-histone chromosomal proteins.
  • the majority of eukaryotic cellular chromatin exists in the form of nucleosomes, wherein a nucleosome core comprises approximately 150 base pairs of DNA associated with an octamer comprising two each of histones H2A, H2B, H3 and H4; and linker DNA (of variable length depending on the organism) extends between nucleosome cores.
  • a molecule of histone HI is generally associated with the linker DNA.
  • chromatin is meant to encompass all types of cellular nucleoprotein, both prokaryotic and eukaryotic.
  • Cellular chromatin includes both chromosomal and episomal chromatin.
  • a "chromosome,” is a chromatin complex comprising all or a portion of the genome of a cell.
  • the genome of a cell is often characterized by its karyotype, which is the collection of all the chromosomes that comprise the genome of the cell.
  • the genome of a cell can comprise one or more chromosomes.
  • An "episome” is a replicating nucleic acid, nucleoprotein complex or other structure comprising a nucleic acid that is not part of the chromosomal karyotype of a cell.
  • Examples of episomes include plasmids and certain viral genomes.
  • target site or "target sequence” is a nucleic acid sequence that defines a portion of a nucleic acid to which a binding molecule will bind, provided sufficient conditions for binding exist.
  • exogenous molecule is a molecule that is not normally present in a cell, but can be introduced into a cell by one or more genetic, biochemical or other methods. "Normal presence in the cell" is determined with respect to the particular developmental stage and environmental conditions of the cell. Thus, for example, a molecule that is present only during embryonic development of muscle is an exogenous molecule with respect to an adult muscle cell. Similarly, a molecule induced by heat shock is an exogenous molecule with respect to a non-heat-shocked cell.
  • An exogenous molecule can comprise, for example, a functioning version of a malfunctioning endogenous molecule or a malfunctioning version of a normally- functioning endogenous molecule.
  • An exogenous molecule can be, among other things, a small molecule, such as is generated by a combinatorial chemistry process, or a macromolecule such as a protein, nucleic acid, carbohydrate, lipid, glycoprotein, lipoprotein,
  • Nucleic acids include DNA and RNA, can be single- or double-stranded; can be linear, branched or circular; and can be of any length. Nucleic acids include those capable of forming duplexes, as well as triplex-forming nucleic acids. See, for example, U.S. Patent Nos. 5,176,996 and 5,422,251.
  • Proteins include, but are not limited to, DNA-binding proteins, transcription factors, chromatin remodeling factors, methylated DNA binding proteins, polymerases, methylases, demethylases, acetylases, deacetylases, kinases, phosphatases, integrases, recombinases, ligases, topoisomerases, gyrases and helicases.
  • an exogenous molecule can be the same type of molecule as an endogenous molecule, e.g. , an exogenous protein or nucleic acid.
  • an exogenous nucleic acid can comprise an infecting viral genome, a plasmid or episome introduced into a cell, or a chromosome that is not normally present in the cell.
  • exogenous molecules into cells are known to those of skill in the art and include, but are not limited to, lipid-mediated transfer (i.e., liposomes, including neutral and cationic lipids), electroporation, direct injection, cell fusion, particle bombardment, calcium phosphate co-precipitation, DEAE-dextran- mediated transfer and viral vector-mediated transfer.
  • An exogeneous molecule can also be the same type of molecule as an endogenous molecule but derived from a different species than the cell is derived from.
  • a human nucleic acid sequence may be introduced into a cell line originally derived from a mouse or hamster.
  • an "endogenous" molecule is one that is normally present in a particular cell at a particular developmental stage under particular environmental conditions.
  • an endogenous nucleic acid can comprise a chromosome, the genome of a mitochondrion, chloroplast or other organelle, or a naturally- occurring episomal nucleic acid.
  • Additional endogenous molecules can include proteins, for example, transcription factors and enzymes.
  • a "fusion" molecule is a molecule in which two or more subunit molecules are linked, preferably covalently.
  • the subunit molecules can be the same chemical type of molecule, or can be different chemical types of molecules.
  • Examples of the first type of fusion molecule include, but are not limited to, fusion proteins (for example, a fusion between a ZFP or TALE DNA-binding domain and one or more activation domains) and fusion nucleic acids (for example, a nucleic acid encoding the fusion protein described supra).
  • Examples of the second type of fusion molecule include, but are not limited to, a fusion between a triplex-forming nucleic acid and a polypeptide, and a fusion between a minor groove binder and a nucleic acid.
  • Fusion protein in a cell can result from delivery of the fusion protein to the cell or by delivery of a polynucleotide encoding the fusion protein to a cell, wherein the polynucleotide is transcribed, and the transcript is translated, to generate the fusion protein.
  • Trans-splicing, polypeptide cleavage and polypeptide ligation can also be involved in expression of a protein in a cell. Methods for polynucleotide and polypeptide delivery to cells are presented elsewhere in this disclosure.
  • a “multimerization domain”, (also referred to as a “dimerization domain” or “protein interaction domain”) is a domain incorporated at the amino, carboxy or amino and carboxy terminal regions of a ZFP TF or TALE TF. These domains allow for multimerization of multiple ZFP TF or TALE TF units such that larger tracts of trinucleotide repeat domains become preferentially bound by multimerized ZFP TFs or TALE TFs relative to shorter tracts with wild-type numbers of lengths. Examples of multimerization domains include leucine zippers.
  • Multimerization domains may also be regulated by small molecules wherein the multimerization domain assumes a proper conformation to allow for interaction with another multimerization domain only in the presence of a small molecule or external ligand. In this way, exogenous ligands can be used to regulate the activity of these domains.
  • Gene expression refers to the conversion of the information, contained in a gene, into a gene product.
  • a gene product can be the direct
  • Gene products also include RNAs which are modified, by processes such as capping, polyadenylation, methylation, and editing, and proteins modified by, for example, methylation, acetylation, phosphorylation, ubiquitination, ADP-ribosylation, myristilation, and glycosylation.
  • Modulation of gene expression refers to a change in the activity of a gene. Modulation of expression can include, but is not limited to, gene activation and gene repression. Genome editing (e.g., cleavage, alteration, inactivation, random mutation) can be used to modulate expression. Gene inactivation refers to any reduction in gene expression as compared to a cell that does not include a ZFP or TALE protein as described herein. Thus, gene inactivation may be partial or complete.
  • a "region of interest” is any region of cellular chromatin, such as, for example, a gene or a non-coding sequence within or adjacent to a gene, in which it is desirable to bind an exogenous molecule. Binding can be for the purposes of targeted DNA cleavage and/or targeted recombination.
  • a region of interest can be present in a chromosome, an episome, an organellar genome (e.g. , mitochondrial, chloroplast), or an infecting viral genome, for example.
  • a region of interest can be within the coding region of a gene, within transcribed non-coding regions such as, for example, leader sequences, trailer sequences or introns, or within non-transcribed regions, either upstream or downstream of the coding region.
  • a region of interest can be as small as a single nucleotide pair or up to 2,000 nucleotide pairs in length, or any integral value of nucleotide pairs.
  • Eukaryotic cells include, but are not limited to, fungal cells (such as yeast), plant cells, animal cells, mammalian cells and human cells (e.g., T-cells).
  • operative linkage and "operatively linked” (or “operably linked”) are used interchangeably with reference to a juxtaposition of two or more components (such as sequence elements), in which the components are arranged such that both components function normally and allow the possibility that at least one of the components can mediate a function that is exerted upon at least one of the other components.
  • a transcriptional regulatory sequence such as a promoter
  • a transcriptional regulatory sequence is operatively linked to a coding sequence if the transcriptional regulatory sequence controls the level of transcription of the coding sequence in response to the presence or absence of one or more transcriptional regulatory factors.
  • transcriptional regulatory sequence is generally operatively linked in cis with a coding sequence, but need not be directly adjacent to it.
  • an enhancer is a transcriptional regulatory sequence that is operatively linked to a coding sequence, even though they are not contiguous.
  • the term "operatively linked" can refer to the fact that each of the components performs the same function in linkage to the other component as it would if it were not so linked.
  • the ZFP or TALE DNA-binding domain and the activation domain are in operative linkage if, in the fusion polypeptide, the ZFP or TALE DNA-binding domain portion is able to bind its target site and/or its binding site, while the activation domain is able to upregulate gene expression.
  • ZFPs fused to domains capable of regulating gene expression are collectively referred to as "ZFP-TFs” or “zinc finger transcription factors”
  • TALEs fused to domains capable of regulating gene expression are collectively referred to as "TALE-TFs” or "TALE transcription factors.”
  • ZFP-TFs ZFP-TFs
  • TALE-TFs TALE transcription factors
  • ZFN ZFN or "zinc finger nuclease
  • the ZFP DNA-binding domain and the cleavage domain are in operative linkage if, in the fusion polypeptide, the ZFP DNA-binding domain portion is able to bind its target site and/or its binding site, while the cleavage domain is able to cleave DNA in the vicinity of the target site.
  • a fusion polypeptide in which a TALE DNA-binding domain is fused to a cleavage domain a "TALEN” or "TALE nuclease"
  • the TALE DNA-binding domain and the cleavage domain are in operative linkage if, in the fusion polypeptide, the TALE DNA-binding domain portion is able to bind its target site and/or its binding site, while the cleavage domain is able to cleave DNA in the vicinity of the target site.
  • a "functional fragment" of a protein, polypeptide or nucleic acid is a protein, polypeptide or nucleic acid whose sequence is not identical to the full-length protein, polypeptide or nucleic acid, yet retains the same function as the full-length protein, polypeptide or nucleic acid.
  • a functional fragment can possess more, fewer, or the same number of residues as the corresponding native molecule, and/or can contain one ore more amino acid or nucleotide substitutions.
  • determining the function of a nucleic acid are well-known in the art.
  • methods for determining protein function are well-known.
  • the DNA-binding function of a polypeptide can be determined, for example, by filter-binding, electrophoretic mobility-shift, or immunoprecipitation assays. DNA cleavage can be assayed by gel electrophoresis. See Ausubel et al, supra.
  • the ability of a protein to interact with another protein can be determined, for example, by co -immunoprecipitation, two- hybrid assays or complementation, both genetic and biochemical. See, for example, Fields et al. (1989) Nature 340:245-246; U.S. Patent No. 5,585,245 and PCT WO 98/44350.
  • a “vector” is capable of transferring gene sequences to target cells.
  • vector construct means any nucleic acid construct capable of directing the expression of a gene of interest and which can transfer gene sequences to target cells.
  • vector transfer vector means any nucleic acid construct capable of directing the expression of a gene of interest and which can transfer gene sequences to target cells.
  • the term includes cloning, and expression vehicles, as well as integrating vectors.
  • reporter gene refers to any sequence that produces a protein product that is easily measured, preferably although not necessarily in a routine assay.
  • Suitable reporter genes include, but are not limited to, sequences encoding proteins that mediate antibiotic resistance (e.g., ampicillin resistance, neomycin resistance, G418 resistance, puromycin resistance), sequences encoding colored or fluorescent or luminescent proteins (e.g., green fluorescent protein, enhanced green fluorescent protein, red fluorescent protein, luciferase), and proteins which mediate enhanced cell growth and/or gene amplification (e.g., dihydrofolate reductase).
  • antibiotic resistance e.g., ampicillin resistance, neomycin resistance, G418 resistance, puromycin resistance
  • sequences encoding colored or fluorescent or luminescent proteins e.g., green fluorescent protein, enhanced green fluorescent protein, red fluorescent protein, luciferase
  • proteins which mediate enhanced cell growth and/or gene amplification e.g., dihydrofolate reduc
  • Epitope tags include, for example, one or more copies of FLAG, His, myc, Tap, HA or any detectable amino acid sequence.
  • “Expression tags” include sequences that encode reporters that may be operably linked to a desired gene sequence in order to monitor expression of the gene of interest.
  • compositions comprising a DNA-binding domain that specifically bind to a target sequence in any gene comprising a trinucleotide repeat, including, but not limited to, Htt. Any DNA-binding domain can be used in the compositions and methods disclosed herein.
  • the DNA binding domain comprises a zinc finger protein.
  • the zinc finger protein is non-naturally occurring in that it is engineered to bind to a target site of choice. See, for example, Beerli et al. (2002)
  • An engineered zinc finger binding domain can have a novel binding specificity, compared to a naturally-occurring zinc finger protein.
  • Engineering methods include, but are not limited to, rational design and various types of selection.
  • Rational design includes, for example, using databases comprising triplet (or quadruplet) nucleotide sequences and individual zinc finger amino acid sequences, in which each triplet or quadruplet nucleotide sequence is associated with one or more amino acid sequences of zinc fingers which bind the particular triplet or quadruplet sequence. See, for example, co-owned U.S. Patents 6,453,242 and 6,534,261, incorporated by reference herein in their entireties.
  • Exemplary selection methods including phage display and two-hybrid systems, are disclosed in US Patents 5,789,538; 5,925,523; 6,007,988; 6,013,453; 6,410,248; 6,140,466; 6,200,759; and 6,242,568; as well as WO 98/37186;
  • zinc finger domains and/or multi-fingered zinc finger proteins may be linked together using any suitable linker sequences, including for example, linkers of 5 or more amino acids in length. See, also, U.S. Patent Nos. 6,479,626; 6,903, 185; and 7,153,949 for exemplary linker sequences 6 or more amino acids in length.
  • the proteins described herein may include any combination of suitable linkers between the individual zinc fingers of the protein.
  • enhancement of binding specificity for zinc finger binding domains has been described, for example, in co-owned WO 02/077227.
  • WO 96/06166 WO 98/53057; WO 98/5431 1 ; WO 00/27878; WO 01/60970 WO 01/88197; WO 02/099084; WO 98/53058; WO 98/53059; WO 98/53060;
  • zinc finger domains and/or multi-fingered zinc finger proteins may be linked together using any suitable linker sequences, including for example, linkers of 5 or more amino acids in length. See, also, U.S. Patent Nos. 6,479,626; 6,903,185; and 7,153,949 for exemplary linker sequences 6 or more amino acids in length.
  • the proteins described herein may include any combination of suitable linkers between the individual zinc fingers of the protein.
  • the DNA binding domain is an engineered zinc finger protein that binds (in a sequence-specific manner) to a target site in a Htt gene and modulates expression of Htt.
  • the ZFPs can bind selectively to either a mutant Htt allele or a wild-type Htt sequence.
  • Htt target sites typically include at least one zinc finger but can include a plurality of zinc fingers (e.g., 2, 3, 4, 5, 6 or more fingers).
  • the ZFPs include at least three fingers. Certain of the ZFPs include four, five or six fingers, while some ZFPs include 8, 9, 10, 11 or 12 fingers.
  • the ZFPs that include three fingers typically recognize a target site that includes 9 or 10 nucleotides; ZFPs that include four fingers typically recognize a target site that includes 12 to 14 nucleotides; while ZFPs having six fingers can recognize target sites that include 18 to 21 nucleotides.
  • the ZFPs can also be fusion proteins that include one or more regulatory domains, which domains can be transcriptional activation or repression domains.
  • the fusion protein comprises two ZFP DNA binding domains linked together. These zinc finger proteins can thus comprise 8, 9, 10, 11, 12 or more fingers.
  • the two DNA binding domains are linked via an extendable flexible linker such that one DNA binding domain comprises 4, 5, or 6 zinc fingers and the second DNA binding domain comprises an additional 4, 5, or 5 zinc fingers.
  • the linker is a standard inter-finger linker such that the finger array comprises one DNA binding domain comprising 8, 9, 10, 11 or 12 or more fingers.
  • the linker is an atypical linker such as a flexible linker.
  • the DNA binding domains are fused to at least one regulatory domain and can be thought of as a 'ZFP-ZFP- TF' architecture. Specific examples of these embodiments can be referred to as "ZFP- ZFP-KOX" which comprises two DNA binding domains linked with a flexible linker and fused to a KOX repressor and "ZFP-KOX-ZFP-KOX" where two ZFP-KOX fusion proteins are fused together via a linker.
  • the DNA-binding domain may be derived from a nuclease.
  • the recognition sequences of homing endonucleases and meganucleases such as l-Scel, l-Ceul, ⁇ -Pspl, Vl-Sce, 1-SceTV, l-Csml, l-Panl, I- Scell, l-Ppol, l-Scelll, l-Crel, l-Tevl, I-73 ⁇ 4vII and I-TevUl are known. See also U.S. Patent No. 5,420,032; U.S. Patent No. 6,833,252; Belfort et a/.
  • Patent Publication No. 20070117128 is a Patent Publication No. 20070117128.
  • Two handed zinc finger proteins are those proteins in which two clusters of zinc finger DNA binding domains are separated by intervening amino acids so that the two zinc finger domains bind to two discontinuous target sites.
  • An example of a two handed type of zinc finger binding protein is SIP1, where a cluster of four zinc fingers is located at the amino terminus of the protein and a cluster of three fingers is located at the carboxyl terminus ⁇ see Remacle et al, (1999) EMBO Journal 18 (18): 5073-5084).
  • Each cluster of zinc fingers in these proteins is able to bind to a unique target sequence and the spacing between the two target sequences can comprise many nucleotides.
  • Two-handed ZFPs may include a functional domain, for example fused to one or both of the ZFPs.
  • the functional domain may be attached to the exterior of one or both ZFPs (see, Figure 1C) or may be positioned between the ZFPs (attached to both ZFPs) (see, Figure 4).
  • the first column in this table is an internal reference name (number) for a ZFP and corresponds to the same name in column 1 of Tables 2 A and 2B.
  • “F” refers to the finger and the number following “F” refers which zinc finger ⁇ e.g., "Fl” refers to finger 1).
  • Table 1A Htt-targeted zinc finger proteins
  • Tables 2A and 2B show the target sequences for the indicated zinc fmger proteins. Nucleotides in the target site that are contacted by the ZFP recognition helices are indicated in uppercase letters; non-contacted nucleotides indicated in lowercase.
  • the DNA-binding domain comprises a naturally occurring or engineered (non-naturally occurring) TAL effector (TALE) DNA binding domain.
  • TALE TAL effector
  • TALE transcription activator-like effectors
  • AvrBs3 from Xanthomonas campestgris pv. Vesicatoria (see Bonas et al (1989) Mol Gen Genet 218: 127-136 and WO2010079430).
  • TALEs contain a centralized domain of tandem repeats, each repeat containing approximately 34 amino acids, which are key to the DNA binding specificity of these proteins.
  • Xanthomonas in the R. solanacearum biovar 1 strain GMI1000 and in the biovar 4 strain S1000 See Heuer et al (2007) Appl and Envir Micro 73(13): 4379-4384.
  • These genes are 98.9% identical in nucleotide sequence to each other but differ by a deletion of 1,575 bp in the repeat domain of hpxl7.
  • both gene products have less than 40% sequence identity with AvrBs3 family proteins of Xanthomonas.
  • TALEs are typically 91-100% homologous with each other (Bonas et al, ibid).
  • Polymorphism of the repeats is usually located at positions 12 and 13 and there appears to be a one-to-one correspondence between the identity of the hypervariable diresidues at positions 12 and 13 with the identity of the contiguous nucleotides in the TALE's target sequence (see Moscou and Bogdanove, (2009) Science 326: 1501 and Boch et al (2009) Science 326:1509-1512).
  • the code for DNA recognition of these TALEs has been determined such that an HD sequence at positions 12 and 13 leads to a binding to cytosine (C), NG binds to T, NI to A, C, G or T, NN binds to A or G, and IG binds to T.
  • C cytosine
  • ZFPs or TALE proteins are listed in Table 3.
  • the amino acid sequences of two types of domain, coiled-coil (CC) and dimerizing zinc finger (DZ) are listed.
  • Fusion proteins comprising DNA-binding proteins (e.g., ZFPs or
  • TALEs as described herein and a heterologous regulatory (functional) domain (or functional fragment thereof) are also provided.
  • Common domains include, e.g., transcription factor domains (activators, repressors, co-activators, co-repressors), silencers, oncogenes (e.g., myc, jun, fos, myb, max, mad, rel, ets, bcl, myb, mos family members etc.); DNA repair enzymes and their associated factors and modifiers; DNA rearrangement enzymes and their associated factors and modifiers; chromatin associated proteins and their modifiers (e.g. kinases, acetylases and deacetylases); and DNA modifying enzymes (e.g., methyltransferases,
  • topoisomerases helicases, ligases, kinases, phosphatases, polymerases,
  • Suitable domains for achieving activation include the HSV VP 16 activation domain (see, e.g., Hagmann et al., J. Virol. 71, 5952-5962 (1997)) nuclear hormone receptors (see, e.g., Torchia et al., Curr. Opin. Cell. Biol. 10:373-383 (1998)); the p65 submit of nuclear factor kappa B (Bitko & Barik, J. Virol. 72:5610- 5618 (1998) and Doyle & Hunt, Neuroreport 8:2937-2942 (1997)); Liu et al, Cancer Gene Ther.
  • HSV VP 16 activation domain see, e.g., Hagmann et al., J. Virol. 71, 5952-5962 (1997)
  • nuclear hormone receptors see, e.g., Torchia et al., Curr. Opin. Cell. Biol. 10:373-383 (1998)
  • the p65 submit
  • chimeric functional domains such as VP64 (Beerli et al, (1998) Proc. Natl. Acad. Sci. USA 95:14623-33), and degron (Molinari et al, (1999) EMBO J. 18, 6439-6447).
  • Additional exemplary activation domains include, Oct 1, Oct-2A, Spl, AP-2, and CTF1 (Seipel et al, EMBO J. 11, 4961-4968 (1992) as well as p300, CBP, PCAF, SRC1 PvALF, AtHD2A and ERF-2. See, for example, Robyr et al. (2000) Mol. Endocrinol.
  • Additional exemplary activation domains include, but are not limited to, OsGAI, HALF-1 , CI, API, ARF- 5,-6,-7, and -8, CPRFl, CPRF4, MYC-RP/GP, and TRABl. See, for example, Ogawa et al. (2000) Gene 245:21-29; Okanami et al. (1996) Genes Cells 1 :87-99; Goff et al. (1991) Genes Dev. 5:298-309; Cho et al. (1999) Plant Mol. Biol. 40:419-429;
  • a fusion protein (or a nucleic acid encoding same) between a DNA-binding domain and a functional domain
  • an activation domain or a molecule that interacts with an activation domain is suitable as a functional domain.
  • any molecule capable of recruiting an activating complex and/or activating activity (such as, for example, histone acetylation) to the target gene is useful as an activating domain of a fusion protein.
  • Insulator domains, localization domains, and chromatin remodeling proteins such as ISWI-containing domains and/or methyl binding domain proteins suitable for use as functional domains in fusion molecules are described, for example, in co-owned U.S. Patent Applications 2002/0115215 and 2003/0082552 and in co- owned WO 02/44376.
  • Exemplary repression domains include, but are not limited to, KRAB
  • TIEG TGF-beta-inducible early gene
  • DNMT1, DNMT3A, DNMT3B members of the DNMT family ⁇ e.g., DNMT1, DNMT3A, DNMT3B), Rb, and MeCP2.
  • Additional exemplary repression domains include, but are not limited to, ROM2 and AtHD2A. See, for example, Chem et al. (1996) Plant Cell 8:305-321; and Wu et al. (2000) Plant J. 22:19
  • Fusion molecules are constructed by methods of cloning and biochemical conjugation that are well known to those of skill in the art. Fusion molecules comprise a DNA-binding domain and a functional domain (e.g., a transcriptional activation or repression domain). Fusion molecules also optionally comprise nuclear localization signals (such as, for example, that from the SV40 medium T-antigen) and epitope tags (such as, for example, FLAG and
  • Fusion proteins are designed such that the translational reading frame is preserved among the components of the fusion.
  • Fusions between a polypeptide component of a functional domain (or a functional fragment thereof) on the one hand, and a non-protein DNA-binding domain (e.g., antibiotic, intercalator, minor groove binder, nucleic acid) on the other, are constructed by methods of biochemical conjugation known to those of skill in the art. See, for example, the Pierce Chemical Company (Rockford, IL) Catalogue. Methods and compositions for making fusions between a minor groove binder and a polypeptide have been described. Mapp et al. (2000) Proc. Natl. Acad. Sci. USA 97:3930-3935.
  • the target site bound by the DNA binding domain is present in an accessible region of cellular chromatin. Accessible regions can be determined as described, for example, in co-owned International Publication WO 01/83732. If the target site is not present in an accessible region of cellular chromatin, one or more accessible regions can be generated as described in co-owned WO 01/83793.
  • the DNA-binding domain of a fusion molecule is capable of binding to cellular chromatin regardless of whether its target site is in an accessible region or not. For example, such DNA-binding domains are capable of binding to linker DNA and/or nucleosomal DNA.
  • the fusion molecule may be formulated with a pharmaceutically acceptable carrier, as is known to those of skill in the art. See, for example,
  • the functional component/domain of a fusion molecule can be selected from any of a variety of different components capable of influencing transcription of a gene once the fusion molecule binds to a target sequence via its DNA binding domain.
  • the functional component can include, but is not limited to, various transcription factor domains, such as activators, repressors, co-activators, compressors, and silencers.
  • transcription factor domains such as activators, repressors, co-activators, compressors, and silencers.
  • Additional exemplary functional domains are disclosed, for example, in co-owned US Patent No. 6,534,261 and US Patent Application Publication No. 2002/0160940.
  • Functional domains that are regulated by exogenous small molecules or ligands may also be selected.
  • RheoSwitch® technology may be employed wherein a functional domain only assumes its active conformation in the presence of the external RheoChemTM ligand (see for example US 20090136465).
  • the ZFP or TALE may be operably linked to the regulatable functional domain wherein the resultant activity of the ZFP-TF or TALE-TF is controlled by the external ligand.
  • the fusion protein comprises a DNA-binding binding domain and cleavage (nuclease) domain.
  • gene modification can be achieved using a nuclease, for example an engineered nuclease.
  • Engineered nuclease technology is based on the engineering of naturally occurring DNA-binding proteins. For example, engineering of homing endonucleases with tailored DNA-binding specificities has been described, (see, Chames et al. (2005) Nucleic Acids Res 33(20):el78; Arnould et al. (2006) J Mol. Biol. 355:443-458).
  • engineering of ZFPs has also been described. See, e.g., U.S. Patent Nos. 6,534,261 ; 6,607,882; 6,824,978; 6,979,539; 6,933,1 13; 7,163,824; and 7,013,219.
  • ZFPs and TALEs have been fused to nuclease domains to create ZFNs and TALENs -functional entities that are able to recognize their intended nucleic acid target through their engineered (ZFP or TALE) DNA binding domains and cause the DNA to be cut near the ZFP or TALE DNA binding site via the nuclease activity.
  • ZFP or TALE engineered DNA binding domains
  • ZFNs have been used for genome modification in a variety of organisms. See, for example, United States Patent Publications 20030232410;
  • nucleases include meganucleases, TALENs and zinc finger nucleases.
  • the nuclease may comprise heterologous DNA-binding and cleavage domains (e.g., zinc finger nucleases; TALENs; meganuclease DNA-binding domains with heterologous cleavage domains) or, alternatively, the DNA-binding domain of a naturally-occurring nuclease may be altered to bind to a selected target site (e.g., a meganuclease that has been engineered to bind to site different than the cognate binding site).
  • a selected target site e.g., a meganuclease that has been engineered to bind to site different than the cognate binding site.
  • the nuclease is a meganuclease (homing endonuclease).
  • Naturally-occurring meganucleases recognize 15-40 base-pair cleavage sites and are commonly grouped into four families: the LAGLIDADG family, the GIY-YIG family, the His-Cyst box family and the HNH family.
  • Exemplary homing endonucleases include l-Scel, l-Ceul, Yl-Pspl, Pl-Sce, 1-SceW, I- Csml, l-Panl, l-Scell, l-Ppol, l-Scelll, l-Crel, I-Tevl, l-Tevll and ⁇ -73 ⁇ 4 ⁇ .
  • Their recognition sequences are known. See also US'. Patent No. 5,420,032; U.S. Patent No. 6,833,252; Belfort et al. (1997) Nucleic Acids Res. 25:3379-3388; Dujon et al.
  • DNA-binding domains from naturally-occurring meganucleases primarily from the LAGLIDADG family, have been used to promote site- specific genome modification in plants, yeast, Drosophila, mammalian cells and mice, but this approach has been limited to the modification of either homologous genes that conserve the meganuclease recognition sequence (Monet et al. (1999), Biochem. Biophysics. Res. Common. 255: 88-93) or to pre-engineered genomes into which a recognition sequence has been introduced (Route et al. (1994), Mol. Cell. Biol.
  • meganucleases have also been operably linked with a cleavage domain from a heterologous nuclease ⁇ e.g., FokT).
  • the nuclease is a zinc finger nuclease (ZFN).
  • ZFNs comprise a zinc finger protein that has been engineered to bind to a target site in a gene of choice and cleavage domain or a cleavage half-domain.
  • zinc finger binding domains can be engineered to bind to a sequence of choice. See, for example, Beerli et al. (2002) Nature Biotechnol. 20: 135-141 ; Pabo et al. (2001) Ann. Rev. Biochem. 70:313-340; Isalan ei a/. (2001) Nature Biotechnol. 19:656-660; Segal et al. (2001) Curr. Opin. Biotechnol. 12:632-637; Choo et al. (2000) Curr. Opin. Struct. Biol. 10:41 1-416.
  • An engineered zinc finger binding domain can have a novel binding specificity, compared to a naturally-occurring zinc finger protein.
  • Engineering methods include, but are not limited to, rational design and various types of selection. Rational design includes, for example, using databases comprising triplet (or quadruplet) nucleotide sequences and individual zinc finger amino acid sequences, in which each triplet or quadruplet nucleotide sequence is associated with one or more amino acid sequences of zinc fingers which bind the particular triplet or quadruplet sequence. See, for example, co- owned U.S. Patents 6,453,242 and 6,534,261, incorporated by reference herein in their entireties.
  • Exemplary selection methods including phage display and two-hybrid systems, are disclosed in US Patents 5,789,538; 5,925,523; 6,007,988; 6,013,453; 6,410,248; 6,140,466; 6,200,759; and 6,242,568; as well as WO 98/37186;
  • zinc finger domains and/or multi-fingered zinc finger proteins may be linked together using any suitable linker sequences, including for example, linkers of 5 or more amino acids in length ⁇ e.g., TGEKP (SEQ ID NO: 135), TGGQRP (SEQ ID NO: 136), TGQKP (SEQ ID NO: 137), and/or TGSQKP (SEQ ID NO: 138)).
  • linkers of 5 or more amino acids in length ⁇ e.g., TGEKP (SEQ ID NO: 135), TGGQRP (SEQ ID NO: 136), TGQKP (SEQ ID NO: 137), and/or TGSQKP (SEQ ID NO: 138)).
  • linkers of 5 or more amino acids in length ⁇ e.g., TGEKP (SEQ ID NO: 135), TGGQRP (SEQ ID NO: 136), TGQKP (SEQ ID NO: 137), and/or TGSQKP (SEQ ID
  • linker sequences 6 or more amino acids in length may include any combination of suitable linkers between the individual zinc fingers of the protein. See, also, U.S. Provisional Patent Publication No. 20110287512.
  • the CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)/Cas (CRISPR Associated) nuclease system is a recently engineered nuclease system based on a bacterial system that can be used for genome engineering. It is based on part of the adaptive immune response of many bacteria and archea. When a virus or plasmid invades a bacterium, segments of the invader's DNA are converted into CRISPR RNAs (crRNA) by the 'immune' response.
  • crRNA CRISPR RNAs
  • This crRNA then associates, through a region of partial complementarity, with another type of RNA called tracrRNA to guide the Cas9 nuclease to a region homologous to the crRNA in the target DNA called a "protospacer.”
  • Cas9 cleaves the DNA to generate blunt ends at the DSB at sites specified by a 20-nucleotide guide sequence contained within the crRNA transcript.
  • Cas9 requires both the crRNA and the tracrRNA for site specific DNA recognition and cleavage.
  • This system has now been engineered such that the crRNA and tracrRNA can be combined into one molecule (the "single guide RNA"), and the crRNA equivalent portion of the single guide RNA can be engineered to guide the Cas9 nuclease to target any desired sequence (see J eket al (2012) Science 337, p. 816-821, Jinekei al, (2013), eLife 2:e00471, and David Segal, (2013) eLife
  • the CRISPR/Cas system can be engineered to create a DSB at a desired target in a genome, and repair of the DSB can be influenced by the use of repair inhibitors to cause an increase in error prone repair.
  • Nucleases such as ZFNs, TALENs and/or meganucleases also comprise a nuclease (cleavage domain, cleavage half-domain).
  • the cleavage domain may be heterologous to the DNA-binding domain, for example a zinc finger DNA-binding domain and a cleavage domain from a nuclease or a meganuclease DNA-binding domain and cleavage domain from a different nuclease.
  • Heterologous cleavage domains can be obtained from any endonuclease or exonuclease.
  • Exemplary endonucleases from which a cleavage domain can be derived include, but are not limited to, restriction endonucleases and homing endonucleases. See, for example, 2002-2003 Catalogue, New England Biolabs, Beverly, MA; and Belfort et al. (1997) Nucleic Acids Res. 25:3379-3388. Additional enzymes which cleave DNA are known ⁇ e.g., SI Nuclease; mung bean nuclease; pancreatic DNase I; micrococcal nuclease; yeast HO endonuclease; see also Linn et al. (eds.) Nucleases, Cold Spring Harbor Laboratory Press, 1993). One or more of these enzymes (or functional fragments thereof) can be used as a source of cleavage domains and cleavage half-domains.
  • a cleavage half-domain can be derived from any nuclease or portion thereof, as set forth above, that requires dimerization for cleavage activity.
  • two fusion proteins are required for cleavage if the fusion proteins comprise cleavage half-domains.
  • a single protein comprising two cleavage half- domains can be used.
  • the two cleavage half-domains can be derived from the same endonuclease (or functional fragments thereof), or each cleavage half-domain can be derived from a different endonuclease (or functional fragments thereof).
  • the target sites for the two fusion proteins are preferably disposed, with respect to each other, such that binding of the two fusion proteins to their respective target sites places the cleavage half-domains in a spatial orientation to each other that allows the cleavage half-domains to form a functional cleavage domain, e.g. , by dimerizing.
  • the near edges of the target sites are separated by 5-8 nucleotides or by 15-18 nucleotides.
  • any integral number of nucleotides or nucleotide pairs can intervene between two target sites ⁇ e.g. , from 2 to 50 nucleotide pairs or more).
  • the site of cleavage lies between the target sites.
  • Restriction endonucleases are present in many species and are capable of sequence-specific binding to DNA (at a recognition site), and cleaving DNA at or near the site of binding.
  • Certain restriction enzymes ⁇ e.g., Type IIS) cleave DNA at sites removed from the recognition site and have separable binding and cleavage domains.
  • Type IIS enzyme Fok I catalyzes double-stranded cleavage of DNA, at 9 nucleotides from its recognition site on one strand and 13 nucleotides from its recognition site on the other. See, for example, US Patents 5,356,802; 5,436,150 and 5,487,994; as well as Li et al.
  • fusion proteins comprise the cleavage domain (or cleavage half-domain) from at least one Type IIS restriction enzyme and one or more zinc finger binding domains, which may or may not be engineered.
  • An exemplary Type IIS restriction enzyme whose cleavage domain is separable from the binding domain, is Fok I. This particular enzyme is active as a dimer. Bitinaite et al. (1998) Proc. Natl. Acad. Sci. USA 95: 10,570-10,575.
  • the portion of the Fok I enzyme used in the disclosed fusion proteins is considered a cleavage half-domain.
  • two fusion proteins each comprising a Fokl cleavage half-domain, can be used to reconstitute a catalytically active cleavage domain.
  • a single polypeptide molecule containing a zinc finger binding domain and two Fok I cleavage half-domains can also be used.
  • a cleavage domain or cleavage half-domain can be any portion of a protein that retains cleavage activity, or that retains the ability to multimerize (e.g. , dimerize) to form a functional cleavage domain.
  • the cleavage domain comprises one or more engineered cleavage half-domain (also referred to as dimerization domain mutants) that minimize or prevent homodimerization, as described, for example, in U.S. Patent Publication Nos. 20050064474 and 20060188987 and in U.S. Application No.
  • Exemplary engineered cleavage half-domains of Fok I that form obligate heterodimers include a pair in which a first cleavage half-domain includes mutations at amino acid residues at positions 490 and 538 of Fok I and a second cleavage half-domain includes mutations at amino acid residues 486 and 499.
  • a mutation at 490 replaces Glu (E) with Lys
  • the engineered cleavage half-domains described herein were prepared by mutating positions 490 (E ⁇ K) and 538 (I ⁇ K) in one cleavage half-domain to produce an engineered cleavage half-domain designated "E490 :I538K” and by mutating positions 486 (Q ⁇ E) and 499 (I ⁇ L) in another cleavage half-domain to produce an engineered cleavage half-domain designated "Q486E:I499L".
  • the engineered cleavage half-domains described herein are obligate heterodimer mutants in which aberrant cleavage is minimized or abolished. See, e.g., U.S. Patent
  • the engineered cleavage half-domain comprises mutations at positions 486, 499 and 496 (numbered relative to wild-type Fokl), for instance mutations that replace the wild type Gin (Q) residue at position 486 with a Glu (E) residue, the wild type Iso (I) residue at position 499 with a Leu (L) residue and the wild-type Asn (N) residue at position 496 with an Asp (D) or Glu (E) residue (also referred to as a "ELD” and "ELE” domains, respectively).
  • the engineered cleavage half- domain comprises mutations at positions 490, 538 and 537 (numbered relative to wild-type Fokl), for instance mutations that replace the wild type Glu (E) residue at position 490 with a Lys (K) residue, the wild type Iso (I) residue at position 538 with a Lys (K) residue, and the wild-type His (H) residue at position 537 with a Lys (K) residue or a Arg (R) residue (also referred to as "KKK” and "K R" domains, respectively).
  • the engineered cleavage half-domain comprises mutations at positions 490 and 537 (numbered relative to wild-type Fokl), for instance mutations that replace the wild type Glu (E) residue at position 490 with a Lys (K) residue and the wild-type His (H) residue at position 537 with a Lys (K) residue or a Arg (R) residue (also referred to as "KIK” and "KIR” domains, respectively).
  • E wild type Glu
  • H His
  • R Arg
  • Engineered cleavage half-domains described herein can be prepared using any suitable method, for example, by site-directed mutagenesis of wild-type cleavage half-domains (Fok l) as described in U.S. Patent Publication Nos.
  • nucleases may be assembled in vivo at the nucleic acid target site using so-called "split-enzyme” technology (see e.g. U.S. Patent Publication No. 20090068164).
  • split-enzyme e.g. U.S. Patent Publication No. 20090068164.
  • Components of such split enzymes may be expressed either on separate expression constructs, or can be linked in one open reading frame where the individual components are separated, for example, by a self-cleaving 2A peptide or IRES sequence.
  • Components may be individual zinc finger binding domains or domains of a meganuclease nucleic acid binding domain.
  • the DNA binding domain is an engineered domain from a TAL effector similar to those derived from the plant pathogens Xanthomonas (see Boch et al, (2009) Science 326: 1509-1512 and Moscou and
  • Nucleases e.g., ZFNs or TALENs
  • ZFNs or TALENs can be screened for activity prior to use, for example in a yeast-based chromosomal system as described in WO
  • Nuclease expression constructs can be readily designed using methods known in the art. See, e.g., United States Patent Publications 20030232410; 20050208489; 20050026157; 20050064474; 20060188987;
  • Expression of the nuclease may be under the control of a constitutive promoter or an inducible promoter, for example the galactokinase promoter which is activated (de-repressed) in the presence of raffinose and/or galactose and repressed in presence of glucose.
  • the proteins e.g., ZFPs, TALEs, CRISPR/Cas
  • polynucleotides encoding same and compositions comprising the proteins and/or polynucleotides described herein may be delivered to a target cell by any suitable means including, for example, by injection of ZFP-TF, TALE-TF proteins or by use of ZFN or TALEN encoding mRNA.
  • suitable cells include but not limited to eukaryotic and prokaryotic cells and/or cell lines.
  • Non-limiting examples of such cells or cell lines generated from such cells include COS, CHO (e.g., CHO-S, CHO-K1, CHO-DG44, CHO- DUXB11, CHO-DUKX, CHOK1SV), VERO, MDCK, WI38, V79, B14AF28-G3, BHK, HaK, NS0, SP2/0-Agl4, HeLa, HEK293 (e.g., HEK293-F, HEK293-H, HEK293-T), and perC6 cells as well as insect cells such as Spodoptera fugiperda (Sf), or fungal cells such as Saccharomyces, Pichia and Schizosaccharomyces.
  • COS CHO
  • CHO-S e.g., CHO-S, CHO-K1, CHO-DG44, CHO- DUXB11, CHO-DUKX, CHOK1SV
  • VERO MDCK
  • WI38
  • the cell line is a CHO-K1, MDCK or HEK293 cell line.
  • Suitable cells also include stem cells such as, by way of example, embiyonic stem cells, induced pluripotent stem cells, hematopoietic stem cells, neuronal stem cells and
  • Zinc finger, TALE or CRISPR/Cas proteins as described herein may also be delivered using vectors containing sequences encoding one or more of the zinc finger, TALE or CRISPR/Cas protein(s).
  • Any vector systems may be used including, but not limited to, plasmid vectors, retroviral vectors, lentiviral vectors, adenovirus vectors, poxvirus vectors; herpesvirus vectors and adeno-associated virus vectors, etc. See, also, U.S. Patent Nos. 6,534,261 ; 6,607,882; 6,824,978; 6,933,113; 6,979,539; 7,013,219; and 7,163,824, incorporated by reference herein in their entireties.
  • any of these vectors may comprise one or more zinc finger or TALE protein-encoding sequences.
  • any of these vectors may comprise one or more zinc finger or TALE protein-encoding sequences.
  • each vector may comprise a sequence encoding one or multiple ZFPs, TALEs or CRISPR/Cas systems.
  • nucleic acids encoding engineered ZFPs, TALEs or CRISPR/Cas systems can be used to introduce nucleic acids encoding engineered ZFPs, TALEs or CRISPR/Cas systems in cells ⁇ e.g., mammalian cells) and target tissues. Such methods can also be used to administer nucleic acids encoding ZFPs, TALEs or a CRISPR/Cas system to cells in vitro. In certain embodiments, nucleic acids encoding the ZFPs, TALEs or CRISPR/Cas system are administered for in vivo or ex vivo gene therapy uses.
  • Non- viral vector delivery systems include DNA plasmids, naked nucleic acid, and nucleic acid complexed with a delivery vehicle such as a liposome or poloxamer.
  • Viral vector delivery systems include DNA and RNA viruses, which have either episomal or integrated genomes after delivery to the cell.
  • Methods of non- viral delivery of nucleic acids include electroporation, lipofection, microinjection, biolistics, virosomes, liposomes, immuno liposomes, polycation or lipid:nucleic acid conjugates, naked DNA, naked RNA, artificial virions, and agent-enhanced uptake of DNA.
  • Sonoporation using, e.g., the Sonitron 2000 system (Rich-Mar) can also be used for delivery of nucleic acids.
  • one or more nucleic acids are delivered as mRNA.
  • capped mRNAs to increase translational efficiency and/or mRNA stability.
  • ARCA anti-reverse cap analog
  • nucleic acid delivery systems include those provided by Amaxa Biosystems (Cologne, Germany), Maxcyte, Inc. (Rockville, Maryland), BTX Molecular Delivery Systems (Holliston, MA) and Copernicus Therapeutics Inc, ⁇ see for example US6008336).
  • Lipofection is described in e.g., U.S. Patent Nos. 5,049,386; 4,946,787; and 4,897,355) and lipofection reagents are sold commercially ⁇ e.g., TransfectamTM and LipofectinTM and LipofectamineTM
  • RNAiMAX RNAiMAX
  • Cationic and neutral lipids that are suitable for efficient receptor- recognition lipofection of polynucleotides include those of Feigner, WO 91/17424, WO 91/16024. Delivery can be to cells ⁇ ex vivo administration) or target tissues ⁇ in vivo administration).
  • lipid:nucleic acid complexes including targeted liposomes such as immunolipid complexes
  • Boese et al Cancer Gene Ther. 2:291-297 (1995); Behr et al, Bioconjugate Chem. 5:382-389 (1994); Remy et al, Bioconjugate Chem. 5:647-654 (1994); Gao et al, Gene Therapy 2:710-722 (1995); Ahmad et a!., Cancer Res. 52:4817-4820 (1992); U.S. Pat. Nos. 4,186,183, 4,217,344, 4,235,871, 4,261,975, 4,485,054, 4,501,728, 4,774,085, 4,837,028, and 4,946,787).
  • Additional methods of delivery include the use of packaging the nucleic acids to be delivered into EnGeneIC delivery vehicles (EDVs). These EDVs are specifically delivered to target tissues using bispecific antibodies where one arm of the antibody has specificity for the target tissue and the other has specificity for the EDV. The antibody brings the EDVs to the target cell surface and then the EDV is brought into the cell by endocytosis. Once in the cell, the contents are released (see MacDiarmid et al (2009) Nature Biotechnology 27(7):643).
  • EDVs EnGeneIC delivery vehicles
  • RNA or DNA viral based systems for the delivery of nucleic acids encoding engineered ZFPs, TALEs or CRISPR/Cas systems take advantage of highly evolved processes for targeting a virus to specific cells in the body and trafficking the viral payload to the nucleus.
  • Viral vectors can be
  • Conventional viral based systems for the delivery of ZFPs, TALEs or CRISPR/Cas systems include, but are not limited to, retroviral, lentivirus, adenoviral, adeno-associated, vaccinia and herpes simplex virus vectors for gene transfer. Integration in the host genome is possible with the retrovirus, lentivirus, and adeno-associated virus gene transfer methods, often resulting in long term expression of the inserted transgene. Additionally, high transduction efficiencies have been observed in many different cell types and target tissues.
  • Lentiviral vectors are retroviral vectors that are able to transduce or infect non-dividing cells and typically produce high viral titers. Selection of a retroviral gene transfer system depends on the target tissue. Retroviral vectors are comprised of cw-acting long terminal repeats with packaging capacity for up to 6-10 kb of foreign sequence. The minimum cz ' s-acting LTRs are sufficient for replication and packaging of the vectors, which are then used to integrate the therapeutic gene into the target cell to provide permanent transgene expression.
  • Widely used retroviral vectors include those based upon mouse leukemia virus (MuLV), gibbon ape leukemia virus (GaLV), Simian Immunodeficiency virus (SIV), human immunodeficiency virus (HIV), and combinations thereof (see, e.g., Buchscher et al, J. Virol. 66:2731-2739 (1992);
  • Adenoviral based systems can be used.
  • Adenoviral based vectors are capable of very high transduction efficiency in many cell types and do not require cell division. With such vectors, high titer and high levels of expression have been obtained. This vector can be produced in large quantities in a relatively simple system.
  • Adeno-associated virus (“AAV”) vectors are also used to transduce cells with target nucleic acids, e.g., in the in vitro production of nucleic acids and peptides, and for in vivo and ex vivo gene therapy procedures (see, e.g., West et al, Virology 160:38-47 (1987); U.S. Patent No. 4,797,368; WO 93/24641; Kotin, Human Gene Therapy 5:793-801 (1994);
  • At least six viral vector approaches are currently available for gene transfer in clinical trials, which utilize approaches that involve complementation of defective vectors by genes inserted into helper cell lines to generate the transducing agent.
  • pLASN and MFG-S are examples of retroviral vectors that have been used in clinical trials (Dunbar et al, Blood 85:3048-305 (1995); Kohn et al, Nat. Med. 1 :1017-102 (1995); Malech e/ a/., PNAS 94:22 12133-12138 (1997)).
  • PA317/pLASN was the first therapeutic vector used in a gene therapy trial. (Blaese et al, Science 270:475-480 (1995)). Transduction efficiencies of 50% or greater have been observed for MFG-S packaged vectors. (Ellem et al, Immunol Immunother. 44(1): 10-20 (1997); Dranoff et al, Hum. Gene Ther. 1 :111-2 (1997).
  • rAAV Recombinant adeno-associated virus vectors
  • All vectors are derived from a plasmid that retains only the AAV 145 bp inverted terminal repeats flanking the transgene expression cassette. Efficient gene transfer and stable transgene delivery due to integration into the genomes of the transduced cell are key features for this vector system.
  • AAV serotypes including AAV1, AAV3, AAV4, AAV5, AAV6, AAV8 AAV 8.2, AAV9, and AAV rhl 0 and pseudotyped AAV such as AAV2/8, AAV2/5 and AAV2/6 can also be used in accordance with the present invention.
  • Replication-deficient recombinant adenoviral vectors can be produced at high titer and readily infect a number of different cell types. Most adenovirus vectors are engineered such that a transgene replaces the Ad Ela, Elb, and/or E3 genes; subsequently the replication defective vector is propagated in human 293 cells that supply deleted gene function in trans. Ad vectors can transduce multiple types of tissues in vivo, including nondividing, differentiated cells such as those found in liver, kidney and muscle. Conventional Ad vectors have a large carrying capacity.
  • Ad vector An example of the use of an Ad vector in a clinical trial involved polynucleotide therapy for antitumor immunization with intramuscular injection (Sterman et al, Hum. Gene Ther. 7:1083-9 (1998)). Additional examples of the use of adenovirus vectors for gene transfer in clinical trials include Rosenecker et al, Infection 24: 1 5-10 (1996); Sterman et al, Hum. Gene Ther. 9:7 1083-1089 (1998); Welsh et al, Hum. Gene Ther. 2:205-18 (1995); Alvarez et al, Hum. Gene Ther. 5:597-613 (1997); Topf et al, Gene Ther. 5:507-513 (1998); Sterman et al, Hum. Gene Ther. 7:1083-1089 (1998).
  • Packaging cells are used to form virus particles that are capable of infecting a host cell. Such cells include 293 cells, which package adenovirus, and ⁇ 2 cells or PA317 cells, which package retrovirus.
  • Viral vectors used in gene therapy are usually generated by a producer cell line that packages a nucleic acid vector into a viral particle. The vectors typically contain the minimal viral sequences required for packaging and subsequent integration into a host (if applicable), other viral sequences being replaced by an expression cassette encoding the protein to be expressed. The missing viral functions are supplied in trans by the packaging cell line.
  • AAV vectors used in gene therapy typically only possess inverted terminal repeat (ITR) sequences from the AAV genome which are required for packaging and integration into the host genome.
  • ITR inverted terminal repeat
  • Viral DNA is packaged in a cell line, which contains a helper plasmid encoding the other AAV genes, namely rep and cap, but lacking ITR sequences.
  • the cell line is also infected with adenovirus as a helper.
  • the helper virus promotes replication of the AAV vector and expression of AAV genes from the helper plasmid.
  • the helper plasmid is not packaged in significant amounts due to a lack of ITR sequences. Contamination with adenovirus can be reduced by, e.g., heat treatment to which adenovirus is more sensitive than AAV.
  • the gene therapy vector be delivered with a high degree of specificity to a particular tissue type.
  • a viral vector can be modified to have specificity for a given cell type by expressing a ligand as a fusion protein with a viral coat protein on the outer surface of the virus.
  • the ligand is chosen to have affinity for a receptor known to be present on the cell type of interest.
  • Han et al Proc. Natl. Acad. Sci. USA 92:91 T - 9751 (1995), reported that Moloney mouse leukemia virus can be modified to express human heregulin fused to gp70, and the recombinant virus infects certain human breast cancer cells expressing human epidermal growth factor receptor.
  • filamentous phage can be engineered to display antibody fragments (e.g., FAB or Fv) having specific binding affinity for virtually any chosen cellular receptor.
  • Gene therapy vectors can be delivered in vivo by administration to an individual patient, typically by systemic administration (e.g., intravenous,
  • vectors can be delivered to cells ex vivo, such as cells explanted from an individual patient (e.g., lymphocytes, bone marrow aspirates, tissue biopsy) or universal donor hematopoietic stem cells, followed by reimplantation of the cells into a patient, usually after selection for cells which have incorporated the vector.
  • cells are isolated from the subject organism, transfected with a ZFP, TALE or CRISPR/Cas system nucleic acid (gene. cDNA or mRNA), and re-infused back into the subject organism (e.g., patient).
  • a ZFP ZFP
  • TALE CRISPR/Cas system nucleic acid
  • one or more nucleic acids are delivered as mRNA.
  • capped mRNAs to increase translational efficiency and/or mRNA stability.
  • ARCA anti-reverse cap analog
  • stem cells are used in ex vivo procedures for cell transfection and gene therapy.
  • the advantage to using stem cells is that they can be differentiated into other cell types in vitro, or can be introduced into a mammal (such as the donor of the cells) where they will engraft in the bone marrow.
  • Methods for differentiating CD34+ cells in vitro into clinically important immune cell types using cytokines such a GM-CSF, IFN- ⁇ and TNF-a are known (see Inaba et al, J. Exp. Med. 176: 1693-1702 (1992)).
  • Stem cells are isolated for transduction and differentiation using known methods. For example, stem cells are isolated from bone marrow cells by panning the bone marrow cells with antibodies which bind unwanted cells, such as CD4+ and CD8+ (T cells), CD45+ (panB cells), GR-1 (granulocytes), and lad (differentiated antigen presenting cells) (see Inaba et al, J. Exp. Med. 176:1693-1702 (1992)).
  • T cells CD4+ and CD8+
  • CD45+ panB cells
  • GR-1 granulocytes
  • lad differentiated antigen presenting cells
  • Stem cells that have been modified may also be used in some embodiments.
  • neuronal stem cells that have been made resistant to apoptosis may be used as therapeutic compositions where the stem cells also contain the ZFP TFs of the invention. Resistance to apoptosis may come about, for example, by knocking out BAX and/or BAK using BAX- or BAK-specific TALENs or ZFNs (see, U.S. Patent Publication No. 20100003756) in the stem cells, or those that are disrupted in a caspase, again using caspase-6 specific ZFNs for example. These cells can be transfected with the ZFP TFs or TALE TFs that are known to regulate mutant or wild-type Htt.
  • Vectors e.g., retroviruses, adenoviruses, liposomes, etc.
  • therapeutic ZFP nucleic acids can also be administered directly to an organism for transduction of cells in vivo.
  • naked DNA can be admimstered.
  • Administration is by any of the routes normally used for introducing a molecule into ultimate contact with blood or tissue cells including, but not limited to, injection, infusion, topical application and electroporation. Suitable methods of administering such nucleic acids are available and well known to those of skill in the art, and, although more than one route can be used to administer a particular composition, a particular route can often provide a more immediate and more effective reaction than another route.
  • Methods for introduction of DNA into hematopoietic stem cells are disclosed, for example, in U.S. Patent No. 5,928,638.
  • Vectors useful for introduction of transgenes into hematopoietic stem cells include adenovirus Type 35.
  • T-cells include non-integrating lentivirus vectors. See, for example, Ory et al. (1996) Proc. Natl. Acad. Sci. USA 93: 11382-11388; Dull er al. (1998) J. Virol. 72:8463- 8471; Zuffery et al. (1998) J Virol. 72:9873-9880; Follenzi et al. (2000) Nature Genetics 25:217-222.
  • compositions are determined in part by the particular composition being admimstered, as well as by the particular method used to administer the composition. Accordingly, there is a wide variety of suitable formulations of pharmaceutical compositions available, as described below (see, e.g., Remington 's Pharmaceutical Sciences, 17th ed., 1989).
  • the disclosed methods and compositions can be used in any type of cell including, but not limited to, prokaryotic cells, fungal cells, Archaeal cells, plant cells, insect cells, animal cells, vertebrate cells, mammalian cells and human cells.
  • Suitable cell lines for protein expression are known to those of skill in the art and include, but are not limited to COS, CHO (e.g. , CHO-S, CHO-K1, CHO-DG44, CHO-DUXB11), VE O, MDCK, WI38, V79, B14AF28-G3, BH ,
  • HEK293 e.g. , HEK293-F, HEK293-H, HEK293-T
  • perC6 insect cells such as Spodoptera fugiperda (Sf)
  • Sf Spodoptera fugiperda
  • fungal cells such as Saccharomyces, Pischia and Schizosaccharomyces . Progeny, variants and derivatives of these cell lines can also be used.
  • compositions and methods can be used for any application in which it is desired to modulate the Htt allele, including but not limited to, therapeutic and research applications.
  • Htt repressing ZFP TFs or TALE TFs can be used as therapeutic agents include, but are not limited to, Huntington's disease. Additionally, methods and compositions comprising ZFNs or TALENs specific for mutant alleles of Htt can be used as a therapeutic for the treatment of Huntington's disease.
  • ZFP-TFs or TALE TFs that repress a HD Htt allele may also be used in conjunction with ZFP-TFs or TALE-TFs that activate neutrotrophic factors including, but not limited to, GDNF and BDNF.
  • ZFPs or TALEs or polynucleotides encoding these ZFPs or TALEs
  • Methods and compositions for the treatment of Huntington's disease also include stem cell compositions wherein a mutant copy of the Htt allele within the stem cells has been modified to a wild-type Htt allele using a Htt-specific ZFN or TALEN.
  • the methods and compositions of the invention are also useful for the design and implementation of in vitro and in vivo models, for example, animal models of trinucleotide repeate disorders, which allows for the study of these disorders.
  • suitable in vitro models include cells or cell lines from any organism, including fibroblasts.
  • suitable animals for use as animal models include, invertebrates (C. elegans, drosophila), rodents (e.g., rat or mouse), primates (e.g., non-human primates).
  • Example 1 Design and Construction of Htt-targeted zinc finger protein transcription factors (ZFP-TFs) and ZFNs
  • Zinc finger proteins targeted to Htt were engineered essentially as described in U.S. Patent No. 6,534,261.
  • Tables 1A and IB show the recognition helices of the DNA binding domain of exemplary Htt-targeted ZFPs, while Tables 2A and 2B show the target sequences of these ZFPs.
  • ZFPs with one contiguous array of zinc fingers were designed to target sites completely within the CAG repeat region ( Figure IB). Such ZFPs may bind longer, mutant tracts with higher affinity and/or a higher net occupancy, achieving selective repression of the mutant allele. ZFNs were also designed that targeted sites which lay partially or wholly outside of the CAG region ( Figure 1 A), and which will therefore bind to the wild type and mutant allele equally, and regulate expression from both alleles with similar efficiency.
  • a set of one- and two-finger modules can be employed in a 'mix and match' combination. Those modules are shown below in Table 2C.
  • Table 2C Zinc finger recognition helices used in ZFP-TFs targeting CAG repeats
  • Target site F2 F3 (F2+F3)
  • CAG RSANLRE none 176
  • CAG RNADRKK none 177
  • Multimerizing ZFP TFs are also constructed as described above except that the vector also contains sequences encoding 1 or more protein interaction domains (also called dimerization or protein interaction domains) that enable multimerization of the expressed protein along a tract of trinucleotide repeats that is operably linked to the sequences encoding the ZFP TF.
  • Table 3 shows dimerization domain designs that are used with ZFPs targeted to the CAG repeat region.
  • Figure 10C shows protein sequences of the four ZFP monomer scaffolds that are designed to multimerize via interactions between dimerizing zinc fingers (DZ), DZ1 - DZ4. Designs are based on work described in Mol. Syst. Biol. (2006) 2:2006.2011.
  • Figure 10D shows protein sequences of the seven ZFP monomer scaffolds that are designed to multimerize via interactions between coiled-coils (CC), CC1 - CC7.
  • CC#1 coiled-coils
  • CC#2 CC#3 and CC#4 are based on (J Am. Chem. Soc. (2000), 122:5658-5659).
  • CC and DZ domains allow the ZFP to polymerize within the major groove of a CAG tract (depicted in figure 10B). By choosing a finger array and dimerization domains with appropriate binding properties, efficient binding will occur only to the expanded CAG tract of a disease allele.
  • ZFP-TFs were constructed as fusion proteins comprising a nuclear localization sequence, the engineered zinc finger DNA-binding domain (Tables 1 A and IB), targeted to the Htt allele, and a KRAB repression domain from the human KOX1 protein. See, Fig 1 A, IB and ID.
  • the designed DNA-binding domains contain 3-6 finger modules, recognizing 9-18 bp sequences (Tables 2A and 2B). Nucleotides in the target site that are contacted by the ZFP recognition helices are indicated in uppercase letters; non-contacted nucleotides indicated in lowercase.
  • ZFP-ZFP-TF molecules were also constructed where two ZFP DNA binding domains were fused with a flexible linker and fused to a K AB repression domain ( Figure IE). DNA binding domains were chosen from Tables 2 A and 2B.
  • Example 2 Repression of both alleles of Htt in human and mouse cells.
  • ZFPs were designed to bind to the Htt promoter and exon 1 region, wherein the target site was not entirely within the CAG repeat. See, Figure 1 A.
  • the ZFP TFs were transfected into human cells and expression of Htt was monitored using real-time RT-PCR.
  • Human HEK293 cells (Graham et al (1977) J Gen Virol 36 :59-74) were cultured in DMEM supplemented with 10% FBS and le 5 cells were transfected with 1 ⁇ g of plasmid DNA encoding indicated ZFP-KOX fusions by Amaxa
  • Htt endogenous human Huntingtin
  • ACTB normalization control beta-actin
  • Lipofectamine® 2000 kit (Invitrogen) according to manufacturer's protocols. mHtt and ACTB mRNA levels were measured at 48 hours after transfection using ABI Taqman® primer/probe set Mm01213820 ml and 4352933E, respectively.
  • mHtt/ ACTB ratios for ZFP transfected samples were normalized to that of the GFP control (set as 1).
  • mouse Htt-specific ZFP-TF repressors can repress mouse Htt in
  • mRNA for indicated ZFPs were generated using the mMessage mMachine kit (Ambion), and 0.1 , 0.5 or 2 ug of these mRNAs were transfected using Amaxa nucleofector as described above. Cells were harvested 48 hours after transfection for mHtt and ACTB expression analysis as described above. More significant repression in the striatal cells compared to that in Neuro2A cells was observed and may be a result of enhanced transfection efficiency achieved via mRNA transfection in straital cells.
  • ZFPs were designed to bind within the CAG repeat.
  • Figure 1 B shows one type of such ZFPs, with a contiguous array of zinc fingers linked to a repression domain (e.g. the KRAB domain from KOX1); these ZFPs can be designed with appropriate affinity such that threshold occupancy required from transcriptional repression can only be established on expanded CAG repeats.
  • Figures 1C, ID and IE show threeother examples of ZFP design that can allow specific binding to the expanded CAG repeats.
  • Htt human Huntingtin
  • ACTB internal control beta-actin
  • FIG. 3A ZFP repressors (fused with KRAB repression domain) designed to bind to CAG repeats (Figure IB), either to top or bottom strand, in HEK293 cells, effectively repressed Htt expression.
  • Figure 3A depicts repressors of transcription where expression was measure in duplicate transfections (separate bars in the Figure) and multiple real-time PCR assays completed (error bars).
  • promoter/exon 1 fragment that contains different CAG repeat lengths were constructed.
  • the human Htt promoter/exon 1 fragment was amplified from HEK293 genomic DNA using forward primer:
  • the forward primer introduces a Bglll site
  • the reverse primer changes the first ATG of Htt into TAG and creates an Avrll site, and also includes a Hindlll site.
  • the PCR product was digested with Bglll and Hindlll and ligated to pRL-TK vector (Promega) that was digested with the same enzymes to generate the construct pRL-Htt.
  • the human Htt exonl fragment (coding sequence minus first ATG) was amplified from HEK293 genomic DNA or genomic DNA from HD patients with expanded CAG repeats using forward primer:
  • the forward primer introduces an Avrll site
  • the reverse primer introduces a Hindlll site.
  • the PCR product was digested with Avrll and Hindlll and ligated to pRL-Htt vector that was digested with the same enzymes. Clones with 10, 17, 23 or 47 CAG repeats (pRL-Htt-CAG(x)) were identified by sequencing.
  • pRL-Htt-C AG(x) reporters 300 ng
  • pGL3 -promoter reporter lOOng, used as normalization control, Progema
  • Firefly (pGL reporter) and renilla (pRT reporter) luciferase activities were measured 24 hours after transfection. Renilla luciferase levels were normalized to those of firefly luciferase from the same transfected sample, and further normalized to the renilla/firefly ratio of the "reporter only" sample.
  • TF 30640 increases with the length of the CAG repeat, suggesting that ZFPs with DNA binding affinities similar to that of 30640 can repress Htt promoter activity via an expanded CAG repeat, and the level of repression is dependent on the CAG repeat lengths.
  • Figure 3C shows a similar experiment as in Figure 3B, except the
  • FIG. 3D shows ZFP-TFs 30640 and 30657 (fused to the KRAB repression domain of KOX1) can repress the knock-in Htt allele (CAG111) in immortalized striatal cells derived from the Hdh(Ql 11/Q7) knock-in mice, demonstrating the ZFPs such as 30640, which drives CAG repeat length-dependent repression of luciferase reporters, can also repress expression from an endogenous Htt allele that has expanded CAG repeat.
  • mRNA for indicated ZFPs were generated using the mMessage mMachine kit (Ambion), and transfected into Hdh(Ql 11/Q7) cells at indicated doses using Amaxa nucleofector.
  • forward primer CAGGTCCGGCAGAGGAACC SEQ ID NO: 193
  • reverse primer TTCACACGGTCTTTCTTGGTGG SEQ ID NO: 194
  • TTCACACGGTCTTTCTTGGTGG (SEQ ID NO: 196) were used.
  • Figure 3E show the result of testing the ZFP-TFs 30640 and 30657 in an HD patient-derived fibroblast line (GM21756, Coriell) that has 15 and 70 CAGs on the normal and mutant Htt allele, respectively.
  • a SNP -based allele-specific real-time PCR assay was first established to allow specific detection from the wild type or the mutant Htt allele. The phasing of the SNP (rs363099 T/C) was determined by Carroll et al. Mol Ther. (2011) 19:2178-85); "T” is on the normal allele and "C” is on the mutant allele.
  • cDNA from the fibroblast was amplified by real-time PGR (SsoFast EvaGreen Supermix, Bio-Rad) using forward primer 099C.F (5 'AGTTTGGAGGGTTTCTC, SEQ ID NO:143) and reverse primer 099.R5 (5' TCGACTAAAGCAGGATTTCAGG, SEQ ID NO: 144); the annealing/extension temperature was 55.6 °C.
  • Fig.3 A ZFP 30640, which showed CAG repeat length-dependent repression of the reporters, gave ⁇ 10% repression of the wild-type allele while repressed the mutant allele >90%.
  • the levels of total Htt in each sample were consistent with those of wt and mutant Htt levels in the same sample.
  • ZFP-30640 was also tested in a normal fibroblast line as well as other
  • HD fibroblast lines that contain different CAG repeat length in the Htt gene (see Figure 3F). Htt expression from each allele was detected as described above. No Htt repression was observed in the normal fibroblast line (CAG18/18). In contrast, excellent allelic discrimination was observed in the CAG 15/67 and CAG15/70 lines at both a high and low dose of transfected 30640 mRNA ; similar results were obtain for the two HD fibroblast lines with intermediate CAG repeat length on the mutant allele (CAG 18/44 and CAG 18/45) - wherein the expanded allele is repressed by -80% at both the high and low doses of 30640, yet the CAG18 allele remained unaffected. Taken together, these data indicate that allele-specific repressors such as 30640 can maintain strong CAG allele length selectivity in the context of more prevalent disease genotypes such as CAG18/44 and CAG18/45.
  • ZFPs such as 30640 selectively down-regulated mutant Htt protein levels in two patient-derived fibroblast lines, confirming allele-specific regulation that was shown by qPCR assays (see Figure 3G).
  • ZFPs were delivered by mRNA transfection (Amaxa nucleofection) at a 300 ng dose into 4 replicates of 1.5e5 cells and pooled prior to plating in 12-well plates. At 48 hours, cells were washed and harvested for protein extract preparation. Approximately 2.5 ug of extract was loaded onto 5% Tris-acetate gels and detected by MAB2166 (Millipore).
  • Figure 4A shows the results of testing ZFP-TFs 30640, 30643, 30645 and 33074 (all targeted to the CAG repeat and uses the RAB repression domain) in a CAG18/45 HD fibroblast line.
  • Different amounts of ZFP mRNA were transfected using Amaxa nucleofector as indicated, expression of the mutant Htt (right bar), wild type Htt (middle bar) and total Htt (both alleles, left bar) were measured as described above at 24 hours after transfection.
  • ZFPs 30640, 30645 and 33074 drive allele- specific repression over the entire 3 ug - 10 ng ZFP mRNA dose range; while 30643 appears to repress both alleles significantly at doses that are 30 ng or higher, and begins to exhibit allele selectivity at the 10 ng dose.
  • Figure 4B shows the results of testing ZFP 30643, 30648, 30657 and
  • CAG repeat containing genes was analyzed, and the results are depicted in Figure 5.
  • the expression levels of the following genes was examined using real-time PCR and normalized to that of Actin: Ataxin 2 ("ATXN2”); Dynamin (“DNM1”); F-box only protein 11 (“FBXOH”), nitrate reductase (“NAP”); Origin recognition complex subunit 4 ("ORC4"); phosphokinase ("PHK”); OCT3/4 protein (“POU3”); THAP domain containing, apoptosis associated protein 2 (" ⁇ ”); TATA binding protein (“TBP”); and stanniocalcin 1("STC1").
  • TSS transcriptional start site
  • HD fibroblasts (CAG18/45) were transfected to study genome-wide specificity of CAG-targeted ZFPs by microarray analysis ( Figure 6).
  • ZFPs were delivered by rnRNA transfection (Amaxa nucleofection) at the indicated doses - ZFPs 30640, 30645 and 33074 were transfected in sextuplicate at the 75 ng, 15 ng and 15 ng dose, respectively;
  • GFP-Kox mRNA 150 ng was transfected as a control, and was used as carrier to bring the total amount of transfected mRNA to 150 ng in all samples.
  • HGU133plus2.0 as follows: GFP replicate 1, 3, 4 and 6; 30640 replicate 2, 3, 5 and 6; 30645 replicate 2, 3, 5 and 6; and 33074 replicate 1, 3, 4 and 5 were used for microarray analysis.
  • Robust Multi-array Average (RMA) was used to normalize raw signals from each probe set; ZFP-transfected samples were compared to GFP- transfected samples using T-test; "change" calls were made on genes (probe sets) with >2 fold difference relative to control samples and T-test P-value ⁇ 0.05.
  • Htt was not detected as a repressed (>2-fold repression) gene because the Htt probe set on the array detects both wt and mutant Htt mRNA. This experiment demonstrates that mutant Htt-specific ZFPs, when expressed at levels that drive efficient allele-specific repression of Htt, can operate with very high specificity genome- wide.
  • HD iPSC/ESCs were passaged with accutase and cultured on matrigel coated plates in E8 media (Life Technologies).
  • Neural stem cells were derived using StemPro Neural Induction Medium (Life Technologies). Briefly, iPSC/ESCs were seeded into geltrex coated 6 well dish with 200,000 cells/well and when 10-20% confluent the medium was changed to StemPro Neural Induction Medium. Medium was changed every 2 days and NSC harvested and expanded on day 7. StemPro NSC SFM medium (Life Technologies) was used to culture NSCs.
  • HD NSCs (CAGl 7/69, derived from Coriell GM23225 iPSC) were transfected with 1.5 or 0.5 ⁇ g ZFP mRNA using nucleofection. Forty-eight hours post transfection cells were harvested and expression quantified by RT-PCR. Allele-specific detection of Htt expression was performed using a SNP (rsl 143646)-based genotyping assay #4351376 (Applied Biosystems).
  • Example 8 Htt repression in differentiated HD neurons
  • HD NSCs were passaged with accutase on geltrex coated plates.
  • Neuron differentiation was induced by changing medium to neural differentiation medium containing StemPRO NSC SFM medium without (bFGF and EGF). Medium was changed every 3-4 days for up to 21 days. Neurons were derived from NSC
  • Example 9 A CAG targeted repressor represses mutant Htt transgene in R6/2 mice
  • -120 CAG repeat see Mangiarini et al, (1996) Cell 15:197) received stereotactic, bilateral striatal injections of 3el0 vector genome of recombinant AAV2/6 encoding either ZFP 30640-KOX or GFP driven by a CMV promoter. Mice were injected at 5 weeks of age and sacrificed for molecular analysis at 8 weeks of age. Left and rightstriata were dissected from each hemisphere and snap frozen. To assess repression of the mutant Htt transgene, total RNA was extracted from each striatum with TRIzol Plus (Life Technologies) followed by cDNA synthesis using High Capacity RT (Life Technologies).
  • dimerization domains can interact in a "parallel” fashion and yield "head-to-head” or "tail-to-tail” dimers of fusion proteins that contain them.
  • One potential dimerization strategy requires an array of identical ZFP-transcription factor fusions that bind in a "head-to-tail” orientation and thus this strategy requires dimerization domains that interact in an "anti-parallel” fashion. See, e.g., McClain et al. (2001) J Am. Chem. Soc. 123:3151-3152) and dimerizing zinc finger peptides (Giesecke et al. (2006), Molecular Systems Biology 2:2006.2011).
  • Dimerization contracts CC1 and CC2 were based on pairs of antiparallel coiled coils (McClain et al , ibid, Ghosh et al. (2000) J Am Chem Soc 122:5658-5659). Dimerization constructs CC3 and CC4 were truncated versions of CC2 that lack either 4 residues or 7 residues respectively. Dimerization constructs DZ1 , DZ2, DZ3, and DZ4 were based on pairs of dimerizing zinc finger domains (Giesecke et al, ibid).
  • one member of the pair was fused to the N- terminus of the zinc finger DNA binding domain and the other member of the pair was fused to the C-terminus of the zinc finger DNA binding domain.
  • Short linkers rich in glycine and serine residues were used to fuse the dimerization domains to the zinc finger binding domain.
  • Additional embodiments of the invention utilize linkers with alternate lengths and/or amino acid composition. Linkers with one or more residues removed or with one or more glycine or serine residues changes to other amino acid residues will reduce the flexibility of these linkers and may result in improved discrimination between long and short CAG repeats.
  • ZFPs were designed as illustrated in Figure ID and Figure 10A and 4B.
  • Figure I OC and 10D show the sequences of the multimerization domains.
  • Figure 11A and 1 IB depict the results that experiments designed to measure the ability of the ZFP-TFs comprising the CC and DZ domains, respectively to repress their targets.
  • indicated ZFP constructs 50 ng were co-transfected with pRL-Htt-CAG17 (200ng), pGL3-Htt-CAG47 (200ng) and pVax-SEAP (secreted alkaline phosphatase, 10 ng, used as normalization control) into HEK293 cells.
  • Luciferase activity and secreted alkaline phosphatase activities were measured 24 hours after transfection.
  • the Renilla luciferase (CAG17)/SEAP and firefly luciferase (CAG47)/SEAP ratios for each sample were normalized to those of the reporter-only samples.
  • the pGL3-Htt- CAG47 reporter was constructed in the same way as the pRL-Htt-CAG47 reporter (see Example 3), except the pGL-promoter construct (Promega) was used instead of the pRL-TK construct.
  • ZFP TFs were tested in HD fibroblasts that were of the ZFP-ZFP-KOX design.
  • the two ZFP DNA binding domains were linked together with a flexible linker (LRQKDAARGSAAMAERP FQ, SEQ ID NO: 179) and fused to a KOX repression domain.
  • the linker was placed between the conserved histidines and cysteines.
  • the proteins were tested as described above using ZFP mPvNA at indicated doses.
  • ZFPs as described herein were also evaluated for their ability to activate Htt expression.
  • ZFPs targeted to the +200 to +467 bp region (relative to the transcription start site) of mouse Htt were fused to the transcriptional activation domain of NFKB p65 subunit. This targeting region was chosen because this fragment was replaced by the corresponding sequence (majority of exon 1 and some intron 1 sequence) from human Htt in various knock-in mouse models of HD
  • ZFPs targeted to this region can selectively activate the wild type allele in those animals but not the knock-in allele.
  • ZFPs were transfected into Neuro2A cells (both Htt alleles are wild type in these cells), mouse Htt and ACTB mRNA levels were measured as described in Example 2 (duplicate transfections and multiple assays).
  • FIG. 13C The generation of the knock-in Htt allele is illustrated in Figure 13C; sequence alignment ( Figure 13D) shows divergence between the mouse sequence that was replaced and the corresponding human sequence.
  • Figure 13E shows that when such ZFP activators were transfected into immortalized striatal cells derived from HdhQl 11/Q7 knock-in mice, only the wild type Htt was selectively activated.
  • Example 13 Regulation of Htt expression in vivo
  • AAV2 vectors encoding the ZFPs are produced. These AAV2 based constructs are then delivered to the brains of mice.
  • AAV vectors are delivered to R6.2 mice or BAC HD mice (C57B1/6 or FVB/N strains) to assess the repression of the human transgene, as well as change in HD-like phenotypes.
  • AAV vectors are delivered to wild-type mice (C57B1/6 or FVB/N) or human Htt knock-in mice (HdhQl 11/Q7, HdhQ140/Q7 or HdhQ175/Q7) to assess the activation or repression of the endogenous mouse Htt expression.
  • AAV vectors are delivered to R6.2 mice or human Htt knock-in mice (HdhQl 1 1/Q7, HdhQl 40/Q7 or HdhQl 75/Q7) to examine the selective repression of wt vs.
  • Htt allele Following sacrifice, brain tissues are analyzed for Htt expression by Taqman real-time RT-PCR, and demonstrate that the Htt genes are modulated by ZFP-TFs.
  • Example 14 Co-transfection of a neurotrophic factor and a HD Htt allele-specific ZFP TF
  • the Htt-specific ZFP TFs identified above are co-transfected with ZFP TFs-specific for a brain neurotrophic factor.
  • the ZFP TF specific for brain neurotrophic factors used are specific for either GDNF or BDNF.
  • Example 15 Design and Construction of Htt-targeted zinc finger nucleases (ZFNs)
  • ZFNs targeting human Htt and mouse Htt were designed to target the sequences flanking the CAG repeats, sequences near the first coding ATG, the stop codon, as well as in early exons. ZFNs were designed and incorporated into plasmids or adenoviral vectors essentially as described in Urnov et al. (2005) Nature
  • K562 cells were obtained from the American Type Culture Collection and grown as recommended in F-12 medium (Invitrogen) supplemented with 10% qualified fetal calf serum (FCS, Cyclone). Cells were disassociated from plastic ware using TrypLE SelectTM protease (Invitrogen). For transfection, one million K562 cells were mixed with 2 ⁇ g of the zinc-finger nuclease plasmid and ⁇ , Amaxa Solution T. Cells were transfected in an Amaxa Nucleofector IITM using program U-23 and recovered into 1.4mL warm F- 12 medium + 10% FCS.
  • FCS fetal calf serum
  • Genomic DNA was harvested and a portion of the Hit locus encompassing the intended cleavage site was PCR amplified. PCR using the
  • Accuprime HiFi polymerase from InVitrogen was performed as follows: after an initial 3 minute denaturation at 94°C, 30 cycles of PCR are performed with a 30 second denaturation step at 94°C followed by a 30 second annealing step at 58°C followed by a 30 second extension step at 68°C. After the completion of 30 cycles, the reaction was incubated at 68°C for 7 minutes, then at 10°C indefinitely.
  • Plasmids encoding the pairs of mouse Htt-specific ZFNs were tested in similar fashion in Neuro-2a cells.
  • Figure 14A and B show that the ZFNs were capable of targeting the
  • Htt genes with a gene modification efficiency of between 8-40%, assayed as described previously by the amount of indels observed.
  • Example 17 Targeted integration of varying lengths of trinucleotide repeats
  • Htt-specific ZFNs with the greatest cleaving activity for sequences flanking the CAG repeat as described above are used in a targeted integration strategy to introduce varying lengths of CAG repeat into a wild-type copy of Htt.
  • Donors are constructed that contain 50, 80, 109 and 180 repeat CAG units. These donors are then transfected into K562 cells with plasmids encoding the Htt-specific ZFNs as described above. Verification of donor integration is achieved by genomic DNA isolation, PCR amplification (as described above) followed by sequencing of the region of interest.
  • ZFNs identified in the K562 cells which result in targeted integration of the donor alleles into the Htt allele are used to insert the variable length donor nucleic acids into human embryonic stem cells (hESC). Successful donor integration is verified by genomic DNA isolation, PCR and sequencing as described above.
  • Example 18 Disruption/knock-out of wild-type and/or mutant Htt
  • ZFNs that cleave in early exons can result in small insertion or deletions (in-dels) as a result non-homologous end joining (NHEJ), this can generate cell models with one or both alleles of Htt disrupted,
  • [0215J Indicated ZFN pairs were prepared as described above and tested for cleavage activity using the Cel I mismatch as described for Example 8. These ZFN pairs target early exons of human Htt, and thus may be used to knock-out either the wild-type or a mutant Htt allele.
  • Example 19 Expression tagging of wild-type and HD Htt alleles.
  • ZFNs with the greatest cleaving activity for the first or last coding exon are used to tag the wild-type and mutant Htt allele with different reporter proteins.
  • Donor DNAs for each reporter (A and B) are designed based on the cleavage site of the lead ZFN pair(s) to allow targeted integration of the reporter gene to produce an in-frame fusion to Htt.
  • Donor DNAs are co-transfected with the lead ZFN pair(s) into K562 cells for selecting the donor DNA construct that gives the highest frequency of integration.
  • ZFN pairs were prepared as described above and tested for cleavage activity using the Cel I mismatch as described for Example 8.
  • the ZFN pairs used target the 3' end of the Htt coding sequence, and thus may be used to target either a wild-type or a mutant Htt allele.
  • ZFP pairs 25917/25916, 25920/25921 and 25923/25922 were capable of cleaving the Htt gene and can thus be utilized for the introduction of a reporter tag.
  • the selected donor DNA construct for reporter A along with corresponding ZFNs are delivered to cells derived from subjects carrying mutant Htt gene (e.g.
  • Clones are derived and screened for the target integration of the reporter A. Heterozygous events are desired and the targeted alleles are identified by PGR. Clones containing a single reporter-tagged Htt allele and unmodified ZFN target sequence on the other allele are selected; the donor construct for reporter B and corresponding ZFNs are transfected to tag the second allele with the reporter B.
  • the resulting mouse embryonic stem cell clone contains the wild-type Htt allele and mutant allele tagged with two different markers that allow tracking of expression from each allele; these cells are used to generate mouse models of trinucleotide repeat disorders using standard protocols.
  • TALE DNA binding domains were linked to the KRAB repression domain from the Koxl protein (TALE TF) and used to test repression of the Htt gene in HD patient (CAG 20/41)-derived fibroblasts.
  • TALE TF Koxl protein
  • the construction of the TALE proteins was done as described previously (see co-owned US Patent publication 20110301073 and co-owned US Patent application 13/679,684, both of which are incorporated herein by reference), and were constructed with three different C- terminal architectures: +63, +231 and +278 as described in US20110301073.
  • the TALEN expression plasmids described previously were used except that the Fokl domain used for in the TALENs was replaced with the KRAB repression domain.
  • the linkages of the C-terminus of the TALE protein and the KRAB domain are shown below, where the KRAB domain sequence is indicated by underline.
  • the bold and italicized text indicates the triple flag tag, the bold text indicates the nuclear localization sequence, "[repeats]" indicates the location of the TALE repeat unit array (full repeats plus the C-terminal half repeat), and the wavy underlined portion shows the sequence of the KRAB domain:
  • AERGGVTAVEAVHAWRNALTGAPLN [repeats ] GGRPALESIVAQLSRPDPALAALTNDHLVALACLGGRP LP AVKKGLPHAPALIKRTHRRIPERTSHRVaGSGMDAKSLTAWSRTLVTFKDVFVDFTREEWKLLDTAQQIVYRNVM
  • TALE code NI for A, HD for C, NN for G (NK in half repeat), NG for T.
  • the protein is designed to bind the sense (5 '-3') strand of the DNA, while in others, the TALE TF is designed to bind to the anti-sense (3 '-5') strand.
  • This set of TALE TFs was designed to target the CAG repeats of the Htt gene.
  • TALE DNA binding proteins often preferentially interact with a 'T' nucleotide base at the 5' end of the target, and so since the targets are CAG repeat regions, it can be predicted that the proteins that bind to the anti-sense DNA strand, and thus CTG repeat sequences with the base 'T' at the 5' 3nd of the target, might have better binding affinity and specificity and thus repressor activity.
  • SBS# specificity for the Sense or Antisense strand is indicated (“S/A), as well as the target, the number of repeat units or RVDs and the type of C-terminus.
  • S/A specificity for the Sense or Antisense strand is indicated
  • the TALE TFs in the table were then tested for Htt repression in HD patient (CAG 20/41) derived fibroblasts, and the results are shown in Figure 15.
  • the cells were transfected with either 1000, 100 or 10 ng of TALE-TF encoding mKNA.
  • the results for each TALE TF assayed are shown in groups of three, representing the three transfected mRNA amounts. In each grouping, there are also three samples: the left bar indicates the total Htt expression, the middle bar indicates the expression from the CAG20 Htt allele, and the right bar indicates the expression from the CAG41 Htt allele.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Disclosed herein are methods and compositions for treating or preventing Huntington's Disease.

Description

METHODS AND COMPOSITIONS FOR TREATING HUNTINGTON'S
DISEASE CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] The present application claims the benefit of U.S. Provisional
Application No. 61/605,028, filed February 29, 2012, the disclosure of which is hereby incorporated by reference in its entirety. TECHNICAL FIELD
[0002] The present disclosure is in the fields of gene expression and genome editing.
BACKGROUND
[0003] Huntington's Disease (HD), also known as Huntington's Chorea, is a progressive disorder of motor, cognitive and psychiatric disturbances. The mean age of onset for this disease is age 35-44 years, although in about 10% of cases, onset occurs prior to age 21, and the average lifespan post-diagnosis of the disease is 15-18 years. Prevalence is about 3 to 7 among 100,000 people of western European descent.
[0004] Huntington's Disease is an example of a trinucleotide repeat expansion disorders were first characterized in the early 1990s {see Di Prospero and Fischbeck (2005) Nature Reviews Genetics 6:756-765). These disorders involve the localized expansion of unstable repeats of sets of three nucleotides and can result in loss of function of the gene in which the expanded repeat resides, a gain of toxic function, or both. Trinucleotide repeats can be located in any part of the gene, including non- coding and coding gene regions. Repeats located within the coding regions typically involve either a repeated glutamine encoding triplet (CAG) or an alanine encoding triplet (CGA). Expanded repeat regions within non-coding sequences can lead to aberrant expression of the gene while expanded repeats within coding regions (also known as codon reiteration disorders) may cause mis-folding and protein aggregation. The exact cause of the pathophysiology associated with the aberrant proteins is often not known. Typically, in the wild-type genes that are subject to trinucleotide expansion, these regions contain a variable number of repeat sequences in the normal population, but in the afflicted populations, the number of repeats can increase from a doubling to a log order increase in the number of repeats. In HD, repeats are inserted within the N terminal coding region of the large cytosolic protein Huntingtin (Htt). Normal Htt alleles contain 15-20 CAG repeats, while alleles containing 35 or more repeats can be considered potentially HD causing alleles and confer risk for developing the disease. Alleles containing 36-39 repeats are considered incompletely penetrant, and those individuals harboring those alleles may or may not develop the disease (or may develop symptoms later in life) while alleles containing 40 repeats or more are considered completely penetrant. In fact, no asymptomatic persons containing HD alleles with this many repeats have been reported. Those individuals with juvenile onset HD (<21 years of age) are often found to have 60 or more CAG repeats. In addition to an increase in CAG repeats, it has also been shown that HD can involve +1 and +2 frameshifts within the repeat sequences such that the region will encode a poly-serine polypeptide (encoded by AGC repeats in the case of a +1 frameshift) track rather than poly-glutamine (Davies and Rubinsztein (2006) Journal of Medical Genetics : 893-896).
[0005] In HD, the mutant Htt allele is usually inherited from one parent as a dominant trait. Any child born of a HD patient has a 50% chance of developing the disease if the other parent was not afflicted with the disorder. In some cases, a parent may have an intermediate HD allele and be asymptomatic while, due to repeat expansion, the child manifests the disease. In addition, the HD allele can also display a phenomenon known as anticipation wherein increasing severity or decreasing age of onset is observed over several generations due to the unstable nature of the repeat region during spermatogenesis.
[0006] Furthermore, trinucleotide expansion in Htt leads to neuronal loss in the medium spiny gamma-aminobutyric acid (GAB A) projection neurons in the striatum, with neuronal loss also occurring in the neocortex. Medium spiny neurons that contain enkephalin and that project to the external globus pallidum are more involved than neurons that contain substance P and project to the internal globus pallidum. Other brain areas greatly affected in people with Huntington's disease include the substantia nigra, cortical layers 3, 5, and 6, the CA1 region of the hippocampus, the angular gyrus in the parietal lobe, Purkinje cells of the cerebellum, lateral tuberal nuclei of the hypothalamus, and the centromedialparafascicular complex of the thalamus (Walker (2007) Lancet 369:218-228).
[0007] The role of the normal Htt protein is poorly understood, but it may be involved in neurogenesis, apoptotic cell death, and vesicle trafficking. In addition, there is evidence that wild-type Htt stimulates the production of brain-derived neurotrophic factor (BDNF), a pro-survival factor for the striatal neurons. It has been shown that progression of HD correlates with a decrease in BDNF expression in mouse models of HD (Zuccato et al (2005) Pharmacological Research 52(2): 133- 139), and that delivery of either BDNF or glial cell line-derived neurotrophic factor (GDNF) via adeno-associated viral (AAV) vector-mediated gene delivery may protect straital neurons in mouse models of HD (Kells et al, (2004) Molecular Therapy 9(5): 682-688).
[0008] Treatment options for HD are currently very limited. Some potential methodologies designed to prevent the toxicities associated with protein aggregation that occurs through the extended poly-glutamine tract such as overexpression of chaperonins or induction of the heat shock response with the compound geldanamycin have shown a reduction in these toxicities in in vitro models. Other treatments target the role of apoptosis in the clinical manifestations of the disease. For example, slowing of disease symptoms has been shown via blockage of caspase activity in animal models in the offspring of a pairing of mice where one parent contained a HD allele and the other parent had a dominant negative allele for caspase 1. Additionally, cleavage of mutant HD Htt by caspase may play a role in the pathogenicity of the disease. Transgenic mice carrying caspase-6 resistant mutant Htt were found to maintain normal neuronal function and did not develop striatal neurodegeneration as compared to mice carrying a non-caspase resistant mutant Htt allele (see Graham et al (2006) Cell 125: 1179-1191). Molecules which target members of the apoptotic pathway have also been shown to have a slowing affect on symptomology. For example, the compounds zVAD-fmk and minocycline, both of which inhibit caspase activity, have been shown to slow disease manifestation in mice. The drug
remacemide has also been used in small HD human trials because the compound was thought to prevent the binding of the mutant Htt to the NDMA receptor to prevent the exertion of toxic effects on the nerve cell. However, no statistically significant improvements were observed in neuron function in these trials. In addition, the Huntington Study Group conducted a randomized, double-blind study using Coenzyme Q. Although a trend towards slower disease progression among patients that were treated with coenzyme Q10 was observed, there was no significant change in the rate of decline of total functional capacity. (Di Prospero and Fischbeck, ibid). U.S. Patent Publication 201 1/0082093 discloses specific zinc finger proteins targeted to Htt.
100091 Thus, there remains a need for compositions and methods for the treatment and prevention of Huntington's Disease. SUMMARY
[0010] Disclosed herein are methods and compositions for treating
Huntington's Disease. In particular, provided herein are methods and compositions for modifying (e.g., modulating expression of) an HD Htt allele so as to treat Huntington Disease. Also provided are methods and compositions for generating animal models of Huntington' s Disease.
[0011] Thus, in one aspect, engineered DNA binding domains (e.g., zinc finger proteins or TAL effector (TALE) proteins) that modulate expression of a HD allele (e.g., Htt) are provided. Engineered zinc finger proteins or TALEs are non- naturally occurring zinc finger or TALE proteins whose DNA binding domains (e.g., recognition helices or RVDs) have been altered (e.g., by selection and/or rational design) to bind to a pre-selected target site. Any of the zinc finger proteins described herein may include 1 , 2, 3, 4, 5, 6 or more zinc fingers, each zinc finger having a recognition helix that binds to a target subsite in the selected sequence(s) (e.g., gene(s)). Similarly, any of the TALE proteins described herein may include any number of TALE RVDs. In some embodiments, at least one RVD has non-specific DNA binding. In some embodiments, at least one recognition helix (or RVD) is non- naturally occurring. In certain embodiments, the zinc finger proteins have the recognition helices shown in Tables 1 A and I B. In other embodiments, the zinc finger proteins bind to the target sequences shown in Tables 2 A and 2B. In some embodiments, the zinc finger proteins comprise the recognition helices in Table 2C. In certain embodiments, the zinc finger proteins are formulated into a pharmaceutical composition, for example, for administration to a subject. [0012] In one aspect, repressors (ZFP-TFs or TALE-TFs) are provided that bind to sequences entirely or partially outside the CAG repeat region of Htt. In another aspect, ZFP or TALE repressors ( ZFP-TFs or TALE-TFs) are provided that bind to sequences within CAG repeat region of Htt. In some embodiments, these ZFP-TFs or TALE-TFs preferentially bind to expanded trinucleotide tracts relative to repeat tracts of a wild-type length, thereby achieving preferential repression of the expanded allele. In some embodiments these ZFP-TFs or TALE-TFs include protein interaction domains (or "dimerization domains") that allow multimerization when bound to DNA. In some embodiments, these ZFP-TFs or TALE TFs achieve cooperative DNA binding to the repeat sequence so that the expanded allele is bound more efficiently by a larger number of ZFPs or TALE proteins than the wild-type allele, allowing preferential repression of the mutant allele. These cooperative binding ZFP-TFs or TALE TFs may or may not further contain protein interaction domains that allow multimerization when bound to DNA. In some embodiments, ZFP TFs or TALE TFs form a stable complex of multimers of a given size, and thus are capable of preferentially interacting with a CAG tract above a certain minimum size, wherein that minimum size is greater than the length of a wild-type CAG tract.
[0013] In certain embodiments, the ZFPs or TALE proteins as described herein (e.g., two-handed, multimerizing, etc.) preferentially modify expression of a mutant Htt allele. In some embodiments, the ZFP or TALE binds specifically to mutant Htt alleles wherein the expanded tract encodes poly-glutamine, while in other embodiments, the ZFP or TALE binds specifically to a mutant Htt allele wherein the expansion tract encodes poly-serine. Thus, in some embodiments, the ZFP-TF or TALE-TF modulates both the wild type and mutant forms of the Htt allele. In certain embodiments, the ZFP or TALE modulates only the wild type Htt allele. In other embodiments, the ZFP or TALE modulates only the mutant form of Htt.
[0014] In other embodiments, repressing ZFP-TFs or TALE-TFs are provided which preferentially bind to known SNPs associated with the expanded HD Htt alleles. In this way, the ZFP-TFs or TALE-TFs are specific for mutant Htt alleles which contain the SNP, allowing for specific repression of the mutant Htt allele. In another aspect, ZFP-TFs or TALE-TFs that specifically activate the wild-type Htt allele by interacting with SNPs associated with wild-type alleles are provided. In this way, only the wild-type Htt allele is activated. [0015] In certain embodiments, the zinc finger proteins (ZFPs) or TALE proteins as described herein can be placed in operative linkage with a regulatory domain (or functional domain) as part of a fusion protein. The functional domain can be, for example, a transcriptional activation domain, a transcriptional repression domain and/or a nuclease (cleavage) domain. By selecting either an activation domain or repression domain for fusion with the ZFP or TALE, such fusion proteins can be used either to activate or to repress gene expression. In some embodiments, a fusion protein comprising a ZFP or TALE targeted to a mutant Htt as described herein fused to a transcriptional repression domain that can be used to down-regulate mutant Htt expression is provided. In some embodiments, a fusion protein comprising a ZFP or TALE targeted to a wild-type Htt allele fused to a transcription activation domain that can up-regulate the wild type Htt allele is provided. In certain embodiments, the activity of the regulatory domain is regulated by an exogenous small molecule or ligand such that interaction with the cell's transcription machinery will not take place in the absence of the exogenous ligand. Such external ligands control the degree of interaction of the ZFP-TF or TALE-TF with the transcription machinery. The regulatory domain(s) may be operatively linked to any portion(s) of one or more of the ZFPs or TALEs, including between one or more ZFPs or TALEs, exterior to one or more ZFPs or TALEs and any combination thereof. Any of the fusion proteins described herein may be formulated into a pharmaceutical composition.
[0016] In some embodiments, the engineered DNA binding domains as described herein can be placed in operative linkage with nuclease (cleavage) domains as part of a fusion protein. In other embodiments, nuclease systems such as the CRISPR/Cas system may be utilized with a specific single guide RNA to target the nuclease to a target location in the DNA. In certain embodiments, such nucleases and nuclease fusions may be utilized for targeting mutant Htt alleles in stem cells such as induced pluripotent stem cells (iPSC), human embryonic stem cells (hESC), mesenchymal stem cells (MSC) or neuronal stem cells wherein the activity of the nuclease fusion will result in an Htt allele containing a wild type number of CAG repeats. In certain embodiments, pharmaceutical compositions comprising the modified stem cells are provided.
[0017] In yet another aspect, a polynucleotide encoding any of the DNA binding proteins described herein is provided. In another aspect, polynucleotides encoding a CRIPSR/Cas nuclease and a single guide RHA are provided. Such polynucleotides can be administered to a subject in which it is desirable to treat Huntington's Disease.
[0018] In still further aspects, the invention provides methods and
compositions for the generation of specific model systems for the study of
Huntington's Disease. In certain embodiments, provided herein are models in which mutant Htt alleles are generated using embryonic stem cells to generate cell and animal lines in which trinucleotide expansion tracts of specific lengths (50, 80, 109 and 180 CAG repeats, for example) are inserted into a wild-type Htt allele using zinc finger nuclease (ZFN), TALE-nuclease (TALEN), or CRISPR/Cas nuclease driven targeted integration. In certain embodiments, the model systems comprise in vitro cell lines, while in other embodiments, the model systems comprise transgenic animals. In any of the animal models described herein, the animal may be, for example, a rodent (e.g., Tat, mouse), a primate (e.g., non-human primate) or a rabbit.
[0019] In yet another aspect, a gene delivery vector comprising any of the polynucleotides described herein is provided. In certain embodiments, the vector is an adenovirus vector (e.g., an Ad5/F35 vector), a lentiviral vector (LV) including integration competent or integration-defective lentiviral vectors, or an adenovirus associated viral vector (AAV). Thus, also provided herein are adenovirus (Ad) vectors, LV or adenovirus associate viral vectors (AAV) comprising a sequence encoding at least one nuclease (ZFN or TALEN) and/or a donor sequence for targeted integration into a target gene. In certain embodiments, the Ad vector is a chimeric Ad vector, for example an Ad5/F35 vector. In certain embodiments, the lentiviral vector is an integrase-defective lentiviral vector (IDLV) or an integration competent lentiviral vector. In certain embodiments the vector is pseudo-typed with a VSV-G envelope, or with other envelopes.
[0020] In some embodiments, model systems are provided for Huntington's disease wherein the target alleles (e.g., mutant Htt) are tagged with expression markers. In certain embodiments, the mutant alleles (e.g., mutant Htt) are tagged. In some embodiments, the wild type allele (e.g., wild-type Htt) is tagged, and in additional embodiments, both wild type and mutant alleles are tagged with separate expression markers. In certain embodiments, the model systems comprise in vitro cell lines, while in other embodiments, the model systems comprise transgenic animals. [0021] Additionally, pharmaceutical compositions comprising the nucleic acids and/or proteins (e.g., ZFPs or TALEs or fusion proteins comprising the ZFPs or TALEs) are also provided. For example, certain compositions include a nucleic acid comprising a sequence that encodes one of the ZFPs or TALEs described herein operably linked to a regulatory sequence, combined with a pharmaceutically acceptable carrier or diluent, wherein the regulatory sequence allows for expression of the nucleic acid in a cell. In certain embodiments, the ZFPs or TALEs encoded are specific for a HD Htt allele. In some embodiments, pharmaceutical compositions comprise ZFPs or TALEs that modulate a HD Htt allele and ZFPs or TALEs that modulate a neurotrophic factor. Protein based compositions include one of more ZFPs or TALEs as disclosed herein and a pharmaceutically acceptable carrier or diluent.
[0022] In yet another aspect also provided is an isolated cell comprising any of the proteins, polynucleotides and/or compositions as described herein.
[0023] In another aspect, provided herein are methods for treating and/or preventing Huntington's Disease using the methods and compositions described herein. In some embodiments, the methods involve compositions where the polynucleotides and/or proteins may be delivered using a viral vector, a non- viral vector (e.g., plasmid) and/or combinations thereof. In some embodiments, the methods involve compositions comprising stem cell populations comprising a ZFP or TALE, or altered with the ZFNs, TALENs or the CRISPPJCas nuclease system of the invention.
[0024] These and other aspects will be readily apparent to the skilled artisan in light of disclosure as a whole.
BRIEF DESCRIPTION OF THE DRAWINGS
[0025] Figure 1, panels A to E, are schematics depicting wild type and mutant
(Huntington's Disease, HD) Huntingtin (Htt) allele and various ZFP-TFs binding to those alleles. Figure 1 A shows ZFP designs that bind outside of the CAG repeat, and therefore are predicted to bind equally to the wild type allele and the mutant (HD) allele. "KRAB" refers to the KRAB repression domain from the KOX1 gene and "ZFP" refers to the zinc finger DNA binding protein. "Standard ZFP TF" is a ZFP transcription factor fusion protein in which the zinc finger DNA binding domains are linked to the KRAB repression domain. Figure IB shows ZFP-TFs designed to bind within the CAG region. Figure 1 C depicts a "two-handed ZFP TF," which is a ZFP transcription factor in which two clusters of zinc finger domains are separated by a rigid protein sequences. The functional (repression) domain is depicted exterior to one ZFP in this Figure, but it will be apparent that the functional domain may be between the ZFPs or exterior to the ZFPs on either end of the protein. Figure ID depicts a "multimerizing ZFP TF," which is a ZFP TF that is capable of
multimerizing through a multimerization domain (depicted as speckled boxes).
Figure IE depicts a ZFP-ZFP- RAB configuration where two zinc finger DNA binding domains are linked by a flexible linker and are also fused to a KRAB domain. It will be apparent to the skilled artisan that in all fusion proteins, the functional domain can be on either end of the DNA binding domain, and that the DNA binding domain may comprise a wide number range of zinc fingers. Also depicted in Figure 1 as a box with black diamonds is a functional domain (e.g., activation, repression, cleavage domain). It will be apparent to the skilled artisan that the exemplary models presented in the Figures may apply to TALE TFs as well.
[0026] Figure 2, panels A through E, depict the repression of both alleles of
Htt by ZFPs as described in Figure 1 A using ZFP TFs that do not bind to the CAG repeat sequences. The ZFP identification numbers as shown in Tables 1 A and IB are indicated below the bars. Figure 2A depicts repression of the human Htt alleles in HEK293 cells using ZFPs targeted to five loci in the human gene. A diagram of the human Htt gene is shown and the locations of ZFP binding sites are shown. For each ZFP group, each bar represents an independent transfection. Figure 2B depicts a Western blot showing Htt protein levels in HEK293 cells transfected with the GFP control or the 18856 ZFP TF repressor (comprising the KRAB repression domain of KOX1), where the NFKB p65 levels ("p65") were used to confirm equal protein loading. The Western blot confirms the repression of Htt expression by the ZFP-TF. Figure 2C depicts a similar set of data as Figure 2A for the mouse Htt specific ZFP in Neuro2A cells. As in Figure 2 A, a diagram of the mouse Htt gene is shown and the locations of ZFP binding sites are indicated. Figure 2D and 2E demonstrate the repression of mouse Htt gene expression (RNA) in immortalized striatal cells, where different doses of ZFP-TF mRNA were used for transfection. In all cases except Figure 2B, Htt mRNA levels were measured by real-time RT-PCR and normalized to those of Actin mRNA.
[0027] Figure 3, panels A to G, depict selective repression of mutant Htt by using ZFPs binding within the CAG repeat region, as illustrated in Figure IB. This model illustrates that the longer CAG repeat region in the mutant allele allows for increased binding of CAG-targeted ZFP repressor molecules. Figure 3A depicts different repressor activities on the endogenous Htt gene (with normal CAG repeat length) by CAG-targeted ZFPs in HEI 293 cells. Figure 3B shows repression of luciferase reporters controlled by Htt promo ter/exonl fragments containing CAG repeats of varying lengths, ranging from 10 to 47 CAG repeats. CAG10 (left-most bar for each of the two indicated conditions) shows results with 10 CAG repeats; CAG17 (bar second from the left for each of the two indicated conditions) shows results with 17 CAG repeats; CAG23 (bar second from the right for each of the two indicated conditions) shows results with 23 CAG repeats; and CAG47 (right-most bar for each of the two indicated conditions) shows results with 47 CAG repeats. The schematic above the graph depicts the arrangement of the Htt promoter, exon 1, the CAG repeats and the reporter luciferase gene used in this system. The data demonstrate that increasing the number of CAGs leads to a decreased expression from the Htt promoter by a CAG-targeted ZFP. Furthermore, Figure 3C demonstrates that, while a relatively weak CAG-targeted ZFP does not repress the luciferase reporter that contains a normal-length CAG repeat as well as a strong CAG repressor, it drives similar repression of a luciferase reporter that contains an expanded CAG repeat as the strong CAG-targeted ZFP.at all doses tested. "pRL-Htt-CAG23-intron 1" (left bar of each pair) corresponds to expression from the wild type allele while "pRL- HttCAG47-intron 1" (right bar of each pair) correlates with expression from the mutant expanded Htt allele (containing 47 CAG repeats). Figure 3D is a graph depicting repression of mutant Htt (1 11 CAG) by CAG-targeted ZFPs in
immortalized mouse striatal cells derived from HdH(Ql 11/Q7) knock-in mice. Wild- type expression is shown in the left bar of each pair and knock-in expression in the right bar of each pair. ZFP-TFs comprising the specified ZFP fused to the KRAB repression domain were tested using three different concentrations of ZFP mRNA in the transfections. Figure 3E depicts mutant Htt repression by CAG-targeted ZFPs in a HD patient derived fibroblast line (CAG15/70). In this fibroblast line, the wild type Htt allele comprises 15 CAG repeats ("099T(CAG15)"5 middle bar of each indicated condition) and the mutant expanded Htt allele comprises 70 CAG repeats
("099C(CAG70)", right bar of each indicated condition). Figure 3F shows selective repression of mutant Htt expression in 4 different HD patient derived fibroblast cell lines. The numbers above each grouping indicate the number of CAG repeats on the wildtype Htt allele (e.g. 15 or 18) and on the mutant allele (e.g. 70, 67, 45 and 44); where two different doses of ZFP mRNA were tested. The left-bar of each pair shows wild-type Htt expression and the right bar of each shows expression of mutant Htt. Figure 3G depicts Htt expression in HD derived patient fibroblasts as assayed by Western blot analysis in the presence of the ZFP-TFs 30640, 32528 and 30657. The slower migrating protein bands are those produced by the expanded mutant Htt alleles. 32528 binds to the transcription start site of Htt (TSS) and thus inhibits expression from both alleles, while 30640 and 30657 bind to the CAG repeats (CAG).
[0028] Figure 4, panels A and B, depict repression of the mutant Htt in a HD patient derived fibroblast line by a panel of ZFPs targeted to the CAG repeat. A range of RNA concentrations were used from 0.1 ng to 3 μg. In Figures 4A and 4B, the left bar of each indicated conditions shows total Htt expression, the middle bar shows expression of Htt in fibroblasts in which the Htt allele comprises 18 CAG repeats ("099T(CAG18)" and the mutant expanded Htt allele comprises 45 CAG repeats 099T (CAG45
[0029] Figure 5 shows the effect of CAG-targeted ZFP repressors on the expression of Htt and other C AG-containing genes in HD patient-derived fibroblasts. The left bar under each indicated condition shows results with 30640; the middle bar under each indicated condition shows results with 30675; and the right bar shows mock transfections.
[0030] Figure 6, panels A and B, depicts an experiment that examines the genome-wide specificity of three CAG-targeted ZFPs. Figure 6A depicts qPCR analysis of Htt repression performed on six biological replicates (six separate transfections) of HD fibroblasts (CAG18 (middle bars)/ CAG45, right bars) using 30640, 30645, or 33074. The four most similar replicates by qPCR were then selected for microarray analysis, and the data is presented in Figure 6B.
[0031] Figure 7 depicts Htt repression in C AG 1 7/69 neuronal stem cells
(NSC). The cells were transfected with ZFP mRNA at indicated doses. Left bars under each of the indicated doses show results in CAG17 cells, middle bars show results in wild-type cells, right bars show results in CAG69 cells.
[0032] Figure 8 depicts Htt expression in neurons differentiated from HD embryonic stem cells (ESC) (CAG 17/48) treated with ZFP TFs. The cells were transfected with ZFP mR A at indicated doses.
[0033] Figure 9 depicts repression of a mutant Htt transgene expression in
R6/2 mice following treatment with the ZFP TF 30640.
[0034] Figure 10, panels A through D, depicts ZFPs with multimerization domains that specifically targets expanded CAG repeats, as illustrated in Figure ID. Figure 10A shows a single ZFP that have four components: (i) a KOX repressor domain (oval labeled "repressor"); (ii) an array of 2-6 fingers (two shown, small ovals marked "Z") that binds to (CAG)N or a permutation of this sequence; and (iii) two dimerization domains (rectangles labeled "dl" and "d2") that interact in an antiparallel configuration. These domains allow the ZFP to polymerize within the major groove of a CAG tract. Figure 10B shows a sketch of the binding event with a multimer of 3 ZFPs. It will be apparent that any number of multimers can be used and that the functional domain may be positioned anywhere on one or more of the individual ZFPs and that these diagrams are applicable to TALE-TFs as well. Figure IOC shows protein sequences of the four ZFP monomer scaffolds that are designed to multimerize via interactions between dimerizing zinc fingers (DZ). Scaffolds are named DZ1 (SEQ ID NO: 180), DZ2 (SEQ ID NO: 181), DZ3 (SEQ ID NO: 182) and DZ4 (SEQ ID NO: 183). Dimerizing zinc finger domains are underlined, while the repression domain and nuclear localization sequence are indicated by bold underline and italic text (respectively). Figure 10D shows protein sequences of the seven ZFP monomer scaffolds that are designed to multimerize via interactions between coiled- coils (CC). Scaffolds are named CC1 (SEQ ID NO: 184), CC2 (SEQ ID NO: 185), CC3 (SEQ ID NO: 186), CC4 (SEQ ID NO: 187), CC5 (SEQ ID NO: 188), CC6 (SEQ ID NO: 189) and CC7 (SEQ ID NO:190). Coiled-coil sequences are underlined, while the repression domain and nuclear localization sequence are indicated by bold underline and italic text (respectively). The location of the ZFP region of each scaffold, which will vary between designs, is indicated by "[ZFP]." The location of the (DNA-binding) ZFP region of each scaffold, which will vary between designs, is indicated by "[ZFP]." [0035] Figure 11, panels A and B, depict activity of ZFP-TFs with dimerization domains. In Figure 11 A, ZFP-TFs with "coiled coil" (CC) domains were tested with luciferase reporters. pRL-Htt CAG 17 (left bar of each pair) stands for renilla luciferase reporter controlled by human Htt promoter/exonl fragment with 17 CAG; pGL3-Htt-CAG47 (right bar of each pair) stands for firefly luciferase reporter controlled by human Htt promoter/exonl fragment with 47 CAG repeats. See text in Example 10 for description of the various dimerization domains. In Figure 1 IB, ZFPs with the dimerizing zinc finger "DZ" domains were tested with the same luciferase reporters, and demonstrates increased repression with some ZFP-TF dimerization domains. The left bar in each doublet indicates the expression from the 17CAG repeat Htt allele while the right bar indicates expression from 47 CAG repeat Htt allele.
[0036] Figure 12, panels A and B, depict repression of Htt by ZFP-ZFP-
KOX proteins. Figure 12A depicts Htt repression by the single 33088 and 33084 ZFP-TFs, and repression by the 33088-33088 and 33088-33084 ZFP-ZFP-KOX proteins in wild-type (left bar), CAG18 (middle bar) and CAG45 (right bar) (Figure 12A) HD fibroblasts; Figure 12B depicts Htt repression by 33088-33088 and 33088- 33084 ZFP-ZFP-KOX in wild type (left bar), CAG 20 (middle bar) and CAG41 (left bar) HD fibroblasts.
[0037] Figure 13, panels A to E, depict activation of mouse Htt. Figure 13A demonstrates ZFP-TF-driven up-regulation of the mouse Htt genes at the RNA level in Neuro2A cells using a ZFP fused to the p65 activation domain. Double bars indicate duplicate transfections. Figure 13B depicts a Western blot demonstrating increased Htt protein production driven by the ZFP. Figure 13C depicts a wild type mouse Htt allele and a "knock in" Htt allele where mouse sequence (most of exonl and part of intron 1, line above wild-type allele schematic) has been replaced with corresponding human sequence with CAG expansion (line over knock-in allele schematic). Figure 13D depicts the alignment between mouse sequence (SEQ ID NO: 191) that was replaced with the corresponding human sequence (SEQ ID
NO: 192) such that the knock-in allele has sufficient sequence divergence to allow ZFPs (shown in A and B) to be designed to bind specifically the mouse sequence. Figure 13E depicts specific activation of the wild type mouse Htt allele in
immortalized striatal cells derived from the HdhQl 11/Q7 knock-in mice. The left-bar shows results in wild-type cells and right bar shows results in knock-in mutant allele cells.
[0038] Figure 14, panels A and B, depicts the results of Cel-I mismatch assays (Surveyor™, Transgenomics) following treatment of K562 cells with Htt specific ZFN pairs. The percent NHEJ activity (in-del) for an active ZFN is shown at the bottom of the corresponding lane. "GFP" indicates cells that have been transfected with a GFP encoding plasmid. Figure 14A depicts results from ZFNs that cleave early Htt exons while Figure 14B depicts results from ZFNs that cleave near the stop codon. Inactive ZFN pairs were also observed (lanes not annotated with in- del percentages).
[0039] Figure 15 depicts graphs of the Htt repression results for several candidate TALE-TF proteins. The TALE-TFs were tested in HD patient derived fibroblasts (CAG 20/41). The results demonstrate that some of the TALE TFs were active in repressing overall Htt expression, while others exhibited mutant Htt- preferential repression.
DETAILED DESCRIPTION
[0040] Disclosed herein are compositions and methods for treating
Huntington's disease (HD). In particular, Htt-modulating transcription factors comprising zinc finger proteins (ZFP TFs) or TALEs (TALE-TF) and methods utilizing such proteins are provided for use in treating or preventing Huntington's disease. For example, ZFP-TFs or TALE-TFs which repress expression of a mutant Htt allele or activate expression of a wild-type Htt allele are provided. In addition, zinc finger nucleases (ZFNs), TALE nucleases (TALENs) or CRISPR/Cas nuclease systems that modify the genomic structure of the genes associated with HD are provided. For example, ZFNs, TALENs or CRISPR/Cas nuclease systems that are able to specifically alter portions of a mutant form of Htt are provided. These include compositions and methods using engineered zinc finger proteins or engineered TALE proteins, i. e., non-naturally occurring proteins which bind to a predetermined nucleic acid target sequence.
[0041] Thus, the methods and compositions described herein provide methods for treatment and prevention of Huntington's Disease, and these methods and compositions can comprise zinc finger transcription factors or TALE transcription factors that are capable of modulating target genes as well as engineered zinc finger and TALE nucleases and CRISPRVCas nuclease systems capable of modifying or editing Htt. General
[0042] Practice of the methods, as well as preparation and use of the
compositions disclosed herein employ, unless otherwise indicated, conventional techniques in molecular biology, biochemistry, chromatin structure and analysis, computational chemistry, cell culture, recombinant DNA and related fields as are within the skill of the art. These techniques are fully explained in the literature. See, for example, Sambrook et al. MOLECULAR CLONING: A LABORATORY MANUAL,
Second edition, Cold Spring Harbor Laboratory Press, 1989 and Third edition, 2001 ; Ausubel et al, CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, New York, 1987 and periodic updates; the series METHODS IN ENZYMOLOGY,
Academic Press, San Diego; Wolffe, CHROMATIN STRUCTURE AND FUNCTION, Third edition, Academic Press, San Diego, 1998; METHODS IN ENZYMOLOGY, Vol. 304, "Chromatin" (P.M. Wassarman and A. P. Wolffe, eds.), Academic Press, San Diego, 1999; and METHODS IN MOLECULAR BIOLOGY, Vol. 119, "Chromatin Protocols"
(P.B. Becker, ed.) Humana Press, Totowa, 1999.
Definitions
[0043] The terms "nucleic acid," "polynucleotide," and "oligonucleotide" are used interchangeably and refer to a deoxynbonucleotide or ribonucleotide polymer, in linear or circular conformation, and in either single- or double-stranded form. For the purposes of the present disclosure, these terms are not to be construed as limiting with respect to the length of a polymer. The terms can encompass known analogues of natural nucleotides, as well as nucleotides that are modified in the base, sugar and/or phosphate moieties (e.g. , phosphorothioate backbones). In general, an analogue of a particular nucleotide has the same base-pairing specificity; i.e. , an analogue of A will base-pair with T.
[0044] The terms "polypeptide," "peptide" and "protein" are used interchangeably to refer to a polymer of amino acid residues. The term also applies to amino acid polymers in which one or more amino acids are chemical analogues or modified derivatives of a corresponding naturally-occurring amino acids. [0045] "Binding" refers to a sequence-specific, non-covalent interaction between macromolecules (e.g. , between a protein and a nucleic acid). Not all
components of a binding interaction need be sequence- specific (e.g. , contacts with phosphate residues in a DNA backbone), as long as the interaction as a whole is sequence-specific. Such interactions are generally characterized by a dissociation constant (¾) of 10"6 M" 1 or lower. "Affinity" refers to the strength of binding:
increased binding affinity being correlated with a lower ¾.
[0046] A "binding protein" is a protein that is able to bind non-covalently to another molecule. A binding protein can bind to, for example, a DNA molecule (a DNA- binding protein), an RNA molecule (an RNA-binding protein) and/or a protein molecule (a protein-binding protein). In the case of a protein-binding protein, it can bind to itself (to form homodimers, homotrimers, etc.) and/or it can bind to one or more molecules of a different protein or proteins. A binding protein can have more than one type of binding activity. For example, zinc finger proteins have DNA-binding, RNA-binding and protein- binding activity.
[0047] A "zinc finger DNA binding protein" (or binding domain) is a protein, or a domain within a larger protein, that binds DNA in a sequence-specific manner through one or more zinc fingers, which are regions of amino acid sequence within the binding domain whose structure is stabilized through coordination of a zinc ion. The term zinc finger DNA binding protein is often abbreviated as zinc finger protein or ZFP.
[0048] A "TALE DNA binding domain" or "TALE" is a polypeptide comprising one or more TALE repeat domains/units. The repeat domains are involved in binding of the TALE to its cognate target DNA sequence. A single "repeat unit" (also referred to as a "repeat") is typically 33-35 amino acids in length and exhibits at least some sequence homology with other TALE repeat sequences within a naturally occurring TALE protein.
[0049] Zinc finger binding domains or TALE DNA binding domains can be
"engineered" to bind to a predetermined nucleotide sequence, for example via
engineering (altering one or more amino acids) of the recognition helix region of a naturally occurring zinc finger protein or by engineering the RVDs of a TALE
protein. Therefore, engineered zinc finger proteins or TALEs are proteins that are non-naturally occurring. Non-limiting examples of methods for engineering zinc finger proteins or TALEs are design and selection. A designed zinc finger protein or TALE is a protein not occurring in nature whose design/composition results principally from rational criteria. Rational criteria for design include application of substitution rules and computerized algorithms for processing information in a database storing information of existing ZFP designs and binding data. See, for example, US Patents 6,140,081 ; 6,453,242; and 6,534,261 ; see also WO 98/53058; WO 98/53059; WO 98/53060; WO 02/016536 and WO 03/016496 and U.S.
Publication No. 201 10301073.
[0050] A "selected" zinc finger protein or TALE is a protein not found in nature whose production results primarily from an empirical process such as phage display, interaction trap or hybrid selection. See e.g. , US 5,789,538; US 5,925,523;
US 6,007,988; US 6,013,453; US 6,200,759; WO 95/19431 ; WO 96/06166;
WO 98/53057; WO 98/5431 1 ; WO 00/27878; WO 01/60970 WO 01/88197, WO 02/099084 and WO 201 1/146121 (U.S. Patent Publication No. 201 10301073).
[0051] "Recombination" refers to a process of exchange of genetic
information between two polynucleotides. For the purposes of this disclosure, "homologous recombination (HR)" refers to the specialized form of such exchange that takes place, for example, during repair of double-strand breaks in cells via homology-directed repair mechanisms. This process requires nucleotide sequence homology, uses a "donor" molecule to template repair of a "target" molecule (i.e. , the one that experienced the double-strand break), and is variously known as "non- crossover gene conversion" or "short tract gene conversion," because it leads to the transfer of genetic information from the donor to the target. Without wishing to be bound by any particular theory, such transfer can involve mismatch correction of heteroduplex DNA that forms between the broken target and the donor, and/or "synthesis-dependent strand annealing," in which the donor is used to resynthesize genetic information that will become part of the target, and/or related processes. Such specialized HR often results in an alteration of the sequence of the target molecule such that part or all of the sequence of the donor polynucleotide is incorporated into the target polynucleotide.
[0052] In the methods of the disclosure, one or more targeted nucleases as described herein create a double-stranded break in the target sequence (e.g., cellular chromatin) at a predetermined site, and a "donor" polynucleotide, having homology to the nucleotide sequence in the region of the break, can be introduced into the cell. The presence of the double-stranded break has been shown to facilitate integration of the donor sequence. The donor sequence may be physically integrated or, alternatively, the donor polynucleotide is used as a template for repair of the break via homologous recombination, resulting in the introduction of all or part of the nucleotide sequence as in the donor into the cellular chromatin. Thus, a first sequence in cellular chromatin can be altered and, in certain embodiments, can be converted into a sequence present in a donor polynucleotide. Thus, the use of the terms "replace" or "replacement" can be understood to represent replacement of one nucleotide sequence by another, (i. e. , replacement of a sequence in the informational sense), and does not necessarily require physical or chemical replacement of one polynucleotide by another.
[0053] In any of the methods described herein, additional pairs of zinc-finger or TALE proteins can be used for additional double-stranded cleavage of additional target sites within the cell.
[0054] In certain embodiments of methods for targeted recombination and/or replacement and/or alteration of a sequence in a region of interest in cellular chromatin, a chromosomal sequence is altered by homologous recombination with an exogenous "donor" nucleotide sequence. Such homologous recombination is stimulated by the presence of a double-stranded break in cellular chromatin, if sequences homologous to the region of the break are present.
[0055] In any of the methods described herein, the first nucleotide sequence
(the "donor sequence") can contain sequences that are homologous, but not identical, to genomic sequences in the region of interest, thereby stimulating homologous recombination to insert a non-identical sequence in the region of interest. Thus, in certain embodiments, portions of the donor sequence that are homologous to sequences in the region of interest exhibit between about 80 to 99% (or any integer therebetween) sequence identity to the genomic sequence that is replaced. In other embodiments, the homology between the donor and genomic sequence is higher than 99%, for example if only 1 nucleotide differs as between donor and genomic sequences of over 100 contiguous base pairs. In certain cases, a non-homologous portion of the donor sequence can contain sequences not present in the region of interest, such that new sequences are introduced into the region of interest. In these instances, the non-homologous sequence is generally flanked by sequences of 50- 1,000 base pairs (or any integral value therebetween) or any number of base pairs greater than 1,000, that are homologous or identical to sequences in the region of interest. In other embodiments, the donor sequence is non-homologous to the first sequence, and is inserted into the genome by non-homologous recombination
mechanisms.
[0056] Any of the methods described herein can be used for partial or
complete inactivation of one or more target sequences in a cell by targeted integration of donor sequence that disrupts expression of the gene(s) of interest. Cell lines with partially or completely inactivated genes are also provided.
[0057] Furthermore, the methods of targeted integration as described herein can also be used to integrate one or more exogenous sequences. The exogenous nucleic acid sequence can comprise, for example, one or more genes or cDNA
molecules, or any type of coding or noncoding sequence, as well as one or more control elements (e.g., promoters). In addition, the exogenous nucleic acid sequence may produce one or more RNA molecules (e.g., small hairpin RNAs (shRNAs), inhibitory RNAs (RNAis), microRNAs (miRNAs), etc.).
[0058] "Cleavage" refers to the breakage of the covalent backbone of a DNA molecule. Cleavage can be initiated by a variety of methods including, but not limited to, enzymatic or chemical hydrolysis of a phosphodiester bond. Both single-stranded cleavage and double-stranded cleavage are possible, and double-stranded cleavage can occur as a result of two distinct single-stranded cleavage events. DNA cleavage can result in the production of either blunt ends or staggered ends. In certain embodiments, fusion polypeptides are used for targeted double-stranded DNA cleavage.
[ 00591 A "cleavage half-domain" is a polypeptide sequence which, in
conjunction with a second polypeptide (either identical or different) forms a complex having cleavage activity (preferably double-strand cleavage activity). The terms "first and second cleavage half-domains;" "+ and - cleavage half-domains" and "right and left cleavage half-domains" are used interchangeably to refer to pairs of cleavage half- domains that dimerize.
[0060] An "engineered cleavage half-domain" is a cleavage half-domain that has been modified so as to form obligate heterodimers with another cleavage half- domain (e.g., another engineered cleavage half-domain). See, also, U.S. Patent
Publication Nos. 2005/0064474, 20070218528 ,2008/0131962 and 2011/0201055, incorporated herein by reference in their entireties. 100611 The term "sequence" refers to a nucleotide sequence of any length, which can be DNA or RNA; can be linear, circular or branched and can be either single-stranded or double stranded. The term "donor sequence" refers to a nucleotide sequence that is inserted into a genome. A donor sequence can be of any length, for example between 2 and 10,000 nucleotides in length (or any integer value
therebetween or thereabove), preferably between about 100 and 1,000 nucleotides in length (or any integer therebetween), more preferably between about 200 and 500 nucleotides in length.
[0062] "Chromatin" is the nucleoprotein structure comprising the cellular genome. Cellular chromatin comprises nucleic acid, primarily DNA, and protein, including histones and non-histone chromosomal proteins. The majority of eukaryotic cellular chromatin exists in the form of nucleosomes, wherein a nucleosome core comprises approximately 150 base pairs of DNA associated with an octamer comprising two each of histones H2A, H2B, H3 and H4; and linker DNA (of variable length depending on the organism) extends between nucleosome cores. A molecule of histone HI is generally associated with the linker DNA. For the purposes of the present disclosure, the term "chromatin" is meant to encompass all types of cellular nucleoprotein, both prokaryotic and eukaryotic. Cellular chromatin includes both chromosomal and episomal chromatin.
[00631 A "chromosome," is a chromatin complex comprising all or a portion of the genome of a cell. The genome of a cell is often characterized by its karyotype, which is the collection of all the chromosomes that comprise the genome of the cell. The genome of a cell can comprise one or more chromosomes.
[0064] An "episome" is a replicating nucleic acid, nucleoprotein complex or other structure comprising a nucleic acid that is not part of the chromosomal karyotype of a cell. Examples of episomes include plasmids and certain viral genomes.
100651 A "target site" or "target sequence" is a nucleic acid sequence that defines a portion of a nucleic acid to which a binding molecule will bind, provided sufficient conditions for binding exist.
[0066] An "exogenous" molecule is a molecule that is not normally present in a cell, but can be introduced into a cell by one or more genetic, biochemical or other methods. "Normal presence in the cell" is determined with respect to the particular developmental stage and environmental conditions of the cell. Thus, for example, a molecule that is present only during embryonic development of muscle is an exogenous molecule with respect to an adult muscle cell. Similarly, a molecule induced by heat shock is an exogenous molecule with respect to a non-heat-shocked cell. An exogenous molecule can comprise, for example, a functioning version of a malfunctioning endogenous molecule or a malfunctioning version of a normally- functioning endogenous molecule.
[0067] An exogenous molecule can be, among other things, a small molecule, such as is generated by a combinatorial chemistry process, or a macromolecule such as a protein, nucleic acid, carbohydrate, lipid, glycoprotein, lipoprotein,
polysaccharide, any modified derivative of the above molecules, or any complex comprising one or more of the above molecules. Nucleic acids include DNA and RNA, can be single- or double-stranded; can be linear, branched or circular; and can be of any length. Nucleic acids include those capable of forming duplexes, as well as triplex-forming nucleic acids. See, for example, U.S. Patent Nos. 5,176,996 and 5,422,251. Proteins include, but are not limited to, DNA-binding proteins, transcription factors, chromatin remodeling factors, methylated DNA binding proteins, polymerases, methylases, demethylases, acetylases, deacetylases, kinases, phosphatases, integrases, recombinases, ligases, topoisomerases, gyrases and helicases.
[0068] An exogenous molecule can be the same type of molecule as an endogenous molecule, e.g. , an exogenous protein or nucleic acid. For example, an exogenous nucleic acid can comprise an infecting viral genome, a plasmid or episome introduced into a cell, or a chromosome that is not normally present in the cell.
Methods for the introduction of exogenous molecules into cells are known to those of skill in the art and include, but are not limited to, lipid-mediated transfer (i.e., liposomes, including neutral and cationic lipids), electroporation, direct injection, cell fusion, particle bombardment, calcium phosphate co-precipitation, DEAE-dextran- mediated transfer and viral vector-mediated transfer. An exogeneous molecule can also be the same type of molecule as an endogenous molecule but derived from a different species than the cell is derived from. For example, a human nucleic acid sequence may be introduced into a cell line originally derived from a mouse or hamster. [0069] By contrast, an "endogenous" molecule is one that is normally present in a particular cell at a particular developmental stage under particular environmental conditions. For example, an endogenous nucleic acid can comprise a chromosome, the genome of a mitochondrion, chloroplast or other organelle, or a naturally- occurring episomal nucleic acid. Additional endogenous molecules can include proteins, for example, transcription factors and enzymes.
[0070] A "fusion" molecule is a molecule in which two or more subunit molecules are linked, preferably covalently. The subunit molecules can be the same chemical type of molecule, or can be different chemical types of molecules.
Examples of the first type of fusion molecule include, but are not limited to, fusion proteins (for example, a fusion between a ZFP or TALE DNA-binding domain and one or more activation domains) and fusion nucleic acids (for example, a nucleic acid encoding the fusion protein described supra). Examples of the second type of fusion molecule include, but are not limited to, a fusion between a triplex-forming nucleic acid and a polypeptide, and a fusion between a minor groove binder and a nucleic acid.
[0071] Expression of a fusion protein in a cell can result from delivery of the fusion protein to the cell or by delivery of a polynucleotide encoding the fusion protein to a cell, wherein the polynucleotide is transcribed, and the transcript is translated, to generate the fusion protein. Trans-splicing, polypeptide cleavage and polypeptide ligation can also be involved in expression of a protein in a cell. Methods for polynucleotide and polypeptide delivery to cells are presented elsewhere in this disclosure.
[0072] A "multimerization domain", (also referred to as a "dimerization domain" or "protein interaction domain") is a domain incorporated at the amino, carboxy or amino and carboxy terminal regions of a ZFP TF or TALE TF. These domains allow for multimerization of multiple ZFP TF or TALE TF units such that larger tracts of trinucleotide repeat domains become preferentially bound by multimerized ZFP TFs or TALE TFs relative to shorter tracts with wild-type numbers of lengths. Examples of multimerization domains include leucine zippers.
Multimerization domains may also be regulated by small molecules wherein the multimerization domain assumes a proper conformation to allow for interaction with another multimerization domain only in the presence of a small molecule or external ligand. In this way, exogenous ligands can be used to regulate the activity of these domains.
[0073] A "gene," for the purposes of the present disclosure, includes a DNA region encoding a gene product (see infra), as well as all DNA regions which regulate the production of the gene product, whether or not such regulatory sequences are adjacent to coding and/or transcribed sequences. Accordingly, a gene includes, but is not necessarily limited to, promoter sequences, terminators, translational regulatory sequences such as ribosome binding sites and internal ribosome entry sites, enhancers, silencers, insulators, boundary elements, replication origins, matrix attachment sites and locus control regions.
[0074] "Gene expression" refers to the conversion of the information, contained in a gene, into a gene product. A gene product can be the direct
transcriptional product of a gene (e.g. , mRNA, tRNA, rRNA, antisense RNA, ribozyme, structural RNA or any other type of RNA) or a protein produced by translation of an mRNA. Gene products also include RNAs which are modified, by processes such as capping, polyadenylation, methylation, and editing, and proteins modified by, for example, methylation, acetylation, phosphorylation, ubiquitination, ADP-ribosylation, myristilation, and glycosylation.
[0075] "Modulation" of gene expression refers to a change in the activity of a gene. Modulation of expression can include, but is not limited to, gene activation and gene repression. Genome editing (e.g., cleavage, alteration, inactivation, random mutation) can be used to modulate expression. Gene inactivation refers to any reduction in gene expression as compared to a cell that does not include a ZFP or TALE protein as described herein. Thus, gene inactivation may be partial or complete.
[0076] A "region of interest" is any region of cellular chromatin, such as, for example, a gene or a non-coding sequence within or adjacent to a gene, in which it is desirable to bind an exogenous molecule. Binding can be for the purposes of targeted DNA cleavage and/or targeted recombination. A region of interest can be present in a chromosome, an episome, an organellar genome (e.g. , mitochondrial, chloroplast), or an infecting viral genome, for example. A region of interest can be within the coding region of a gene, within transcribed non-coding regions such as, for example, leader sequences, trailer sequences or introns, or within non-transcribed regions, either upstream or downstream of the coding region. A region of interest can be as small as a single nucleotide pair or up to 2,000 nucleotide pairs in length, or any integral value of nucleotide pairs.
[0077] "Eukaryotic" cells include, but are not limited to, fungal cells (such as yeast), plant cells, animal cells, mammalian cells and human cells (e.g., T-cells).
[0078] The terms "operative linkage" and "operatively linked" (or "operably linked") are used interchangeably with reference to a juxtaposition of two or more components (such as sequence elements), in which the components are arranged such that both components function normally and allow the possibility that at least one of the components can mediate a function that is exerted upon at least one of the other components. By way of illustration, a transcriptional regulatory sequence, such as a promoter, is operatively linked to a coding sequence if the transcriptional regulatory sequence controls the level of transcription of the coding sequence in response to the presence or absence of one or more transcriptional regulatory factors. A
transcriptional regulatory sequence is generally operatively linked in cis with a coding sequence, but need not be directly adjacent to it. For example, an enhancer is a transcriptional regulatory sequence that is operatively linked to a coding sequence, even though they are not contiguous.
[0079] With respect to fusion polypeptides, the term "operatively linked" can refer to the fact that each of the components performs the same function in linkage to the other component as it would if it were not so linked. For example, with respect to a fusion polypeptide in which a ZFP or TALE DNA-binding domain is fused to an activation domain, the ZFP or TALE DNA-binding domain and the activation domain are in operative linkage if, in the fusion polypeptide, the ZFP or TALE DNA-binding domain portion is able to bind its target site and/or its binding site, while the activation domain is able to upregulate gene expression. ZFPs fused to domains capable of regulating gene expression are collectively referred to as "ZFP-TFs" or "zinc finger transcription factors", while TALEs fused to domains capable of regulating gene expression are collectively referred to as "TALE-TFs" or "TALE transcription factors." When a fusion polypeptide in which a ZFP DNA-binding domain is fused to a cleavage domain (a "ZFN" or "zinc finger nuclease"), the ZFP DNA-binding domain and the cleavage domain are in operative linkage if, in the fusion polypeptide, the ZFP DNA-binding domain portion is able to bind its target site and/or its binding site, while the cleavage domain is able to cleave DNA in the vicinity of the target site. When a fusion polypeptide in which a TALE DNA-binding domain is fused to a cleavage domain (a "TALEN" or "TALE nuclease"), the TALE DNA-binding domain and the cleavage domain are in operative linkage if, in the fusion polypeptide, the TALE DNA-binding domain portion is able to bind its target site and/or its binding site, while the cleavage domain is able to cleave DNA in the vicinity of the target site.
[0080] A "functional fragment" of a protein, polypeptide or nucleic acid is a protein, polypeptide or nucleic acid whose sequence is not identical to the full-length protein, polypeptide or nucleic acid, yet retains the same function as the full-length protein, polypeptide or nucleic acid. A functional fragment can possess more, fewer, or the same number of residues as the corresponding native molecule, and/or can contain one ore more amino acid or nucleotide substitutions. Methods for
determining the function of a nucleic acid (e.g., coding function, ability to hybridize to another nucleic acid) are well-known in the art. Similarly, methods for determining protein function are well-known. For example, the DNA-binding function of a polypeptide can be determined, for example, by filter-binding, electrophoretic mobility-shift, or immunoprecipitation assays. DNA cleavage can be assayed by gel electrophoresis. See Ausubel et al, supra. The ability of a protein to interact with another protein can be determined, for example, by co -immunoprecipitation, two- hybrid assays or complementation, both genetic and biochemical. See, for example, Fields et al. (1989) Nature 340:245-246; U.S. Patent No. 5,585,245 and PCT WO 98/44350.
[0081] A "vector" is capable of transferring gene sequences to target cells. Typically, "vector construct," "expression vector," and "gene transfer vector," mean any nucleic acid construct capable of directing the expression of a gene of interest and which can transfer gene sequences to target cells. Thus, the term includes cloning, and expression vehicles, as well as integrating vectors.
100821 A "reporter gene" or "reporter sequence" refers to any sequence that produces a protein product that is easily measured, preferably although not necessarily in a routine assay. Suitable reporter genes include, but are not limited to, sequences encoding proteins that mediate antibiotic resistance (e.g., ampicillin resistance, neomycin resistance, G418 resistance, puromycin resistance), sequences encoding colored or fluorescent or luminescent proteins (e.g., green fluorescent protein, enhanced green fluorescent protein, red fluorescent protein, luciferase), and proteins which mediate enhanced cell growth and/or gene amplification (e.g., dihydrofolate reductase). Epitope tags include, for example, one or more copies of FLAG, His, myc, Tap, HA or any detectable amino acid sequence. "Expression tags" include sequences that encode reporters that may be operably linked to a desired gene sequence in order to monitor expression of the gene of interest.
DNA-binding domains
[0083] Described herein are compositions comprising a DNA-binding domain that specifically bind to a target sequence in any gene comprising a trinucleotide repeat, including, but not limited to, Htt. Any DNA-binding domain can be used in the compositions and methods disclosed herein.
[0084] In certain embodiments, the DNA binding domain comprises a zinc finger protein. Preferably, the zinc finger protein is non-naturally occurring in that it is engineered to bind to a target site of choice. See, for example, Beerli et al. (2002)
Nature Biotechnol. 20: 135-141 ; Pabo et al. (2001) Ann. Rev. Biochem. 70:313-340;
Isalan ei a/. (2001) Nature Biotechnol. 19:656-660; Segal et al. (2001) Curr. Opin.
Biotechnol. 12:632-637; Choo et al. (2000) Curr. Opin. Struc Biol. 10:41 1-416; U.S. Patent Nos. 6,453,242; 6,534,261; 6,599,692; 6,503,717; 6,689,558; 7,030,215;
6,794,136; 7,067,317; 7,262,054; 7,070,934; 7,361,635; 7,253,273; and U.S. Patent
Publication Nos. 2005/0064474; 2007/0218528; 2005/0267061 , all incorporated herein by reference in their entireties.
[0085] An engineered zinc finger binding domain can have a novel binding specificity, compared to a naturally-occurring zinc finger protein. Engineering methods include, but are not limited to, rational design and various types of selection.
Rational design includes, for example, using databases comprising triplet (or quadruplet) nucleotide sequences and individual zinc finger amino acid sequences, in which each triplet or quadruplet nucleotide sequence is associated with one or more amino acid sequences of zinc fingers which bind the particular triplet or quadruplet sequence. See, for example, co-owned U.S. Patents 6,453,242 and 6,534,261, incorporated by reference herein in their entireties. [0086] Exemplary selection methods, including phage display and two-hybrid systems, are disclosed in US Patents 5,789,538; 5,925,523; 6,007,988; 6,013,453; 6,410,248; 6,140,466; 6,200,759; and 6,242,568; as well as WO 98/37186;
WO 98/53057; WO 00/27878; WO 01/88197 and GB 2,338,237. In addition, enhancement of binding specificity for zinc finger binding domains has been described, for example, in co-owned WO 02/077227.
[0087] In addition, as disclosed in these and other references, zinc finger domains and/or multi-fingered zinc finger proteins may be linked together using any suitable linker sequences, including for example, linkers of 5 or more amino acids in length. See, also, U.S. Patent Nos. 6,479,626; 6,903, 185; and 7,153,949 for exemplary linker sequences 6 or more amino acids in length. The proteins described herein may include any combination of suitable linkers between the individual zinc fingers of the protein. In addition, enhancement of binding specificity for zinc finger binding domains has been described, for example, in co-owned WO 02/077227.
[0088] Selection of target sites; ZFPs and methods for design and construction of fusion proteins (and polynucleotides encoding same) are known to those of skill in the art and described in detail in U.S. Patent Nos. 6,140,0815; 789,538; 6,453,242; 6,534,261 ; 5,925,523; 6,007,988; 6,013,453; 6,200,759; WO 95/19431 ;
WO 96/06166; WO 98/53057; WO 98/5431 1 ; WO 00/27878; WO 01/60970 WO 01/88197; WO 02/099084; WO 98/53058; WO 98/53059; WO 98/53060;
WO 02/016536 and WO 03/016496.
[0089] In addition, as disclosed in these and other references, zinc finger domains and/or multi-fingered zinc finger proteins may be linked together using any suitable linker sequences, including for example, linkers of 5 or more amino acids in length. See, also, U.S. Patent Nos. 6,479,626; 6,903,185; and 7,153,949 for exemplary linker sequences 6 or more amino acids in length. The proteins described herein may include any combination of suitable linkers between the individual zinc fingers of the protein.
[0090] In certain embodiments, the DNA binding domain is an engineered zinc finger protein that binds (in a sequence-specific manner) to a target site in a Htt gene and modulates expression of Htt. The ZFPs can bind selectively to either a mutant Htt allele or a wild-type Htt sequence. Htt target sites typically include at least one zinc finger but can include a plurality of zinc fingers (e.g., 2, 3, 4, 5, 6 or more fingers). Usually, the ZFPs include at least three fingers. Certain of the ZFPs include four, five or six fingers, while some ZFPs include 8, 9, 10, 11 or 12 fingers. The ZFPs that include three fingers typically recognize a target site that includes 9 or 10 nucleotides; ZFPs that include four fingers typically recognize a target site that includes 12 to 14 nucleotides; while ZFPs having six fingers can recognize target sites that include 18 to 21 nucleotides. The ZFPs can also be fusion proteins that include one or more regulatory domains, which domains can be transcriptional activation or repression domains. In some embodiments, the fusion protein comprises two ZFP DNA binding domains linked together. These zinc finger proteins can thus comprise 8, 9, 10, 11, 12 or more fingers. In some embodiments, the two DNA binding domains are linked via an extendable flexible linker such that one DNA binding domain comprises 4, 5, or 6 zinc fingers and the second DNA binding domain comprises an additional 4, 5, or 5 zinc fingers. In some embodiments, the linker is a standard inter-finger linker such that the finger array comprises one DNA binding domain comprising 8, 9, 10, 11 or 12 or more fingers. In other embodiments, the linker is an atypical linker such as a flexible linker. The DNA binding domains are fused to at least one regulatory domain and can be thought of as a 'ZFP-ZFP- TF' architecture. Specific examples of these embodiments can be referred to as "ZFP- ZFP-KOX" which comprises two DNA binding domains linked with a flexible linker and fused to a KOX repressor and "ZFP-KOX-ZFP-KOX" where two ZFP-KOX fusion proteins are fused together via a linker.
[0091] Alternatively, the DNA-binding domain may be derived from a nuclease. For example, the recognition sequences of homing endonucleases and meganucleases such as l-Scel, l-Ceul, Ι-Pspl, Vl-Sce, 1-SceTV, l-Csml, l-Panl, I- Scell, l-Ppol, l-Scelll, l-Crel, l-Tevl, I-7¾vII and I-TevUl are known. See also U.S. Patent No. 5,420,032; U.S. Patent No. 6,833,252; Belfort et a/. (1997) Nucleic Acids Res. 25:3379-3388; Dujon ef a/. (1989) Gene 82: 115-118; Perler et al. (1994) Nucleic Acids Res. 22, 1125-1127; Jasin (1996) Trends Genet. 12:224-228; Gimble et al. (1996) J Mol. Biol. 263: 163-180; Argast ei a/. (1998) J. Mol. Biol. 280:345- 353 and the New England Biolabs catalogue. In addition, the DNA-binding specificity of homing endonucleases and meganucleases can be engineered to bind non-natural target sites. See, for example, Chevalier et al. (2002) Molec. Cell 10:895- 905; Epinat ei a/. (2003) Nucleic Acids Res. 31:2952-2962; Ashworth et al. (2006) Nature 441:656-659; Paques et al. (2007) Current Gene Therapy 7:49-66; U.S.
Patent Publication No. 20070117128.
[0092] "Two handed" zinc finger proteins are those proteins in which two clusters of zinc finger DNA binding domains are separated by intervening amino acids so that the two zinc finger domains bind to two discontinuous target sites. An example of a two handed type of zinc finger binding protein is SIP1, where a cluster of four zinc fingers is located at the amino terminus of the protein and a cluster of three fingers is located at the carboxyl terminus {see Remacle et al, (1999) EMBO Journal 18 (18): 5073-5084). Each cluster of zinc fingers in these proteins is able to bind to a unique target sequence and the spacing between the two target sequences can comprise many nucleotides. Two-handed ZFPs may include a functional domain, for example fused to one or both of the ZFPs. Thus, it will be apparent that the functional domain may be attached to the exterior of one or both ZFPs (see, Figure 1C) or may be positioned between the ZFPs (attached to both ZFPs) (see, Figure 4).
[0093] Specific examples of Htt-targeted ZFPs are disclosed in Tables 1A and
IB. The first column in this table is an internal reference name (number) for a ZFP and corresponds to the same name in column 1 of Tables 2 A and 2B. "F" refers to the finger and the number following "F" refers which zinc finger {e.g., "Fl" refers to finger 1).
Table 1A: Htt-targeted zinc finger proteins
SBS
# Design
Fl F2 F3 F4 F5 F6
RSDDLSR
(SEQ ID RNDNRTK RSDDLTR RSDDRKT RSADLTR QSSDLRR NO: (SEQ ID (SEQ ID (SEQ ID (SEQ ID (SEQ ID
18856 1) NO: 2) NO: 3) NO: 4 ) NO: 5) NO: 6)
RSAALSR RSDALAR RSDNLSE KRCNLRC QSSDLRR
(SEQ ID (SEQ ID (SEQ ID (SEQ ID (SEQ ID NO: NO: NO: NO: NO:
25920 58) 59) 60) 61) 6) NA
WRSCRSA DRSNLSR QRTHLTQ RSAHLSR TSGHLSR
(SEQ ID (SEQ ID (SEQ ID (SEQ ID (SEQ ID
NO: NO: NO: NO: NO:
25921 62) 9) 53) 46) 43) NA
RSDDLSR RNDNRTK WRSCRSA RSDNLAR QSGHLSR
(SEQ ID (SEQ ID (SEQ ID (SEQ ID (SEQ ID NO: NO: NO: NO: NO:
25923 1) 2) 62) 7) 41) NA
RSAALSR RSDALAR RSDNLSE KRCNLRC QSSDLSR DRSHLAR
(SEQ ID (SEQ ID (SEQ ID (SEQ ID (SEQ ID (SEQ ID
NO: NO: NO: NO: NO: NO:
25922 58) 59) 60) 61) 31) 13) Table IB: Human and Mouse Htt-targeted zinc finger proteins
SBS
# Design
Fl F2 F3 F4 F5 F6
RSDNLAR WRGDRVK DRSNLSR TSGSLTR ERGTLAR RSDDRKT
(SEQ ID (SEQ ID (SEQ ID (SEQ ID (SEQ ID (SEQ ID NO: NO: NO: NO: NO: NO:
32468 7) 8) 9) 10) 11) 4)
RSDALSR DRSHLAR RSDHLSR QSSDLTR TSGNLTR DRSHLAR
(SEQ ID (SEQ ID (SEQ ID (SEQ ID (SEQ ID (SEQ ID NO: NO: NO: NO: NO: NO:
32501 12) 13) 14) 15) 16) 13)
RSDDLSR RNDNRTK RSDDLTR RSDDRKT RSDDLTR QSSDLRR
(SEQ ID (SEQ ID (SEQ ID (SEQ ID (SEQ ID (SEQ ID NO: NO: NO: NO: NO: NO:
31809 1) 2) 3) 4) 3) 6)
QSGHLQR TSGNLTR QSGDLTR DRSHLAR RSDVLST VRSRLRR
(SEQ ID (SEQ ID (SEQ ID (SEQ ID (SEQ ID (SEQ ID NO: NO: NO: NO: NO: NO:
32528 17) 16) 18) 13) 19) 20)
RSDNLAR WRGDRVK DRSDLSR RSDALAR ERGTLAR RSDDRKT
(SEQ ID (SEQ ID (SEQ ID (SEQ ID (SEQ ID (SEQ ID NO: NO: NO: NO: NO: NO:
30580 7) 8) 22) 59) 11) 4)
DRSTLRQ DRSDLSR QSSTRAR RSDTLSE HRRSRWG
(SEQ ID (SEQ ID (SEQ ID (SEQ ID (SEQ ID
NO: NO: NO: NO: NO:
30929 21) 22) 23) 24) 25) NA
DRSDLSR RRDTLRS RSDHLST QSAHRIT QSGDLTR DRSHLAR
(SEQ ID (SEQ ID (SEQ ID (SEQ ID (SEQ ID (SEQ ID
NO: NO: NO: NO: NO: NO:
32538 22) 26) 27) 28) 18) 13)
RSDHLSE QNAHRKT QSSDLSR HRSTRNR QSSDLSR HRSTRNR
(SEQ ID (SEQ ID (SEQ ID (SEQ ID (SEQ ID (SEQ ID NO: NO: NO: NO: NO: NO:
32567 29) 30) 3D 32) 31) 32)
DRSNLSR LRQDLKR DRSHLTR DRSNLTR RSDHLST QSAHRIT
(SEQ ID (SEQ ID (SEQ ID (SEQ ID (SEQ ID (SEQ ID NO: NO: NO: NO: NO: NO:
29627 9) 33) 34) 35) 27) 28)
TSGNLTR LKQMLAV RSDSLSA DRSDLSR RSDALST DRSTRTK
(SEQ ID (SEQ ID (SEQ ID (SEQ ID (SEQ ID (SEQ ID
NO: NO: NO: NO: NO: NO:
29628 16) 36) 37) 22) 38) 39)
QSSDLSR DRSALAR QSSDLSR QSGHLSR RSDVLSE TSGHLSR
(SEQ ID (SEQ ID (SEQ ID (SEQ ID (SEQ ID (SEQ ID NO: NO: NO: NO: NO: NO:
29631 31) 40) 31) 41) 42) 43)
RSDTLSE KLCNRKC TSGNLTR HRTSLTD RSAHLSR QSGNLAR
(SEQ ID (SEQ ID (SEQ ID ( SEQ ID (SEQ ID (SEQ ID NO: NO: NO: NO: NO: NO:
29632 24) 44) 16) 45) 46) 47)
DRSNLSR QSGNLAR DRSNLSR LKHHLTD QSGDLTR YRWLRNN
(SEQ ID (SEQ ID (SEQ ID (SEQ ID (SEQ ID (SEQ ID NO: NO: NO: NO: NO: NO:
29637 9) 47) 9) 48) 18) 49)
29638 RSDHLSQ RSAVRKN QSSDLSR QSGDLTR WSTSLRA NA (SEQ ID (SEQ ID (SEQ ID (SEQ ID (SEQ ID
NO: NO: NO: NO: NO:
50) 51) 31) 18) 52)
DRSNLSR QRTHLTQ RSSHLSR TSGSLSR TRQNRDT
(SEQ ID (SEQ ID (SEQ ID (SEQ ID (SEQ ID
NO: NO: NO: NO: NO:
25917 9) 53) 54) 55) 56) NA
DQSTLRN RSAALSR RSDALAR RSDNLSE KRCNLRC
(SEQ ID (SEQ ID (SEQ ID (SEQ ID (SEQ ID
NO: NO: NO: NO: NO:
25916 57) 58) 59) 60) 61) NA
RSDNLSE KRCNLRC QSGDLTR QSGDLTR RSDNLSE KRCNLRC
(SEQ ID (SEQ ID (SEQ ID (SEQ ID (SEQ ID (SEQ ID
NO: NO: NO: NO: NO: NO:
33074 60) 61) 18) 18) 60) 61)
QSGDLTR QSGDLTR RSDNLSE KRCNLRC QSGDLTR QSGDLTR
(SEQ ID (SEQ ID (SEQ ID (SEQ ID (SEQ ID (SEQ ID
NO: NO: NO: NO: NO: NO:
33080 18) 18) 60) 61) 18) 18)
QSSDLSR HRSTRNR RSDTLSE RRWTLVG
(SEQ ID (SEQ ID (SEQ ID (SEQ ID
NO: NO: NO: NO:
33084 31) 32) 24) 64) NA NA
QSSDLSR HRSTRNR RSAVLSE QSSDLSR HRSTRNR
(SEQ ID (SEQ ID (SEQ ID (SEQ ID (SEQ ID
NO: NO: NO: NO: NO:
33088 31) 32) 148) 31) 32) NA
RSDNLSE KRCNLRC QSSDLSR QWSTRKR QSSDLSR QWSTRKR
(SEQ ID (SEQ ID (SEQ ID (SEQ ID (SEQ ID (SEQ ID
NO: NO: NO: NO: NO: NO:
30643 60) 61) 31) 63) 31) 63)
RSDNLSE KRCNLRC RSDNLSE KRCNLRC RSDNLSE KRCNLRC
(SEQ ID (SEQ ID (SEQ ID (SEQ ID (SEQ ID (SEQ ID
NO: NO: NO: NO: NO: NO:
30648 60) 61) 60) 61) 60) 61)
RSDNLSE KRCNLRC QSSDLSR QWSTRKR QSGDLTR
(SEQ ID (SEQ ID (SEQ ID (SEQ ID (SEQ ID
NO: NO: NO: NO: NO:
30645 60) 61) 3D 63) 18) NA
QSSDLSR QWSTRKR QSSDLSR QWSTRKR QSGDLTR
(SEQ ID (SEQ ID (SEQ ID (SEQ ID (SEQ ID
NO: NO: NO: NO: NO:
30640 31) 63) 31) 63) 18) NA
RSDTLSE RRWTLVG QSSDLSR HRSTRNR QSSDLSR HRSTRNR
(SEQ ID (SEQ ID (SEQ ID (SEQ ID (SEQ ID (SEQ ID NO: NO: NO: NO: NO: NO:
30657 24) 64) 31) 32) 31) 32)
QSGDLTR QSSDLSR QWSTRKR QSSDLSR QWSTRKR
(SEQ ID (SEQ ID (SEQ ID (SEQ ID (SEQ ID
NO: NO: NO: NO: NO:
30642 18) 31) 63) 31) 63) NA
RSDNLSE KRCNLRC QSGDLTR QSSDLSR QWSTRKR
(SEQ ID (SEQ ID (SEQ ID (SEQ ID (SEQ ID
NO: NO: NO: NO: NO:
30646 60) 61) 18) 3D 63) NA
RSDVLSE QSSDLSR HRSTRNR
(SEQ ID (SEQ ID (SEQ ID
NO: NO: NO:
32220 42) 31) 32) NA NA NA QSGDLTR QSSDLSR QWSTRKR
(SEQ ID (SEQ ID (SEQ ID
NO: NO: NO:
32210 18) 31) 63) NA NA NA
RSDNLRE RSDNLSE KRCNLRC
(SEQ ID (SEQ ID (SEQ ID
NO: NO: NO:
32215 65) 60) 61) NA NA NA
QSSDLSR HRSTRNR QSSDLSR HRSTRNR QSSDLSR
(SEQ ID (SEQ ID (SEQ ID (SEQ ID (SEQ ID
30658 NO:31) NO: 32) NO:31) NO: 32) NO: 31) NA
QSSDLSR QSSDLSR
(SEQ ID (SEQ ID
NO: NO:
32218 31) 31) NA NA NA NA
ERGTLAR TSGSLTR RSDNLAR DPSNRVG RSDDLSK DNSNRIK
(SEQ ID (SEQ ID (SEQ ID (SEQ ID (SEQ ID (SEQ ID
32427 NO:ll) NO: 10) NO: 7) NO : 78 ) NO : 149 ) NO: 150)
RSDHLSE QSGHLSR RSDDLTR YRWLLRS QSSDLSR RKDALVA
(SEQ ID (SEQ ID (SEQ ID (SEQ ID (SEQ ID (SEQ ID
NO: NO: NO: NO: NO: NO:
32653 29) 41) 3) 66) 31) 67)
QSGDLTR RRADLSR DRSHLTR DRSHLAR DRSNLSR LAQPRNK
(SEQ ID (SEQ ID (SEQ ID (SEQ ID (SEQ ID (SEQ ID NO: NO: NO: NO: NO: NO:
32677 18) 68) 34) 13) 9) 69)
ERGTLAR QSGSLTR RSDNLAR DDSHRKD RSDDLSK DNSNRIK
(SEQ ID (SEQ ID (SEQ ID (SEQ ID (SEQ ID (SEQ ID
33560 NO: 11) NO: 84) NO: 7) NO: 151) NO: 149) NO: 150)
DRSNLSR HKQHRDA DRSDLSR RRTDLRR RSANLAR DRSHLAR
(SEQ ID (SEQ ID (SEQ ID (SEQ ID (SEQ ID (SEQ ID
33583 NO: 9) NO: 76) NO: 22) NO:77) NO:73) NO: 13)
RSDHLSA RSADRTR RSDVLSE TSGHLSR RSDDLTR TSSDRKK
(SEQ ID (SEQ ID (SEQ ID (SEQ ID (SEQ ID (SEQ ID
NO: NO: NO: NO: NO: NO:
32685 70) 71) 42) 43) 3) 72)
RSANLAR RSDDLTR RSDTLSE HHSARRC ERGTLAR DRSNLTR
(SEQ ID (SEQ ID (SEQ ID (SEQ ID (SEQ ID (SEQ ID
NO: NO: NO: NO: NO: NO:
32422 73) 3) 24) 74) 11) 35)
RSDVLST DNSSRTR DRSNLSR HKQHRDA DRSDLSR RRTDLRR
(SEQ ID (SEQ ID (SEQ ID (SEQ ID (SEQ ID (SEQ ID
NO: NO: NO: NO: NO: NO:
, 32428 19) 75) 9) 76) 22) 77)
RSDVLST VRSRLRR ERGTLAR TSGSLTR RSDNLAR DPSNRVG
(SEQ ID (SEQ ID (SEQ ID (SEQ ID (SEQ ID (SEQ ID
NO: NO: NO: NO: NO: NO:
32430 19) 20) 11) 10) 7) 78)
RSDVLST VRSRLRR ERGTLAR TSGSLTR RSDHLSA RSADLSR
(SEQ ID (SEQ ID (SEQ ID (SEQ ID (SEQ ID (SEQ ID
NO: NO: NO: NO: NO: NO:
32432 19) 20) 11) 10) 70) 79)
RSDVLST DNSSRTR ERGTLAR QSGNLAR DRSHLTR RNDDRKK
(SEQ ID (SEQ ID (SEQ ID (SEQ ID (SEQ ID (SEQ ID
NO: NO: NO: NO: NO: NO:
32714 19) 75) 11) 47) 34) 80)
DRSNLSR QKVTLAA RSAHLSR TSGNLTR DRSDLSR RRSTLRS
(SEQ ID (SEQ ID (SEQ ID (SEQ ID (SEQ ID (SEQ ID NO: NO: NO: NO: NO: NO:
32733 9) 81) 46) 16) 22) 82) DRSALSR QSGSLTR QSSDLSR LKWNLRT RSDNLAR LKWDRQT ( SEQ ID (SEQ ID (SEQ ID (SEQ ID (SEQ ID (SEQ ID
NO: NO: NO: NO: NO: NO:
30901 83) 84) 3D 85) 7) 86)
QSCALAR RSDDLTR DRSALSR RSDHLTQ QSGDLTR WSTSLRA
(SEQ ID (SEQ ID (SEQ ID (SEQ ID (SEQ ID (SEQ ID
31952 NO: 147) NO: 3) NO: 83) NO: 152) NO: 18) NO:52)
RSDSLLR RSDDLTR QSGDLTR RRDWLPQ DRSNLSR RSDDRKT
(SEQ ID (SEQ ID (SEQ ID (SEQ ID (SEQ ID (SEQ ID
31921 NO: 153) NO: 3) NO: 18) NO: 154 ) NO: 9) NO: 4)
DRSHLSR TSGNLTR QSGDLTR DRSHLAR RSDVLST VRSRLRR
(SEQ ID (SEQ ID (SEQ ID (SEQ ID (SEQ ID (SEQ ID NO: NO: NO: NO: NO: NO:
30906 87) 16) 18) 13) 19) 20)
[0094] The sequence and location for the target sites of these proteins are disclosed in Tables 2A and 2B. Tables 2A and 2B show the target sequences for the indicated zinc fmger proteins. Nucleotides in the target site that are contacted by the ZFP recognition helices are indicated in uppercase letters; non-contacted nucleotides indicated in lowercase.
Table 2A: Target sites on human and mouse Htt
SBS # Target Site
18856 AcGCTGCGCCGGCGGAGGCGgggccgcg (SEQ ID NO: 88)
25920 gcGCTCAGCAGGTGGTGaccttgtggac_ ( SEQ ID NO: 103)
25921 atGGTGGGAGAGACTGTgaggcggcagc_ ( SEQ ID NO: 104)
25923 tgGGAGAGacTGTGAGGCGgcagctggg (SEQ ID NO: 105)
25922 atGGCGCTCAGCAGGTGGTGaccttgtg_ ( SEQ ID NO: 106)
Table 2B: Target sites on human and mouse Htt
SBS # Target Site
32468 agCCGGCCGTGGACTCTGAGccgaggtg_ ( SEQ ID NO: 89)
32427 cgCACTCGcCGCGAGgGTTGCCgggacg_ ( SEQ ID NO: 155)
32501 gtGGCGATGCGGGGGGCGTGgtgaggta_ ( SEQ ID NO: 90)
31809 acGCTGCGCCGGCGGAGGCGgggccgcg_ ( SEQ ID NO: 88)
32528 ccGGGACGGGTCCAaGATGGAcggccgc_ ( SEQ ID NO: 91)
30580 agCCGGCCGTGGACTCTGAGccgaggtgJSEQ ID NO: 89)
30929 ccGTCCCGGCAGCCCCCacggcgccttg_(SEQ ID NO: 92)
30658 ctGCTGCTGCTGCTGCTgctggaaggac_ ( SEQ ID NO: 108)
32538 cgGGTCCAAGATGGACGGCCgctcaggt_ ( SEQ ID NO: 93)
32567 ctGCTGCTGCTGCTGGAAGGacttgagg_ ( SEQ ID NO: 94)
29627 tcAGATGGGACGGCGCTGACctggctgg_ ( SEQ ID NO: 95)
29628 ctGCCATGGACCTGAATGATgggaccca_ ( SEQ ID NO: 96)
29631 gtGGTCTGGGAGCTGTCGCTgatgggcg_ ( SEQ ID NO: 97)
29632 ccGAAGGGCCTGATtCAGCTGttacccc_ ( SEQ ID NO: 98)
29637 aaCTTGCAAGTAACaGAAGACtcatcct_ ( SEQ ID NO: 99) 29638 ctTGTACAGCTGTGAGGgtgagcataat_(SEQ ID NO: 100)
25917 gcCATGGTGGGAGAGACtgtgaggcggc_ ( SEQ ID NO: 101)
25916 ctCAGCAGGTGGTGACCttgtggacatt_(SEQ ID NO: 102)
33074 agCAGCAGcaGCAGCAgCAGCAGcagca_(SEQ ID NO: 157)
33080 caGCAGCAgCAGCAGcaGCAGCAgcagc (SEQ ID NO: 107)
33084 tgCTGCTGctGCTGCTgctgctggaagg_(SEQ ID NO: 109)
33088 ctGCTGCTgCTGctGCTGCTgctggaag (SEQ ID NO: 158)
30643 caGCAGCAGCAGCAgCAGCAGcagcagc_ ( SEQ ID NO: 107)
30648 agCAGCAGCAGCAGCAGCAGcagcagca_(SEQ ID NO: 157)
30645 caGCAGCAGCAgCAGCAGcagcagcagc_ (SEQ ID NO: 107)
30640 caGCAGCAGCAGCAGCAgcagcagcagcJSEQ ID NO: 107)
30657 ctGCTGCTGCTGCTgCTGCTGgaaggac SEQ ID NO:108)
30642 caGCAGCAGCAGCAGCAgcagcagcagc_ ( SEQ ID NO: 107)
30646 caGCAGCAGCAgCAGCAGcagcagcagcJSEQ ID NO: 107)
32220 ctGCTGCTgCTGctgctgctgctggaagg_(SEQ ID NO: 109)
32210 caGCAGCAGCAgcagcagcagcagcagc_ ( SEQ ID NO: 107)
32215 agCAGCAGCAGcagcagcagcagcagca (SEQ ID NO: 110)
32218 tGCTGCTgctgctgctgctgctggaagg (SEQ ID NO: 111)
32653 ggCTGGCTTTTGCGGGAAGGggcggggc (SEQ ID NO: 112)
32677 gaATTGACaGGCGGAtGCGTCGtcctct_ ( SEQ ID NO: 113)
33560 cgCACTCGcCGCGAGgGTTGCCgggacg_(SEQ ID NO: 155)
33583 gcGGCGAGtGCGTCCCGTGACgtcatgc_ ( SEQ ID NO: 158)
32685 atTCTGCGGGTCTGGCGTGGcctcgtct_ ( SEQ ID NO: 114)
32422 gtGACGTCATGCCGGCGGAGacgaggcc_ ( SEQ ID NO: 115)
32428 gtGCGTCCCGTGACGTCATGccggcggaJSEQ ID NO: 116)
32430 gcCGCGAGgGTTGCCGGGACGggcccaa_ ( SEQ ID NO: 117)
32432 ccGCGAGGGTTGCCGGGACGggcccaagJSEQ ID NO: 118 )
32714 caTCGGGCagGAAGCCGTCATGgcaacc_ ( SEQ ID NO: 119)
32733 tcCTGCCCGATGGGACAGACcctgaaga_ ( SEQ ID NO: 120)
30901 gtACTGAGcAATGCTGTAGTCagcaatcJSEQ ID NO: 121)
31952 ccTGTCCAgAGGGTCGCGGTAcctccct_ ( SEQ ID NO: 159)
31921 tgCCGGACCTGGCAGCGGCGgtggtggc_ ( SEQ ID NO: 160)
30906 ccGGGACGGGTCCAaGATGGAcggccgc_ ( SEQ ID NO: 91)
[0095] In certain embodiments, the DNA-binding domain comprises a naturally occurring or engineered (non-naturally occurring) TAL effector (TALE) DNA binding domain. See, e.g., U.S. Patent Publication No. 20110301073, incorporated by reference in its entirety herein. The plant pathogenic bacteria of the genus Xanthomonas are known to cause many diseases in important crop plants. Pathogenicity of Xanthomonas depends on a conserved type III secretion (T3S) system which injects more than 25 different effector proteins into the plant cell.
Among these injected proteins are transcription activator-like effectors (TALE) which mimic plant transcriptional activators and manipulate the plant transcriptome (see Kay et al (2007) Science 318:648-651). These proteins contain a DNA binding domain and a transcriptional activation domain. One of the most well characterized TALEs is AvrBs3 from Xanthomonas campestgris pv. Vesicatoria (see Bonas et al (1989) Mol Gen Genet 218: 127-136 and WO2010079430). TALEs contain a centralized domain of tandem repeats, each repeat containing approximately 34 amino acids, which are key to the DNA binding specificity of these proteins. In addition, they contain a nuclear localization sequence and an acidic transcriptional activation domain (for a review see Schornack S, et al (2006) J Plant Physiol 163(3): 256-272). In addition, in the phytopathogenic bacteria Ralstonia solanacearum two genes, designated brgl 1 and hpxl7 have been found that are homologous to the AvrBs3 family of
Xanthomonas in the R. solanacearum biovar 1 strain GMI1000 and in the biovar 4 strain S1000 (See Heuer et al (2007) Appl and Envir Micro 73(13): 4379-4384). These genes are 98.9% identical in nucleotide sequence to each other but differ by a deletion of 1,575 bp in the repeat domain of hpxl7. However, both gene products have less than 40% sequence identity with AvrBs3 family proteins of Xanthomonas.
[0096] Specificity of these TALEs depends on the sequences found in the tandem repeats. The repeated sequence comprises approximately 102 bp and the repeats are typically 91-100% homologous with each other (Bonas et al, ibid).
Polymorphism of the repeats is usually located at positions 12 and 13 and there appears to be a one-to-one correspondence between the identity of the hypervariable diresidues at positions 12 and 13 with the identity of the contiguous nucleotides in the TALE's target sequence (see Moscou and Bogdanove, (2009) Science 326: 1501 and Boch et al (2009) Science 326:1509-1512). Experimentally, the code for DNA recognition of these TALEs has been determined such that an HD sequence at positions 12 and 13 leads to a binding to cytosine (C), NG binds to T, NI to A, C, G or T, NN binds to A or G, and IG binds to T. These DNA binding repeats have been assembled into proteins with new combinations and numbers of repeats, to make artificial transcription factors that are able to interact with new sequences and activate the expression of a non-endogenous reporter gene in plant cells (Boch et al, ibid). Engineered TAL proteins have been linked to a Fokl cleavage half domain to yield a TAL effector domain nuclease fusion (TALEN) exhibiting activity in a yeast reporter assay (plasmid based target). Christian et al ((2010)< Genetics epub
10.1534/genetics.l 10.120717). See, also, U.S. Patent Publication No. 20110301073, incorporated by reference in its entirety. [0097] Specific examples of designed dimerization domains to be used with
ZFPs or TALE proteins are listed in Table 3. The amino acid sequences of two types of domain, coiled-coil (CC) and dimerizing zinc finger (DZ) are listed.
Table 3: Designed dimerization domains
Design Amino acid sequence
name
TKCVHCGIVFLDEVMYALHMSCHGFRDPFECNICGYHSQDRYEFSSHIVRG
DZ1 EH (SEQ ID NO: 122)
TKCVHCGIVFLDEVMYALHMSCHGFRDPFECNICGYHSQDRYEFSSHIVRG
EH (SEQ ID NO: 122)
FKCEHCRILFLDHVMFTIHMGCHGFRDPFKCNMCGEKCDGPVGLFVHMARN
DZ2 AH ( SEQ ID NO:123)
TKCVHCGIVFLDEVMYALHMSCHGFRDPFECNICGYHSQDRYEFSSHIVRG
EH (SEQ ID NO: 122)
FKCEHCRILFLDHVMFTIHMGCHGFRDPFKCNMCGEKCDGPVGLFVHMARN
DZ3 AH (SEQ ID NO: 123)
HHCQHCDMYFADNILYTIHMGCHGYENPFECNICGYHSQDRYEFSSHIVRG
EH (SEQ ID NO: 124)
HHCQHCDMYFADNILYTIHMGCHSCDDVFKCNMCGEKCDGPVGLFVHMARN
AHGEKPTKCVHCGIVFLDEVMYALHMSCHGFRDPFECNICGYHSQDRYEFS
DZ4 SHIVRGEH ( SEQ ID NO: 125)
FKCEHCRILFLDHVMFTIHMGCHGFRDPFKCNMCGEKCDGPVGLFVHMARN
AHGEKPFYCEHCEITFRDVVMYSLHKGYHGFRDPFECNICGYHSQDRYEFS
SHIVRGEH (SEQ ID NO: 126)
AQLEKELQALEKKLAQLEWENQALEKELAQ (SEQ ID NO: 127)
CC1 AQLKKKLQANKKELAQLKWKLQALKKKLAQ ( SEQ ID NO : 128 )
EQLEKKLQALEKKLAQLEWKNQALEKKLAQ (SEQ ID NO: 129)
CC2 ALKKELQANKKELAQLKWELQALKKELAQ (SEQ ID NO: 130)
EQLEKKLQALEKKLAQLEWKNQALEK (SEQ ID NO: 131)
CCS ELQANKKELAQLKWELQALKKELAQ (SEQ ID NO: 132)
EQLEKKLQALEKKLAQLEWKNQA ( SEQ ID NO: 133)
CC4 QANKKELAQLKWELQALKKELAQ (SEQ ID NO: 134)
CC5 EQLEKKLQALEKKLAQLEWKNQALEKKLAQ ( SEQ ID NO : 129 ) ALKKELQANKKELAQLKWELQALKKELAQ (SEQ ID NO: 130)
CC6 EQLEKKLQALEKKLAQLEWKNQALEKKLAQ (SEQ ID NO: 129)
ALKKELQANKKELAQLKWELQALKKELAQ (SEQ ID NO: 130)
CC7 EQLEKKLQALEKKLAQLEWKNQALEKKLAQ (SEQ ID NO: 129)
ALKKELQANKKELAQLKWELQALKKELAQ (SEQ ID NO : 130 )
Fusion proteins
[0098] Fusion proteins comprising DNA-binding proteins (e.g., ZFPs or
TALEs) as described herein and a heterologous regulatory (functional) domain (or functional fragment thereof) are also provided. Common domains include, e.g., transcription factor domains (activators, repressors, co-activators, co-repressors), silencers, oncogenes (e.g., myc, jun, fos, myb, max, mad, rel, ets, bcl, myb, mos family members etc.); DNA repair enzymes and their associated factors and modifiers; DNA rearrangement enzymes and their associated factors and modifiers; chromatin associated proteins and their modifiers (e.g. kinases, acetylases and deacetylases); and DNA modifying enzymes (e.g., methyltransferases,
topoisomerases, helicases, ligases, kinases, phosphatases, polymerases,
endonucleases) and their associated factors and modifiers. U.S. Patent Application Publication Nos. 20050064474; 20060188987 and 2007/0218528 for details regarding fusions of DNA-binding domains and nuclease cleavage domains, incorporated by reference in their entireties herein
[0099] Suitable domains for achieving activation include the HSV VP 16 activation domain (see, e.g., Hagmann et al., J. Virol. 71, 5952-5962 (1997)) nuclear hormone receptors (see, e.g., Torchia et al., Curr. Opin. Cell. Biol. 10:373-383 (1998)); the p65 submit of nuclear factor kappa B (Bitko & Barik, J. Virol. 72:5610- 5618 (1998) and Doyle & Hunt, Neuroreport 8:2937-2942 (1997)); Liu et al, Cancer Gene Ther. 5:3-28 (1998)), or artificial chimeric functional domains such as VP64 (Beerli et al, (1998) Proc. Natl. Acad. Sci. USA 95:14623-33), and degron (Molinari et al, (1999) EMBO J. 18, 6439-6447). Additional exemplary activation domains include, Oct 1, Oct-2A, Spl, AP-2, and CTF1 (Seipel et al, EMBO J. 11, 4961-4968 (1992) as well as p300, CBP, PCAF, SRC1 PvALF, AtHD2A and ERF-2. See, for example, Robyr et al. (2000) Mol. Endocrinol. 14:329-347; Collmgwood et al. (1999) J Mol. Endocrinol. 23:255-275; Leo et al. (2000) Gene 245:1-11; Manteuffel- Cymborowska (1999) Acta Biochim. Pol. 46:77-89; McKenna et al. (1999) J Steroid Biochem. Mol. Biol. 69:3-12; Malik et al. (2000) Trends Biochem. Sci. 25:277-283; and Lemon et al. (1999) Curr. Opin. Genet. Dev. 9:499-504. Additional exemplary activation domains include, but are not limited to, OsGAI, HALF-1 , CI, API, ARF- 5,-6,-7, and -8, CPRFl, CPRF4, MYC-RP/GP, and TRABl. See, for example, Ogawa et al. (2000) Gene 245:21-29; Okanami et al. (1996) Genes Cells 1 :87-99; Goff et al. (1991) Genes Dev. 5:298-309; Cho et al. (1999) Plant Mol. Biol. 40:419-429;
Ulmason ei a/. (1999) Proc. Natl. Acad. Sci. USA 96:5844-5849; Sprenger-Haussels et al. (2000) Plant J. 22:1-8; Gong et al. (1999) Plant Mol. Biol. 41 :33-44; and Hobo et al. (1999) Proc. Natl. Acad. Sci. USA 96:15,348-15,353.
[0100] It will be clear to those of skill in the art that, in the formation of a fusion protein (or a nucleic acid encoding same) between a DNA-binding domain and a functional domain, either an activation domain or a molecule that interacts with an activation domain is suitable as a functional domain. Essentially any molecule capable of recruiting an activating complex and/or activating activity (such as, for example, histone acetylation) to the target gene is useful as an activating domain of a fusion protein. Insulator domains, localization domains, and chromatin remodeling proteins such as ISWI-containing domains and/or methyl binding domain proteins suitable for use as functional domains in fusion molecules are described, for example, in co-owned U.S. Patent Applications 2002/0115215 and 2003/0082552 and in co- owned WO 02/44376.
[0101] Exemplary repression domains include, but are not limited to, KRAB
A/B, KOX, TGF-beta-inducible early gene (TIEG), v-erbA, SID, MBD2, MBD3, members of the DNMT family {e.g., DNMT1, DNMT3A, DNMT3B), Rb, and MeCP2. See, for example, Bird et al. (1999) Cell 99:451-454; Tyler et al. (1999) Cell 99:443-446; Knoepfler et al. (1999) Cell 99:447-450; and Robertson et al. (2000) Nature Genet. 25:338-342. Additional exemplary repression domains include, but are not limited to, ROM2 and AtHD2A. See, for example, Chem et al. (1996) Plant Cell 8:305-321; and Wu et al. (2000) Plant J. 22:19-27.
[0102] Fusion molecules are constructed by methods of cloning and biochemical conjugation that are well known to those of skill in the art. Fusion molecules comprise a DNA-binding domain and a functional domain (e.g., a transcriptional activation or repression domain). Fusion molecules also optionally comprise nuclear localization signals (such as, for example, that from the SV40 medium T-antigen) and epitope tags (such as, for example, FLAG and
hemagglutinin). Fusion proteins (and nucleic acids encoding them) are designed such that the translational reading frame is preserved among the components of the fusion.
[0103] Fusions between a polypeptide component of a functional domain (or a functional fragment thereof) on the one hand, and a non-protein DNA-binding domain (e.g., antibiotic, intercalator, minor groove binder, nucleic acid) on the other, are constructed by methods of biochemical conjugation known to those of skill in the art. See, for example, the Pierce Chemical Company (Rockford, IL) Catalogue. Methods and compositions for making fusions between a minor groove binder and a polypeptide have been described. Mapp et al. (2000) Proc. Natl. Acad. Sci. USA 97:3930-3935.
[0104] In certain embodiments, the target site bound by the DNA binding domain is present in an accessible region of cellular chromatin. Accessible regions can be determined as described, for example, in co-owned International Publication WO 01/83732. If the target site is not present in an accessible region of cellular chromatin, one or more accessible regions can be generated as described in co-owned WO 01/83793. In additional embodiments, the DNA-binding domain of a fusion molecule is capable of binding to cellular chromatin regardless of whether its target site is in an accessible region or not. For example, such DNA-binding domains are capable of binding to linker DNA and/or nucleosomal DNA. Examples of this type of "pioneer" DNA binding domain are found in certain steroid receptor and in hepatocyte nuclear factor 3 (HNF3). Cordingley et al. (1987) Cell 48:261 -270; Pina et al. (1990) Cell 60:719-731 ; and Cirillo et al. (1998) EMBO J. 17:244-254.
[0105] The fusion molecule may be formulated with a pharmaceutically acceptable carrier, as is known to those of skill in the art. See, for example,
Remington's Pharmaceutical Sciences, 17th ed., 1985; and co-owned WO 00/42219.
[0106] The functional component/domain of a fusion molecule can be selected from any of a variety of different components capable of influencing transcription of a gene once the fusion molecule binds to a target sequence via its DNA binding domain. Hence, the functional component can include, but is not limited to, various transcription factor domains, such as activators, repressors, co-activators, compressors, and silencers. [0107] Additional exemplary functional domains are disclosed, for example, in co-owned US Patent No. 6,534,261 and US Patent Application Publication No. 2002/0160940.
[0108] Functional domains that are regulated by exogenous small molecules or ligands may also be selected. For example, RheoSwitch® technology may be employed wherein a functional domain only assumes its active conformation in the presence of the external RheoChem™ ligand (see for example US 20090136465). Thus, the ZFP or TALE may be operably linked to the regulatable functional domain wherein the resultant activity of the ZFP-TF or TALE-TF is controlled by the external ligand.
Nucleases
[0109] In certain embodiments, the fusion protein comprises a DNA-binding binding domain and cleavage (nuclease) domain. As such, gene modification can be achieved using a nuclease, for example an engineered nuclease. Engineered nuclease technology is based on the engineering of naturally occurring DNA-binding proteins. For example, engineering of homing endonucleases with tailored DNA-binding specificities has been described, (see, Chames et al. (2005) Nucleic Acids Res 33(20):el78; Arnould et al. (2006) J Mol. Biol. 355:443-458). In addition, engineering of ZFPs has also been described. See, e.g., U.S. Patent Nos. 6,534,261 ; 6,607,882; 6,824,978; 6,979,539; 6,933,1 13; 7,163,824; and 7,013,219.
[0110] In addition, ZFPs and TALEs have been fused to nuclease domains to create ZFNs and TALENs -functional entities that are able to recognize their intended nucleic acid target through their engineered (ZFP or TALE) DNA binding domains and cause the DNA to be cut near the ZFP or TALE DNA binding site via the nuclease activity. See, e.g., Kim et al. (1996) Proc Natl Acad Sci USA 93(3): 1156- 1 160. More recently, ZFNs have been used for genome modification in a variety of organisms. See, for example, United States Patent Publications 20030232410;
20050208489; 20050026157; 20050064474; 20060188987; 20060063231 ; and International Publication WO 07/014275.
[0111] Thus, the methods and compositions described herein are broadly applicable and may involve any nuclease of interest. Non-limiting examples of nucleases include meganucleases, TALENs and zinc finger nucleases. The nuclease may comprise heterologous DNA-binding and cleavage domains (e.g., zinc finger nucleases; TALENs; meganuclease DNA-binding domains with heterologous cleavage domains) or, alternatively, the DNA-binding domain of a naturally-occurring nuclease may be altered to bind to a selected target site (e.g., a meganuclease that has been engineered to bind to site different than the cognate binding site).
[0112] In certain embodiments, the nuclease is a meganuclease (homing endonuclease). Naturally-occurring meganucleases recognize 15-40 base-pair cleavage sites and are commonly grouped into four families: the LAGLIDADG family, the GIY-YIG family, the His-Cyst box family and the HNH family.
Exemplary homing endonucleases include l-Scel, l-Ceul, Yl-Pspl, Pl-Sce, 1-SceW, I- Csml, l-Panl, l-Scell, l-Ppol, l-Scelll, l-Crel, I-Tevl, l-Tevll and Ι-7¾νΠΙ. Their recognition sequences are known. See also US'. Patent No. 5,420,032; U.S. Patent No. 6,833,252; Belfort et al. (1997) Nucleic Acids Res. 25:3379-3388; Dujon et al. (1989) Gene 82:115-1 18; Perler et a/. (1994) Nucleic Acids Res. 22, 1125-1 127; Jasin (1996) Trends Genet. 12:224-228; Gimble et al. (1996) J Mol. Biol. 263: 163- 180; Argast et al. (1998) J. Mol. Biol. 280:345-353 and the New England Biolabs catalogue.
[0113] DNA-binding domains from naturally-occurring meganucleases, primarily from the LAGLIDADG family, have been used to promote site- specific genome modification in plants, yeast, Drosophila, mammalian cells and mice, but this approach has been limited to the modification of either homologous genes that conserve the meganuclease recognition sequence (Monet et al. (1999), Biochem. Biophysics. Res. Common. 255: 88-93) or to pre-engineered genomes into which a recognition sequence has been introduced (Route et al. (1994), Mol. Cell. Biol.
14:8096-106; Chilton et al. (2003) Plant Physiology 133 :956-65; Puchta et al. (1996), Proc. Natl. Acad. Sci. USA 93: 5055-60; Rong et al. (2002), Genes Dev. 16: 1568-81; Gouble et al. (2006), J Gene Med. 8(5):616-622). Accordingly, attempts have been made to engineer meganucleases to exhibit novel binding specificity at medically or biotechnologically relevant sites (Porteus et al. (2005), Nat. Biotechnol. 23: 967-73; Sussman et al. (2004), J. Mol. Biol. 342: 31-41 ; Epinat et al. (2003), Nucleic Acids
Res. 31 : 2952-62; Chevalier et al. (2002) Molec. Cell 10:895-905; Epinat et al. (2003) Nucleic Acids Res. 31:2952-2962; Ashworth et al. (2006) Nature 441:656-659;
Paques et al. (2007) Current Gene Therapy 7:49-66; U.S. Patent Publication Nos. 200701 17128; 20060206949; 20060153826; 20060078552; and 20040002092). In addition, naturally-occurring or engineered DNA-binding domains from
meganucleases have also been operably linked with a cleavage domain from a heterologous nuclease {e.g., FokT).
[0114] In other embodiments, the nuclease is a zinc finger nuclease (ZFN).
ZFNs comprise a zinc finger protein that has been engineered to bind to a target site in a gene of choice and cleavage domain or a cleavage half-domain.
[01 15] As described in detail above, zinc finger binding domains can be engineered to bind to a sequence of choice. See, for example, Beerli et al. (2002) Nature Biotechnol. 20: 135-141 ; Pabo et al. (2001) Ann. Rev. Biochem. 70:313-340; Isalan ei a/. (2001) Nature Biotechnol. 19:656-660; Segal et al. (2001) Curr. Opin. Biotechnol. 12:632-637; Choo et al. (2000) Curr. Opin. Struct. Biol. 10:41 1-416. An engineered zinc finger binding domain can have a novel binding specificity, compared to a naturally-occurring zinc finger protein. Engineering methods include, but are not limited to, rational design and various types of selection. Rational design includes, for example, using databases comprising triplet (or quadruplet) nucleotide sequences and individual zinc finger amino acid sequences, in which each triplet or quadruplet nucleotide sequence is associated with one or more amino acid sequences of zinc fingers which bind the particular triplet or quadruplet sequence. See, for example, co- owned U.S. Patents 6,453,242 and 6,534,261, incorporated by reference herein in their entireties.
[0116] Exemplary selection methods, including phage display and two-hybrid systems, are disclosed in US Patents 5,789,538; 5,925,523; 6,007,988; 6,013,453; 6,410,248; 6,140,466; 6,200,759; and 6,242,568; as well as WO 98/37186;
WO 98/53057; WO 00/27878; WO 01/88197 and GB 2,338,237. In addition, enhancement of binding specificity for zinc finger binding domains has been described, for example, in co-owned WO 02/077227.
[0117] In addition, as disclosed in these and other references, zinc finger domains and/or multi-fingered zinc finger proteins may be linked together using any suitable linker sequences, including for example, linkers of 5 or more amino acids in length {e.g., TGEKP (SEQ ID NO: 135), TGGQRP (SEQ ID NO: 136), TGQKP (SEQ ID NO: 137), and/or TGSQKP (SEQ ID NO: 138)). See, e.g., U.S. Patent Nos.
6,479,626; 6,903,185; and 7,153,949 for exemplary linker sequences 6 or more amino acids in length. The proteins described herein may include any combination of suitable linkers between the individual zinc fingers of the protein. See, also, U.S. Provisional Patent Publication No. 20110287512.
[0118] The CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)/Cas (CRISPR Associated) nuclease system is a recently engineered nuclease system based on a bacterial system that can be used for genome engineering. It is based on part of the adaptive immune response of many bacteria and archea. When a virus or plasmid invades a bacterium, segments of the invader's DNA are converted into CRISPR RNAs (crRNA) by the 'immune' response. This crRNA then associates, through a region of partial complementarity, with another type of RNA called tracrRNA to guide the Cas9 nuclease to a region homologous to the crRNA in the target DNA called a "protospacer." Cas9 cleaves the DNA to generate blunt ends at the DSB at sites specified by a 20-nucleotide guide sequence contained within the crRNA transcript. Cas9 requires both the crRNA and the tracrRNA for site specific DNA recognition and cleavage. This system has now been engineered such that the crRNA and tracrRNA can be combined into one molecule (the "single guide RNA"), and the crRNA equivalent portion of the single guide RNA can be engineered to guide the Cas9 nuclease to target any desired sequence (see J eket al (2012) Science 337, p. 816-821, Jinekei al, (2013), eLife 2:e00471, and David Segal, (2013) eLife
2:e00563). Thus, the CRISPR/Cas system can be engineered to create a DSB at a desired target in a genome, and repair of the DSB can be influenced by the use of repair inhibitors to cause an increase in error prone repair.
[0119] Nucleases such as ZFNs, TALENs and/or meganucleases also comprise a nuclease (cleavage domain, cleavage half-domain). As noted above, the cleavage domain may be heterologous to the DNA-binding domain, for example a zinc finger DNA-binding domain and a cleavage domain from a nuclease or a meganuclease DNA-binding domain and cleavage domain from a different nuclease. Heterologous cleavage domains can be obtained from any endonuclease or exonuclease. Exemplary endonucleases from which a cleavage domain can be derived include, but are not limited to, restriction endonucleases and homing endonucleases. See, for example, 2002-2003 Catalogue, New England Biolabs, Beverly, MA; and Belfort et al. (1997) Nucleic Acids Res. 25:3379-3388. Additional enzymes which cleave DNA are known {e.g., SI Nuclease; mung bean nuclease; pancreatic DNase I; micrococcal nuclease; yeast HO endonuclease; see also Linn et al. (eds.) Nucleases, Cold Spring Harbor Laboratory Press, 1993). One or more of these enzymes (or functional fragments thereof) can be used as a source of cleavage domains and cleavage half-domains.
[0120] Similarly, a cleavage half-domain can be derived from any nuclease or portion thereof, as set forth above, that requires dimerization for cleavage activity. In general, two fusion proteins are required for cleavage if the fusion proteins comprise cleavage half-domains. Alternatively, a single protein comprising two cleavage half- domains can be used. The two cleavage half-domains can be derived from the same endonuclease (or functional fragments thereof), or each cleavage half-domain can be derived from a different endonuclease (or functional fragments thereof). In addition, the target sites for the two fusion proteins are preferably disposed, with respect to each other, such that binding of the two fusion proteins to their respective target sites places the cleavage half-domains in a spatial orientation to each other that allows the cleavage half-domains to form a functional cleavage domain, e.g. , by dimerizing. Thus, in certain embodiments, the near edges of the target sites are separated by 5-8 nucleotides or by 15-18 nucleotides. However any integral number of nucleotides or nucleotide pairs can intervene between two target sites {e.g. , from 2 to 50 nucleotide pairs or more). In general, the site of cleavage lies between the target sites.
[0121] Restriction endonucleases (restriction enzymes) are present in many species and are capable of sequence-specific binding to DNA (at a recognition site), and cleaving DNA at or near the site of binding. Certain restriction enzymes {e.g., Type IIS) cleave DNA at sites removed from the recognition site and have separable binding and cleavage domains. For example, the Type IIS enzyme Fok I catalyzes double-stranded cleavage of DNA, at 9 nucleotides from its recognition site on one strand and 13 nucleotides from its recognition site on the other. See, for example, US Patents 5,356,802; 5,436,150 and 5,487,994; as well as Li et al. (1992) Proc. Natl. Acad. Sci. USA 89:4275-4279; Li ef a/. (1993) Proc. Natl. Acad. Sci. USA 90:2764- 2768; Kim et al. (1994a) Proc. Natl. Acad. Sci. USA 91:883-887; Kim et al. (1994b) J Biol. Chem. 269:31,978-31,982. Thus, in one embodiment, fusion proteins comprise the cleavage domain (or cleavage half-domain) from at least one Type IIS restriction enzyme and one or more zinc finger binding domains, which may or may not be engineered. [0122] An exemplary Type IIS restriction enzyme, whose cleavage domain is separable from the binding domain, is Fok I. This particular enzyme is active as a dimer. Bitinaite et al. (1998) Proc. Natl. Acad. Sci. USA 95: 10,570-10,575.
Accordingly, for the purposes of the present disclosure, the portion of the Fok I enzyme used in the disclosed fusion proteins is considered a cleavage half-domain. Thus, for targeted double-stranded cleavage and/or targeted replacement of cellular sequences using zinc finger- or TA E-Fok I fusions, two fusion proteins, each comprising a Fokl cleavage half-domain, can be used to reconstitute a catalytically active cleavage domain. Alternatively, a single polypeptide molecule containing a zinc finger binding domain and two Fok I cleavage half-domains can also be used.
Parameters for targeted cleavage and targeted sequence alteration using zinc finger- or TALE-Fok I fusions are provided elsewhere in this disclosure.
[0123] A cleavage domain or cleavage half-domain can be any portion of a protein that retains cleavage activity, or that retains the ability to multimerize (e.g. , dimerize) to form a functional cleavage domain.
[0124] Exemplary Type IIS restriction enzymes are described in International
Publication WO 07/014275, incorporated herein in its entirety. Additional restriction enzymes also contain separable binding and cleavage domains, and these are contemplated by the present disclosure. See, for example, Roberts et al. (2003) Nucleic Acids Res. 31:418-420.
[0125] In certain embodiments, the cleavage domain comprises one or more engineered cleavage half-domain (also referred to as dimerization domain mutants) that minimize or prevent homodimerization, as described, for example, in U.S. Patent Publication Nos. 20050064474 and 20060188987 and in U.S. Application No.
11/805,850 (filed May 23, 2007), the disclosures of all of which are incorporated by reference in their entireties herein. Amino acid residues at positions 446, 447, 479, 483, 484, 486, 487, 490, 491, 496, 498, 499, 500, 531, 534, 537, and 538 of Fok I are all targets for influencing dimerization of the Fok I cleavage half-domains. Exemplary engineered cleavage half-domains of Fok I that form obligate heterodimers include a pair in which a first cleavage half-domain includes mutations at amino acid residues at positions 490 and 538 of Fok I and a second cleavage half-domain includes mutations at amino acid residues 486 and 499. [0126] Thus, in one embodiment, a mutation at 490 replaces Glu (E) with Lys
(K); the mutation at 538 replaces Iso (I) with Lys (K); the mutation at 486 replaced Gin (Q) with Glu (E); and the mutation at position 499 replaces Iso (I) with Lys (K). Specifically, the engineered cleavage half-domains described herein were prepared by mutating positions 490 (E→K) and 538 (I→K) in one cleavage half-domain to produce an engineered cleavage half-domain designated "E490 :I538K" and by mutating positions 486 (Q→E) and 499 (I→L) in another cleavage half-domain to produce an engineered cleavage half-domain designated "Q486E:I499L". The engineered cleavage half-domains described herein are obligate heterodimer mutants in which aberrant cleavage is minimized or abolished. See, e.g., U.S. Patent
Publication No. 2008/0131962 and 2011/0201055, the disclosure of which is incorporated by reference in its entirety for all purposes. In certain embodiments, the engineered cleavage half-domain comprises mutations at positions 486, 499 and 496 (numbered relative to wild-type Fokl), for instance mutations that replace the wild type Gin (Q) residue at position 486 with a Glu (E) residue, the wild type Iso (I) residue at position 499 with a Leu (L) residue and the wild-type Asn (N) residue at position 496 with an Asp (D) or Glu (E) residue (also referred to as a "ELD" and "ELE" domains, respectively). In other embodiments, the engineered cleavage half- domain comprises mutations at positions 490, 538 and 537 (numbered relative to wild-type Fokl), for instance mutations that replace the wild type Glu (E) residue at position 490 with a Lys (K) residue, the wild type Iso (I) residue at position 538 with a Lys (K) residue, and the wild-type His (H) residue at position 537 with a Lys (K) residue or a Arg (R) residue (also referred to as "KKK" and "K R" domains, respectively). In other embodiments, the engineered cleavage half-domain comprises mutations at positions 490 and 537 (numbered relative to wild-type Fokl), for instance mutations that replace the wild type Glu (E) residue at position 490 with a Lys (K) residue and the wild-type His (H) residue at position 537 with a Lys (K) residue or a Arg (R) residue (also referred to as "KIK" and "KIR" domains, respectively). (See US Patent Publication No. 20110201055).
[0127] Engineered cleavage half-domains described herein can be prepared using any suitable method, for example, by site-directed mutagenesis of wild-type cleavage half-domains (Fok l) as described in U.S. Patent Publication Nos.
20050064474 and 20080131962. [0128] Alternatively, nucleases may be assembled in vivo at the nucleic acid target site using so-called "split-enzyme" technology (see e.g. U.S. Patent Publication No. 20090068164). Components of such split enzymes may be expressed either on separate expression constructs, or can be linked in one open reading frame where the individual components are separated, for example, by a self-cleaving 2A peptide or IRES sequence. Components may be individual zinc finger binding domains or domains of a meganuclease nucleic acid binding domain.
[0129 j In some embodiments, the DNA binding domain is an engineered domain from a TAL effector similar to those derived from the plant pathogens Xanthomonas (see Boch et al, (2009) Science 326: 1509-1512 and Moscou and
Bogdanove, (2009) Science326: 1501) and Ralstonia (see Heuer et al (2007) Applied and Environmental Microbiology 73(13): 4379-4384). Also, see PCT publication WO2010/079430.
[0130] Nucleases (e.g., ZFNs or TALENs) can be screened for activity prior to use, for example in a yeast-based chromosomal system as described in WO
2009/042163 and 20090068164. Nuclease expression constructs can be readily designed using methods known in the art. See, e.g., United States Patent Publications 20030232410; 20050208489; 20050026157; 20050064474; 20060188987;
20060063231 ; and International Publication WO 07/014275. Expression of the nuclease may be under the control of a constitutive promoter or an inducible promoter, for example the galactokinase promoter which is activated (de-repressed) in the presence of raffinose and/or galactose and repressed in presence of glucose.
Delivery
[0131 ] The proteins (e.g., ZFPs, TALEs, CRISPR/Cas), polynucleotides encoding same and compositions comprising the proteins and/or polynucleotides described herein may be delivered to a target cell by any suitable means including, for example, by injection of ZFP-TF, TALE-TF proteins or by use of ZFN or TALEN encoding mRNA. Suitable cells include but not limited to eukaryotic and prokaryotic cells and/or cell lines. Non-limiting examples of such cells or cell lines generated from such cells include COS, CHO (e.g., CHO-S, CHO-K1, CHO-DG44, CHO- DUXB11, CHO-DUKX, CHOK1SV), VERO, MDCK, WI38, V79, B14AF28-G3, BHK, HaK, NS0, SP2/0-Agl4, HeLa, HEK293 (e.g., HEK293-F, HEK293-H, HEK293-T), and perC6 cells as well as insect cells such as Spodoptera fugiperda (Sf), or fungal cells such as Saccharomyces, Pichia and Schizosaccharomyces. In certain embodiments, the cell line is a CHO-K1, MDCK or HEK293 cell line. Suitable cells also include stem cells such as, by way of example, embiyonic stem cells, induced pluripotent stem cells, hematopoietic stem cells, neuronal stem cells and
mesenchymal stem cells.
[0132] Methods of delivering proteins comprising zinc finger proteins as described herein are described, for example, in U.S. Patent Nos. 6,453,242;
6,503,717; 6,534,261 ; 6,599,692; 6,607,882; 6,689,558; 6,824,978; 6,933,113;
6,979,539; 7,013,219; and 7,163,824, the disclosures of all of which are incorporated by reference herein in their entireties.
[01 3] Zinc finger, TALE or CRISPR/Cas proteins as described herein may also be delivered using vectors containing sequences encoding one or more of the zinc finger, TALE or CRISPR/Cas protein(s). Any vector systems may be used including, but not limited to, plasmid vectors, retroviral vectors, lentiviral vectors, adenovirus vectors, poxvirus vectors; herpesvirus vectors and adeno-associated virus vectors, etc. See, also, U.S. Patent Nos. 6,534,261 ; 6,607,882; 6,824,978; 6,933,113; 6,979,539; 7,013,219; and 7,163,824, incorporated by reference herein in their entireties.
Furthermore, it will be apparent that any of these vectors may comprise one or more zinc finger or TALE protein-encoding sequences. Thus, when one or more
ZFPs,TALEs or CRISPR/Cas proteins are introduced into the cell, the sequences encoding the ZFPs, TALEs or CRISPR/Cas proteins may be carried on the same vector or on different vectors. When multiple vectors are used, each vector may comprise a sequence encoding one or multiple ZFPs, TALEs or CRISPR/Cas systems.
[0134] Conventional viral and non-viral based gene transfer methods can be used to introduce nucleic acids encoding engineered ZFPs, TALEs or CRISPR/Cas systems in cells {e.g., mammalian cells) and target tissues. Such methods can also be used to administer nucleic acids encoding ZFPs, TALEs or a CRISPR/Cas system to cells in vitro. In certain embodiments, nucleic acids encoding the ZFPs, TALEs or CRISPR/Cas system are administered for in vivo or ex vivo gene therapy uses. Non- viral vector delivery systems include DNA plasmids, naked nucleic acid, and nucleic acid complexed with a delivery vehicle such as a liposome or poloxamer. Viral vector delivery systems include DNA and RNA viruses, which have either episomal or integrated genomes after delivery to the cell. For a review of gene therapy procedures, see Anderson, Science 256:808-813 (1992); Nabel & Feigner, TIBTECH 11 :211-217 (1993); Mitani & Caskey, TIBTECH 1 1 : 162-166 (1993); Dillon,
TIBTECH 11 :167-175 (1993); Miller, Nature 357:455-460 (1992); Van Brunt, Biotechnology 6(10): 1 149-1154 (1988); Vigne, Restorative Neurology and
Neuroscience 8:35-36 (1995); Kremer & Perricaudet, British Medical Bulletin 51 (1):31 -44 (1995); Haddada et al., in Current Topics in Microbiology and
Immunology Doerfler and Bohm (eds.) (1995); and Yu et al, Gene Therapy 1 : 13-26 (1994).
[0135] Methods of non- viral delivery of nucleic acids include electroporation, lipofection, microinjection, biolistics, virosomes, liposomes, immuno liposomes, polycation or lipid:nucleic acid conjugates, naked DNA, naked RNA, artificial virions, and agent-enhanced uptake of DNA. Sonoporation using, e.g., the Sonitron 2000 system (Rich-Mar) can also be used for delivery of nucleic acids. In a preferred embodiment, one or more nucleic acids are delivered as mRNA. Also preferred is the use of capped mRNAs to increase translational efficiency and/or mRNA stability. Especially preferred are ARCA (anti-reverse cap analog) caps or variants thereof. See US patents US7074596 and US8153773, incorporated by reference herein.
[Θ136] Additional exemplary nucleic acid delivery systems include those provided by Amaxa Biosystems (Cologne, Germany), Maxcyte, Inc. (Rockville, Maryland), BTX Molecular Delivery Systems (Holliston, MA) and Copernicus Therapeutics Inc, {see for example US6008336). Lipofection is described in e.g., U.S. Patent Nos. 5,049,386; 4,946,787; and 4,897,355) and lipofection reagents are sold commercially {e.g., Transfectam™ and Lipofectin™ and Lipofectamine™
RNAiMAX). Cationic and neutral lipids that are suitable for efficient receptor- recognition lipofection of polynucleotides include those of Feigner, WO 91/17424, WO 91/16024. Delivery can be to cells {ex vivo administration) or target tissues {in vivo administration).
[0137] The preparation of lipid:nucleic acid complexes, including targeted liposomes such as immunolipid complexes, is well known to one of skill in the art {see, e.g., Crystal, Science 270:404-410 (1995); Blaese et al, Cancer Gene Ther. 2:291-297 (1995); Behr et al, Bioconjugate Chem. 5:382-389 (1994); Remy et al, Bioconjugate Chem. 5:647-654 (1994); Gao et al, Gene Therapy 2:710-722 (1995); Ahmad et a!., Cancer Res. 52:4817-4820 (1992); U.S. Pat. Nos. 4,186,183, 4,217,344, 4,235,871, 4,261,975, 4,485,054, 4,501,728, 4,774,085, 4,837,028, and 4,946,787).
[0138] Additional methods of delivery include the use of packaging the nucleic acids to be delivered into EnGeneIC delivery vehicles (EDVs). These EDVs are specifically delivered to target tissues using bispecific antibodies where one arm of the antibody has specificity for the target tissue and the other has specificity for the EDV. The antibody brings the EDVs to the target cell surface and then the EDV is brought into the cell by endocytosis. Once in the cell, the contents are released (see MacDiarmid et al (2009) Nature Biotechnology 27(7):643).
[0139] The use of RNA or DNA viral based systems for the delivery of nucleic acids encoding engineered ZFPs, TALEs or CRISPR/Cas systems take advantage of highly evolved processes for targeting a virus to specific cells in the body and trafficking the viral payload to the nucleus. Viral vectors can be
administered directly to patients (in vivo) or they can be used to treat cells in vitro and the modified cells are administered to patients (ex vivo). Conventional viral based systems for the delivery of ZFPs, TALEs or CRISPR/Cas systems include, but are not limited to, retroviral, lentivirus, adenoviral, adeno-associated, vaccinia and herpes simplex virus vectors for gene transfer. Integration in the host genome is possible with the retrovirus, lentivirus, and adeno-associated virus gene transfer methods, often resulting in long term expression of the inserted transgene. Additionally, high transduction efficiencies have been observed in many different cell types and target tissues.
[0140] The tropism of a retrovirus can be altered by incorporating foreign envelope proteins, expanding the potential target population of target cells. Lentiviral vectors are retroviral vectors that are able to transduce or infect non-dividing cells and typically produce high viral titers. Selection of a retroviral gene transfer system depends on the target tissue. Retroviral vectors are comprised of cw-acting long terminal repeats with packaging capacity for up to 6-10 kb of foreign sequence. The minimum cz's-acting LTRs are sufficient for replication and packaging of the vectors, which are then used to integrate the therapeutic gene into the target cell to provide permanent transgene expression. Widely used retroviral vectors include those based upon mouse leukemia virus (MuLV), gibbon ape leukemia virus (GaLV), Simian Immunodeficiency virus (SIV), human immunodeficiency virus (HIV), and combinations thereof (see, e.g., Buchscher et al, J. Virol. 66:2731-2739 (1992);
Johann es/., J. Virol. 66:1635-1640 (1992); Sommerfelt et al, Virol. 176:58-59 (1990); Wilson et al, J. Virol. 63:2374-2378 (1989); Miller et al, J. Virol. 65:2220- 2224 (1991); PCT/US94/05700).
[0141] In applications in which transient expression is preferred, adenoviral based systems can be used. Adenoviral based vectors are capable of very high transduction efficiency in many cell types and do not require cell division. With such vectors, high titer and high levels of expression have been obtained. This vector can be produced in large quantities in a relatively simple system. Adeno-associated virus ("AAV") vectors are also used to transduce cells with target nucleic acids, e.g., in the in vitro production of nucleic acids and peptides, and for in vivo and ex vivo gene therapy procedures (see, e.g., West et al, Virology 160:38-47 (1987); U.S. Patent No. 4,797,368; WO 93/24641; Kotin, Human Gene Therapy 5:793-801 (1994);
Muzyczka, J. Clin. Invest. 94: 1351 (1994). Construction of recombinant AAV vectors are described in a number of publications, including U.S. Pat. No. 5,173,414; Tratschin et al, Mol. Cell. Biol. 5:3251-3260 (1985); Tratschin, et al, Mol Cell. Biol. 4:2072-2081 (1984); Hermonat & Muzyczka, PNAS 81 :6466-6470 (1984); and Samulski e/ fl/., J Virol 63:03822-3828 (1989).
[0142] At least six viral vector approaches are currently available for gene transfer in clinical trials, which utilize approaches that involve complementation of defective vectors by genes inserted into helper cell lines to generate the transducing agent.
[0143] pLASN and MFG-S are examples of retroviral vectors that have been used in clinical trials (Dunbar et al, Blood 85:3048-305 (1995); Kohn et al, Nat. Med. 1 :1017-102 (1995); Malech e/ a/., PNAS 94:22 12133-12138 (1997)).
PA317/pLASN was the first therapeutic vector used in a gene therapy trial. (Blaese et al, Science 270:475-480 (1995)). Transduction efficiencies of 50% or greater have been observed for MFG-S packaged vectors. (Ellem et al, Immunol Immunother. 44(1): 10-20 (1997); Dranoff et al, Hum. Gene Ther. 1 :111-2 (1997).
[0144] Recombinant adeno-associated virus vectors (rAAV) are a promising alternative gene delivery systems based on the defective and nonpathogenic parvovirus adeno-associated type 2 virus. All vectors are derived from a plasmid that retains only the AAV 145 bp inverted terminal repeats flanking the transgene expression cassette. Efficient gene transfer and stable transgene delivery due to integration into the genomes of the transduced cell are key features for this vector system. (Wagner et al, Lancet 351 :9117 1702-3 (1998), earns et al, Gene Ther. 9:748-55 (1996)). Other AAV serotypes, including AAV1, AAV3, AAV4, AAV5, AAV6, AAV8 AAV 8.2, AAV9, and AAV rhl 0 and pseudotyped AAV such as AAV2/8, AAV2/5 and AAV2/6 can also be used in accordance with the present invention.
[0145] Replication-deficient recombinant adenoviral vectors (Ad) can be produced at high titer and readily infect a number of different cell types. Most adenovirus vectors are engineered such that a transgene replaces the Ad Ela, Elb, and/or E3 genes; subsequently the replication defective vector is propagated in human 293 cells that supply deleted gene function in trans. Ad vectors can transduce multiple types of tissues in vivo, including nondividing, differentiated cells such as those found in liver, kidney and muscle. Conventional Ad vectors have a large carrying capacity. An example of the use of an Ad vector in a clinical trial involved polynucleotide therapy for antitumor immunization with intramuscular injection (Sterman et al, Hum. Gene Ther. 7:1083-9 (1998)). Additional examples of the use of adenovirus vectors for gene transfer in clinical trials include Rosenecker et al, Infection 24: 1 5-10 (1996); Sterman et al, Hum. Gene Ther. 9:7 1083-1089 (1998); Welsh et al, Hum. Gene Ther. 2:205-18 (1995); Alvarez et al, Hum. Gene Ther. 5:597-613 (1997); Topf et al, Gene Ther. 5:507-513 (1998); Sterman et al, Hum. Gene Ther. 7:1083-1089 (1998).
[0146] Packaging cells are used to form virus particles that are capable of infecting a host cell. Such cells include 293 cells, which package adenovirus, and ψ2 cells or PA317 cells, which package retrovirus. Viral vectors used in gene therapy are usually generated by a producer cell line that packages a nucleic acid vector into a viral particle. The vectors typically contain the minimal viral sequences required for packaging and subsequent integration into a host (if applicable), other viral sequences being replaced by an expression cassette encoding the protein to be expressed. The missing viral functions are supplied in trans by the packaging cell line. For example, AAV vectors used in gene therapy typically only possess inverted terminal repeat (ITR) sequences from the AAV genome which are required for packaging and integration into the host genome. Viral DNA is packaged in a cell line, which contains a helper plasmid encoding the other AAV genes, namely rep and cap, but lacking ITR sequences. The cell line is also infected with adenovirus as a helper. The helper virus promotes replication of the AAV vector and expression of AAV genes from the helper plasmid. The helper plasmid is not packaged in significant amounts due to a lack of ITR sequences. Contamination with adenovirus can be reduced by, e.g., heat treatment to which adenovirus is more sensitive than AAV.
[0147] In many gene therapy applications, it is desirable that the gene therapy vector be delivered with a high degree of specificity to a particular tissue type.
Accordingly, a viral vector can be modified to have specificity for a given cell type by expressing a ligand as a fusion protein with a viral coat protein on the outer surface of the virus. The ligand is chosen to have affinity for a receptor known to be present on the cell type of interest. For example, Han et al, Proc. Natl. Acad. Sci. USA 92:91 T - 9751 (1995), reported that Moloney mouse leukemia virus can be modified to express human heregulin fused to gp70, and the recombinant virus infects certain human breast cancer cells expressing human epidermal growth factor receptor. This principle can be extended to other virus-target cell pairs, in which the target cell expresses a receptor and the virus expresses a fusion protein comprising a ligand for the cell- surface receptor. For example, filamentous phage can be engineered to display antibody fragments (e.g., FAB or Fv) having specific binding affinity for virtually any chosen cellular receptor. Although the above description applies primarily to viral vectors, the same principles can be applied to nonviral vectors. Such vectors can be engineered to contain specific uptake sequences which favor uptake by specific target cells.
[0148] Gene therapy vectors can be delivered in vivo by administration to an individual patient, typically by systemic administration (e.g., intravenous,
intraperitoneal, intramuscular, subdermal, or intracranial infusion) or topical application, as described below. Alternatively, vectors can be delivered to cells ex vivo, such as cells explanted from an individual patient (e.g., lymphocytes, bone marrow aspirates, tissue biopsy) or universal donor hematopoietic stem cells, followed by reimplantation of the cells into a patient, usually after selection for cells which have incorporated the vector.
[0149] Ex vivo cell transfection for diagnostics, research, or for gene therapy
(e.g., via re-infusion of the transfected cells into the host organism) is well known to those of skill in the art. In a preferred embodiment, cells are isolated from the subject organism, transfected with a ZFP, TALE or CRISPR/Cas system nucleic acid (gene. cDNA or mRNA), and re-infused back into the subject organism (e.g., patient). In a preferred embodiment, one or more nucleic acids are delivered as mRNA. Also preferred is the use of capped mRNAs to increase translational efficiency and/or mRNA stability. Especially preferred are ARCA (anti-reverse cap analog) caps or variants thereof. See U.S. patents 7,074,596 and 8,153,773, incorporated by reference herein in their entireties. Various cell types suitable for ex vivo transfection are well known to those of skill in the art (see, e.g., Freshney et al, Culture of Animal Cells, A Manual of Basic Technique (3rd ed. 1994)) and the references cited therein for a discussion of how to isolate and culture cells from patients).
[01501 In one embodiment, stem cells are used in ex vivo procedures for cell transfection and gene therapy. The advantage to using stem cells is that they can be differentiated into other cell types in vitro, or can be introduced into a mammal (such as the donor of the cells) where they will engraft in the bone marrow. Methods for differentiating CD34+ cells in vitro into clinically important immune cell types using cytokines such a GM-CSF, IFN-γ and TNF-a are known (see Inaba et al, J. Exp. Med. 176: 1693-1702 (1992)).
[0151] Stem cells are isolated for transduction and differentiation using known methods. For example, stem cells are isolated from bone marrow cells by panning the bone marrow cells with antibodies which bind unwanted cells, such as CD4+ and CD8+ (T cells), CD45+ (panB cells), GR-1 (granulocytes), and lad (differentiated antigen presenting cells) (see Inaba et al, J. Exp. Med. 176:1693-1702 (1992)).
[01521 Stem cells that have been modified may also be used in some embodiments. For example, neuronal stem cells that have been made resistant to apoptosis may be used as therapeutic compositions where the stem cells also contain the ZFP TFs of the invention. Resistance to apoptosis may come about, for example, by knocking out BAX and/or BAK using BAX- or BAK-specific TALENs or ZFNs (see, U.S. Patent Publication No. 20100003756) in the stem cells, or those that are disrupted in a caspase, again using caspase-6 specific ZFNs for example. These cells can be transfected with the ZFP TFs or TALE TFs that are known to regulate mutant or wild-type Htt. [0153] Vectors (e.g., retroviruses, adenoviruses, liposomes, etc.) containing therapeutic ZFP nucleic acids can also be administered directly to an organism for transduction of cells in vivo. Alternatively, naked DNA can be admimstered.
Administration is by any of the routes normally used for introducing a molecule into ultimate contact with blood or tissue cells including, but not limited to, injection, infusion, topical application and electroporation. Suitable methods of administering such nucleic acids are available and well known to those of skill in the art, and, although more than one route can be used to administer a particular composition, a particular route can often provide a more immediate and more effective reaction than another route.
[0154] Methods for introduction of DNA into hematopoietic stem cells are disclosed, for example, in U.S. Patent No. 5,928,638. Vectors useful for introduction of transgenes into hematopoietic stem cells, e.g., CD34+ cells, include adenovirus Type 35.
[0155] Vectors suitable for introduction of transgenes into immune cells (e.g.,
T-cells) include non-integrating lentivirus vectors. See, for example, Ory et al. (1996) Proc. Natl. Acad. Sci. USA 93: 11382-11388; Dull er al. (1998) J. Virol. 72:8463- 8471; Zuffery et al. (1998) J Virol. 72:9873-9880; Follenzi et al. (2000) Nature Genetics 25:217-222.
[0156] Pharmaceutically acceptable carriers are determined in part by the particular composition being admimstered, as well as by the particular method used to administer the composition. Accordingly, there is a wide variety of suitable formulations of pharmaceutical compositions available, as described below (see, e.g., Remington 's Pharmaceutical Sciences, 17th ed., 1989).
[0157] As noted above, the disclosed methods and compositions can be used in any type of cell including, but not limited to, prokaryotic cells, fungal cells, Archaeal cells, plant cells, insect cells, animal cells, vertebrate cells, mammalian cells and human cells. Suitable cell lines for protein expression are known to those of skill in the art and include, but are not limited to COS, CHO (e.g. , CHO-S, CHO-K1, CHO-DG44, CHO-DUXB11), VE O, MDCK, WI38, V79, B14AF28-G3, BH ,
HaK, NS0, SP2/0-Agl4, HeLa, HEK293 (e.g. , HEK293-F, HEK293-H, HEK293-T), perC6, insect cells such as Spodoptera fugiperda (Sf), and fungal cells such as Saccharomyces, Pischia and Schizosaccharomyces . Progeny, variants and derivatives of these cell lines can also be used.
Applications
[0158] The disclosed compositions and methods can be used for any application in which it is desired to modulate the Htt allele, including but not limited to, therapeutic and research applications.
[0159] Diseases and conditions which Htt repressing ZFP TFs or TALE TFs can be used as therapeutic agents include, but are not limited to, Huntington's disease. Additionally, methods and compositions comprising ZFNs or TALENs specific for mutant alleles of Htt can be used as a therapeutic for the treatment of Huntington's disease.
[0160] ZFP-TFs or TALE TFs that repress a HD Htt allele may also be used in conjunction with ZFP-TFs or TALE-TFs that activate neutrotrophic factors including, but not limited to, GDNF and BDNF. These ZFPs or TALEs (or polynucleotides encoding these ZFPs or TALEs) may be administered concurrently {e.g., in the same pharmaceutical compositions) or may be administered sequentially in any order.
[0161] Methods and compositions for the treatment of Huntington's disease also include stem cell compositions wherein a mutant copy of the Htt allele within the stem cells has been modified to a wild-type Htt allele using a Htt-specific ZFN or TALEN.
[0162] The methods and compositions of the invention are also useful for the design and implementation of in vitro and in vivo models, for example, animal models of trinucleotide repeate disorders, which allows for the study of these disorders. Non- limiting examples of suitable in vitro models include cells or cell lines from any organism, including fibroblasts. Non-limiting examples of suitable animals for use as animal models include, invertebrates (C. elegans, drosophila), rodents (e.g., rat or mouse), primates (e.g., non-human primates). EXAMPLES
Example 1: Design and Construction of Htt-targeted zinc finger protein transcription factors (ZFP-TFs) and ZFNs
[0163] Zinc finger proteins targeted to Htt were engineered essentially as described in U.S. Patent No. 6,534,261. Tables 1A and IB show the recognition helices of the DNA binding domain of exemplary Htt-targeted ZFPs, while Tables 2A and 2B show the target sequences of these ZFPs.
[0164] ZFPs with one contiguous array of zinc fingers were designed to target sites completely within the CAG repeat region (Figure IB). Such ZFPs may bind longer, mutant tracts with higher affinity and/or a higher net occupancy, achieving selective repression of the mutant allele. ZFNs were also designed that targeted sites which lay partially or wholly outside of the CAG region (Figure 1 A), and which will therefore bind to the wild type and mutant allele equally, and regulate expression from both alleles with similar efficiency. When designing zinc finger proteins to recognize the CAG region, a set of one- and two-finger modules can be employed in a 'mix and match' combination. Those modules are shown below in Table 2C.
Table 2C: Zinc finger recognition helices used in ZFP-TFs targeting CAG repeats
SEQ ID NO:
Target site F2 F3 (F2+F3)
CAGCAG RSDNLSE KRCNLRC 161
CAGCAG RSDNLSE KPYNLRT 162
CAGCAG RSDNLSE RLWNRKQ 163
CAGCAG RSDNLSV RRWNLRA 164
CAGCAG RSDNLSV RKWNRDS 165
CAGCAG RSDNLSE NTSPLML 166
CAGCAG RSDNLSE RRYNLVK 167
CTGCTG RSDTLSE RRWTLVG 168
GCAGCA QSSDLSR QWSTRKR 169
GCAGCA RSAHLSR QSGDLTR 170
GCAGCA QSGDLTR QSGDLTR 171
GCAGCA QSGDLTR QSSDLRR 172
GCTGCT QSSDLSR QSSDLRR 173
GCTGCT QSSDLSR HRSTRNR 174
AGC MACCRYA none 175
CAG RSANLRE none 176 CAG RNADRKK none 177
CTG RSDVLSE none 42
CTG RSAVLSE none 148
GCA QSGDLTR none 18
GCA QSSDLRR none 6
GCA QNATRIK none 178
GCT QSSDLSR none 31
AAG RSDNLRE none 65
[0165] Multimerizing ZFP TFs are also constructed as described above except that the vector also contains sequences encoding 1 or more protein interaction domains (also called dimerization or protein interaction domains) that enable multimerization of the expressed protein along a tract of trinucleotide repeats that is operably linked to the sequences encoding the ZFP TF. See, Figure ID and Figure 10. Table 3 shows dimerization domain designs that are used with ZFPs targeted to the CAG repeat region. Figure 10C shows protein sequences of the four ZFP monomer scaffolds that are designed to multimerize via interactions between dimerizing zinc fingers (DZ), DZ1 - DZ4. Designs are based on work described in Mol. Syst. Biol. (2006) 2:2006.2011. Figure 10D shows protein sequences of the seven ZFP monomer scaffolds that are designed to multimerize via interactions between coiled-coils (CC), CC1 - CC7. The design of CC#1 is based on the work described in (J Am. Chem. Soc. (2001), 123:3151-3152), while CC#2, CC#3 and CC#4 are based on (J Am. Chem. Soc. (2000), 122:5658-5659). CC and DZ domains allow the ZFP to polymerize within the major groove of a CAG tract (depicted in figure 10B). By choosing a finger array and dimerization domains with appropriate binding properties, efficient binding will occur only to the expanded CAG tract of a disease allele.
[0166] ZFP-TFs were constructed as fusion proteins comprising a nuclear localization sequence, the engineered zinc finger DNA-binding domain (Tables 1 A and IB), targeted to the Htt allele, and a KRAB repression domain from the human KOX1 protein. See, Fig 1 A, IB and ID. The designed DNA-binding domains contain 3-6 finger modules, recognizing 9-18 bp sequences (Tables 2A and 2B). Nucleotides in the target site that are contacted by the ZFP recognition helices are indicated in uppercase letters; non-contacted nucleotides indicated in lowercase. ZFP-ZFP-TF molecules were also constructed where two ZFP DNA binding domains were fused with a flexible linker and fused to a K AB repression domain (Figure IE). DNA binding domains were chosen from Tables 2 A and 2B.
Example 2: Repression of both alleles of Htt in human and mouse cells.
[ 01671 To repress both alleles of the Htt (non-allele-specific), ZFPs were designed to bind to the Htt promoter and exon 1 region, wherein the target site was not entirely within the CAG repeat. See, Figure 1 A. To test the activity of the Htt repressing ZFP TFs, the ZFP TFs were transfected into human cells and expression of Htt was monitored using real-time RT-PCR.
[0168] Human HEK293 cells (Graham et al (1977) J Gen Virol 36 :59-74) were cultured in DMEM supplemented with 10% FBS and le5 cells were transfected with 1 μg of plasmid DNA encoding indicated ZFP-KOX fusions by Amaxa
Nucleofector® following the manufacturer's instructions.
[0169] Transfected cells were incubated for 2 days, and the levels of endogenous human Huntingtin (Htt) and normalization control beta-actin (ACTB) were analyzed by real-time PCR using Hs00918176_ml and 4352935E primers and probes (Applied Biosystems), respectively, according to standard protocols. Htt levels were expressed as Htt/ ACTB ratios normalized to that of the mock-transfected samples (set as 1).
[01701 As shown in Figure 2 A, Htt-targeted ZFPs repressed Htt expression.
Western blot analyses were done using standard protocols to confirm the reduction in Htt protein level (Figure 2B); p65 protein was used as loading control.
[0171] Mouse Htt-specific ZFP TFs repressors were transiently transfected into Neuro2A cells (Klebe & Ruddle (1969) J Cell Biol. 43: 69A) using the
Lipofectamine® 2000 kit (Invitrogen) according to manufacturer's protocols. mHtt and ACTB mRNA levels were measured at 48 hours after transfection using ABI Taqman® primer/probe set Mm01213820 ml and 4352933E, respectively.
mHtt/ ACTB ratios for ZFP transfected samples were normalized to that of the GFP control (set as 1).
[0172] As shown in Figure 2C, the ZFPs repressed mouse Htt expression. In addition, mouse Htt-specific ZFP-TF repressors can repress mouse Htt in
immortalized striatal cells, STHdh(Ql 11/Q7), derived from Htt knock-in mice (Trettel et al. (2000) Hum. Mol. Genet 9: 2799-2809). See, Figures 2D and 2E. mRNA for indicated ZFPs were generated using the mMessage mMachine kit (Ambion), and 0.1 , 0.5 or 2 ug of these mRNAs were transfected using Amaxa nucleofector as described above. Cells were harvested 48 hours after transfection for mHtt and ACTB expression analysis as described above. More significant repression in the striatal cells compared to that in Neuro2A cells was observed and may be a result of enhanced transfection efficiency achieved via mRNA transfection in straital cells.
Example 3: Selective Repression of mutant Htt in human and mouse cells
[0173] To achieve selective repression of the mutant Htt allele, ZFPs were designed to bind within the CAG repeat. Figure 1 B shows one type of such ZFPs, with a contiguous array of zinc fingers linked to a repression domain (e.g. the KRAB domain from KOX1); these ZFPs can be designed with appropriate affinity such that threshold occupancy required from transcriptional repression can only be established on expanded CAG repeats. Figures 1C, ID and IE show threeother examples of ZFP design that can allow specific binding to the expanded CAG repeats.
[0174] ZFPs designed as illustrated in Figure I B were introduced into
ΡΓΕΚ293 cells and Htt expression evaluated. ZFP-encoding constructs were transfected into HEK293 cells using FugeneHD using standard protocols. Seventy- two hours after transfection total RNA was isolated and the levels of endogenous human Huntingtin (Htt) relative to internal control beta-actin (ACTB) were analyzed by real-time PCR using Hs00918176_ml and 4352935E primers and probes (Applied Biosystems), respectively. Htt/ACTB ratios for ZFP transfected samples were normalized to that of the GFP control (set as 1).
[0175] As shown in Figure 3A, ZFP repressors (fused with KRAB repression domain) designed to bind to CAG repeats (Figure IB), either to top or bottom strand, in HEK293 cells, effectively repressed Htt expression. Figure 3A depicts repressors of transcription where expression was measure in duplicate transfections (separate bars in the Figure) and multiple real-time PCR assays completed (error bars).
Different levels of repression by individual ZFPs suggest that they have different affinity to the CAG repeat region. Because Htt alleles in HEK293 cells have 16 and 17 CAG, this result also suggests that "weaker" ZFPs, such as 30640, do not repress Htt alleles with wild-type (unexpanded) CAG repeat length effectively. [0176] To test whether ZFPs such as 30640 can repress transcription of Htt alleles with expanded CAG repeats, luciferase reporters controlled by Htt
promoter/exon 1 fragment that contains different CAG repeat lengths were constructed. First, the human Htt promoter/exon 1 fragment was amplified from HEK293 genomic DNA using forward primer:
5' GAAGATCTCACTTGGGGTCCTCAGGTCGTGCCGAC (SEQ ID NO: 139) and reverse primer:
5' GTATCCAAGCTTCAGCTTTTCCAGGGTCGCCTAGGCGGTCT. (SEQ ID NO: 140).
[0177] The forward primer introduces a Bglll site, the reverse primer changes the first ATG of Htt into TAG and creates an Avrll site, and also includes a Hindlll site. The PCR product was digested with Bglll and Hindlll and ligated to pRL-TK vector (Promega) that was digested with the same enzymes to generate the construct pRL-Htt. Then the human Htt exonl fragment (coding sequence minus first ATG) was amplified from HEK293 genomic DNA or genomic DNA from HD patients with expanded CAG repeats using forward primer:
5' GCCTAGGCGACCCTGGAAAAGCTGATGAAGGCC (SEQ ID NO:141) and reverse primer: 5'
5' GTATCCAAGCTTGAGCTGCAGCGGGCCCAAACTCACG (SEQ ID NO: 142).
[0178] The forward primer introduces an Avrll site, the reverse primer introduces a Hindlll site. The PCR product was digested with Avrll and Hindlll and ligated to pRL-Htt vector that was digested with the same enzymes. Clones with 10, 17, 23 or 47 CAG repeats (pRL-Htt-CAG(x)) were identified by sequencing.
[0179] pRL-Htt-C AG(x) reporters (300 ng) and pGL3 -promoter reporter (lOOng, used as normalization control, Progema) were transfected into HEK293 cells with or without 100 ng of ZFP 30640 expression vector. Firefly (pGL reporter) and renilla (pRT reporter) luciferase activities were measured 24 hours after transfection. Renilla luciferase levels were normalized to those of firefly luciferase from the same transfected sample, and further normalized to the renilla/firefly ratio of the "reporter only" sample.
[0180] As shown in Figure 3B, repression of the luciferase reporters by ZFP-
TF 30640 increases with the length of the CAG repeat, suggesting that ZFPs with DNA binding affinities similar to that of 30640 can repress Htt promoter activity via an expanded CAG repeat, and the level of repression is dependent on the CAG repeat lengths.
[0181] Figure 3C shows a similar experiment as in Figure 3B, except the
"strong" ZFP-TF 30657 was also tested, and both 30640 and 30657 were tested at multiple doses as indicated. At every dose level, 30640 gave more repression of the pRL-Htt-CAG47 reporter than the pRL-Htt-CAG23 reporter (CAG repeat length- dependent repression), while 30657 repressed both reporters to similar levels. On the pRL-Htt-CAG23 reporter, 30640 gave less repression than 30657 at every dose level, recapitulating the difference in their activities on the endogenous Htt allele with normal CAG repeat length (HEK293 cells, Figure 3 A); but on the pRL-Htt-CAG47 reporter, 30640 and 30657 gave similar repression at every dose level, suggesting that "weaker" ZFPs such as 30640 can efficiently repress Htt promoter through an expanded CAG repeat, most likely because only an expanded CAG target can allow threshold occupancy required for repression to be established by such ZFPs.
[0182] Figure 3D shows ZFP-TFs 30640 and 30657 (fused to the KRAB repression domain of KOX1) can repress the knock-in Htt allele (CAG111) in immortalized striatal cells derived from the Hdh(Ql 11/Q7) knock-in mice, demonstrating the ZFPs such as 30640, which drives CAG repeat length-dependent repression of luciferase reporters, can also repress expression from an endogenous Htt allele that has expanded CAG repeat. mRNA for indicated ZFPs were generated using the mMessage mMachine kit (Ambion), and transfected into Hdh(Ql 11/Q7) cells at indicated doses using Amaxa nucleofector. To detect expression from the wt mouse Htt allele, forward primer CAGGTCCGGCAGAGGAACC (SEQ ID NO: 193) and reverse primer TTCACACGGTCTTTCTTGGTGG (SEQ ID NO: 194) were used in the real-time RT-PCR; to detect expression from the knockin Htt allele, forward primer GCCCGGCTGTGGCTGA (SEQ ID NO: 195) and reverse primer
TTCACACGGTCTTTCTTGGTGG (SEQ ID NO: 196) were used.
[0183] Figure 3E show the result of testing the ZFP-TFs 30640 and 30657 in an HD patient-derived fibroblast line (GM21756, Coriell) that has 15 and 70 CAGs on the normal and mutant Htt allele, respectively. A SNP -based allele-specific real-time PCR assay was first established to allow specific detection from the wild type or the mutant Htt allele. The phasing of the SNP (rs363099 T/C) was determined by Carroll et al. Mol Ther. (2011) 19:2178-85); "T" is on the normal allele and "C" is on the mutant allele. To detect Htt expression from the mutant allele (099C), cDNA from the fibroblast was amplified by real-time PGR (SsoFast EvaGreen Supermix, Bio-Rad) using forward primer 099C.F (5 'AGTTTGGAGGGTTTCTC, SEQ ID NO:143) and reverse primer 099.R5 (5' TCGACTAAAGCAGGATTTCAGG, SEQ ID NO: 144); the annealing/extension temperature was 55.6 °C. To detect Htt expression from the wild type allele (099T), real-time PGR of the fibroblast cDNA were done using forward primer 099T.F (5 ' AGTTTGG AGGGTTTCTT, SEQ ID NO:145), reverse primer 099.R5 and the 3'phosphorylated blocker oligo 099T.BL
(5'AGGGTTTCTCCGCTCAGC-3'phos, SEQ ID NO: 146); the annealing/extension temperature was 58.3°C. Total human Huntingtin (hHtt, both wt and mutant allele) levels and normalization control beta-actin (ACTB) levels were analyzed by real-time PCR using primer/probe Hs00918176_ml and 4352935E (Applied Biosystems), respectively. For the experiment shown in Figure 3E, mRNA for indicated ZFPs were generated using the mMessage mMachine kit (Ambion), 1 ug of mRNA was transfected using Amaxa nucleofector as above. Cells were harvested 48 hours after transfection; mRNA levels from the normal (CAG15, 099T),the mutant (CAG70, 099C) Htt allele and total Htt (hHtt) were quantified as described above and normalized to the levels of ACTB; the Htt/ACTB ratios for each sample was further normalized to that of the mock-transfected sample. The "strong" CAG-targeted ZFP 30657 repressed both alleles, as expected (based on its activity in HEK293 cells
Fig.3 A). ZFP 30640, which showed CAG repeat length-dependent repression of the reporters, gave <10% repression of the wild-type allele while repressed the mutant allele >90%. The levels of total Htt in each sample were consistent with those of wt and mutant Htt levels in the same sample.
[0184] ZFP-30640 was also tested in a normal fibroblast line as well as other
HD fibroblast lines that contain different CAG repeat length in the Htt gene (see Figure 3F). Htt expression from each allele was detected as described above. No Htt repression was observed in the normal fibroblast line (CAG18/18). In contrast, excellent allelic discrimination was observed in the CAG 15/67 and CAG15/70 lines at both a high and low dose of transfected 30640 mRNA ; similar results were obtain for the two HD fibroblast lines with intermediate CAG repeat length on the mutant allele (CAG 18/44 and CAG 18/45) - wherein the expanded allele is repressed by -80% at both the high and low doses of 30640, yet the CAG18 allele remained unaffected. Taken together, these data indicate that allele-specific repressors such as 30640 can maintain strong CAG allele length selectivity in the context of more prevalent disease genotypes such as CAG18/44 and CAG18/45.
[0185] Western blot analysis was used to show that that ZFPs such as 30640 selectively down-regulated mutant Htt protein levels in two patient-derived fibroblast lines, confirming allele-specific regulation that was shown by qPCR assays (see Figure 3G). ZFPs were delivered by mRNA transfection (Amaxa nucleofection) at a 300 ng dose into 4 replicates of 1.5e5 cells and pooled prior to plating in 12-well plates. At 48 hours, cells were washed and harvested for protein extract preparation. Approximately 2.5 ug of extract was loaded onto 5% Tris-acetate gels and detected by MAB2166 (Millipore). Additionally, the same samples were loaded on a 4-15% Tris- HC1 gels (Bio-Rad) and transferred using standard methods for detection by an anti B- Actin (1 :20,000, Sigma) as loading controls. Based on qPCR studies that measure Htt mRNA, 30640 is an allele-specific repressor targeting the CAG repeat; 32528 is biallelic repressors targeting the transcription start site (TSS), and 30657 is CAG- targeted repressor that repress both Htt alleles at the dose that was used. Western blot showed that 30640 specifically reduced the levels of mutant Htt (upper band) in both HD patient-derived cell lines, while 32528 and 30657 repressed both alleles similarly. Example 4: Additional CAG-targeted ZFP designs that drive allele specific repression of Htt.
[0186] Figure 4A shows the results of testing ZFP-TFs 30640, 30643, 30645 and 33074 (all targeted to the CAG repeat and uses the RAB repression domain) in a CAG18/45 HD fibroblast line. Different amounts of ZFP mRNA were transfected using Amaxa nucleofector as indicated, expression of the mutant Htt (right bar), wild type Htt (middle bar) and total Htt (both alleles, left bar) were measured as described above at 24 hours after transfection. ZFPs 30640, 30645 and 33074 drive allele- specific repression over the entire 3 ug - 10 ng ZFP mRNA dose range; while 30643 appears to repress both alleles significantly at doses that are 30 ng or higher, and begins to exhibit allele selectivity at the 10 ng dose.
[0187] Figure 4B shows the results of testing ZFP 30643, 30648, 30657 and
30658 (all targeted to CAG repeat and uses the KRAB repression domain) in a CAG 15/70 HD fibroblast line. Different amounts of ZFP mRNA were transfected using Amaxa nucleofector as indicated, expression of the mutant Htt (right bar), wild type Htt (middle bar) and total Htt (both alleles, left bar) were measured as described above at 24 hours after transfection. Compared to the ZFPs that were tested in the previous figure (30640, 30645 and 33074), these ZFPs drive mutant Hit-specific repression at lower doses. These results suggest that depend on ZFP expression levels that can be achieved in vivo (e.g. in the brains of HD patients), allele-specific repression of mutant Htt can be achieved using appropriate ZFP designs.
Example 5: Repression of alternate C AG-containing genes
[0188] Using the RNAs isolated in Example 3 (Fig. 3E), repression of other
CAG repeat containing genes was analyzed, and the results are depicted in Figure 5. The expression levels of the following genes was examined using real-time PCR and normalized to that of Actin: Ataxin 2 ("ATXN2"); Dynamin ("DNM1"); F-box only protein 11 ("FBXOH"), nitrate reductase ("NAP"); Origin recognition complex subunit 4 ("ORC4"); phosphokinase ("PHK"); OCT3/4 protein ("POU3"); THAP domain containing, apoptosis associated protein 2 ("ΤΗΑΡΠ"); TATA binding protein ("TBP"); and stanniocalcin 1("STC1"). In addition, the location of the CAG repeat sequence relative to the transcriptional start site (TSS) was noted, and is indicated in Figure 3F as "TSS@", where "+" indicates base position of CAG repeats that are downstream of TSS, and "-" indicates base position of CAG repeats that are upstream of TSS. Also, the number of CAG repeats ("#CAG") is indicated for each gene.
[0189] The data demonstrate that repression of the mutant expanded Htt allele by 30640 is highly specific, and only a subset of CAG repeat-containing genes whose CAG repeats are relatively close to their respective transcroption start sites maybe repression targets of ZFPs such as 30640.
Example 6: Genome- wide specificity of allele-speeific ZFP repressors of Htt
[0190] HD fibroblasts (CAG18/45) were transfected to study genome-wide specificity of CAG-targeted ZFPs by microarray analysis (Figure 6). ZFPs were delivered by rnRNA transfection (Amaxa nucleofection) at the indicated doses - ZFPs 30640, 30645 and 33074 were transfected in sextuplicate at the 75 ng, 15 ng and 15 ng dose, respectively; GFP-Kox mRNA (150 ng) was transfected as a control, and was used as carrier to bring the total amount of transfected mRNA to 150 ng in all samples. Expression from CAG18 (099T, middle bars) and CAG45 (099C, right bars) alleles was measured by allele-specific qPCR reagents at 24 hours after transfection as described above where each of the samples (1-6) are biological replicates (separate transfections). Htt levels were normalized to those of GAPDH. Mutant allele-specific repression of Htt was observed for all three ZFPs. The four most similar replicates were then chosen for microarray analysis (Affymetrix
HGU133plus2.0) as follows: GFP replicate 1, 3, 4 and 6; 30640 replicate 2, 3, 5 and 6; 30645 replicate 2, 3, 5 and 6; and 33074 replicate 1, 3, 4 and 5 were used for microarray analysis. Robust Multi-array Average (RMA) was used to normalize raw signals from each probe set; ZFP-transfected samples were compared to GFP- transfected samples using T-test; "change" calls were made on genes (probe sets) with >2 fold difference relative to control samples and T-test P-value<0.05. Based on that criterion, 30640 repressed only two genes, stanniocalcin 1 (STC1) and extended synaptotagmin-like protein 1 (ESYT1); 30645 and 33074 only repressed one gene each, STC1 and interleukin 17 receptor A (ILR17RA), respectively. Htt was not detected as a repressed (>2-fold repression) gene because the Htt probe set on the array detects both wt and mutant Htt mRNA. This experiment demonstrates that mutant Htt-specific ZFPs, when expressed at levels that drive efficient allele-specific repression of Htt, can operate with very high specificity genome- wide.
Example 7: Allele specific repression in HD neural stem cells (NSCs)
[0191] HD iPSC/ESCs were passaged with accutase and cultured on matrigel coated plates in E8 media (Life Technologies). Neural stem cells were derived using StemPro Neural Induction Medium (Life Technologies). Briefly, iPSC/ESCs were seeded into geltrex coated 6 well dish with 200,000 cells/well and when 10-20% confluent the medium was changed to StemPro Neural Induction Medium. Medium was changed every 2 days and NSC harvested and expanded on day 7. StemPro NSC SFM medium (Life Technologies) was used to culture NSCs. HD NSCs(CAGl 7/69, derived from Coriell GM23225 iPSC) were transfected with 1.5 or 0.5 μg ZFP mRNA using nucleofection. Forty-eight hours post transfection cells were harvested and expression quantified by RT-PCR. Allele-specific detection of Htt expression was performed using a SNP (rsl 143646)-based genotyping assay #4351376 (Applied Biosystems). At the ZFP doses that were tested, 30640 gave allele-specific repression of mutant Htt, 30643 gave -50% repression of wt Htt and -90% repression of mutant Htt, and 30648 repressed both alleles (Figure 7); the behavior of these ZFPs is consistent with that in HD fibroblasts (Figure 4). The total Htt levels (middle bars) for each sample is consistent with levels of mutant and wt Htt levels.
Example 8: Htt repression in differentiated HD neurons
[0192] HD NSCs were passaged with accutase on geltrex coated plates.
Neuron differentiation was induced by changing medium to neural differentiation medium containing StemPRO NSC SFM medium without (bFGF and EGF). Medium was changed every 3-4 days for up to 21 days. Neurons were derived from NSC
(CAG17/48, derived from HD ESCs) by culture in neural differentiation medium. On day 15 post neural induction cells were transfected with 1.0 or 0.5 μg ZFP mRNA using nucleofection. Forty-eight hours post transfection cells were harvested and gene expression quantified by RT-PCR. Because this patient line does not contain a SNP that allows qPCR-based allele-specific detection of wt and mutant Htt, only total Htt levels can be measured. Because we showed that 30640 and 33074 does not repress the CAG18 or CAG17 allele in HD fibroblasts and NSCs, the levelsof total Htt observed in 30640- and 33074-treated samples are consistent with allele-specific repression of the mutant allele (CAG48). More potent repression by 30643 and 30648 at the ZFP doses tested is also consistent with the behavior of these ZFPs in HD fibroblasts (Figure 8).
Example 9: A CAG targeted repressor represses mutant Htt transgene in R6/2 mice
[0193] R6/2 mice (which carries a transgene of mutant human Htt exon 1 with
-120 CAG repeat, see Mangiarini et al, (1996) Cell 15:197) received stereotactic, bilateral striatal injections of 3el0 vector genome of recombinant AAV2/6 encoding either ZFP 30640-KOX or GFP driven by a CMV promoter. Mice were injected at 5 weeks of age and sacrificed for molecular analysis at 8 weeks of age. Left and rightstriata were dissected from each hemisphere and snap frozen. To assess repression of the mutant Htt transgene, total RNA was extracted from each striatum with TRIzol Plus (Life Technologies) followed by cDNA synthesis using High Capacity RT (Life Technologies). Subsequently, R6/2 transgene expression was measured by qPCR and normalized to the geometric mean of three reference genes (Atp5b, Eif4a2, UbC) as previously described by Benn et al. ((2008) Molecular Neurodegeneration: 3, 17). We observed statistically significant repression (P <0.001) of the mutant Htt transgene in four ZFP-treated striata relative to the four GFP-treated control striata (Figure 9). The average R6/2 repression was 64.9% of the GFP-treated controls. Because complete coverage of the striatum was not achieved using a single stereotactic injection and AAV2/6 preferentially transduces neuronal cells, the fold of repression observed (-35%) is likely an underestimate of actual repression in cells that were transduced with the AAV vector.
Example 10: Selective Repression of mutant Htt using ZFPs with
dimerization/multimerization domains
[0194] In order to engineer zinc finger transcription factors to better discriminate between short CAG and long GAG repeats, we sought to both decrease the DNA-binding affinity of individual zinc finger transcription factors and increase the interaction strength between different copies of fusion protein bound to adjacent subsites within the CAG repeat. In order to decrease the DNA-binding affinity of individual zinc finger transcription factors, we generated zinc finger domains with fewer zinc fingers and/or with amino acid sequences expected to bind DNA with less than optimal affinity. In order increase the interaction strength between different copies of fusion protein bound to adjacent subsites within the CAG repeat, we fused various dimerization domains to our zinc finger transcription factors. The
dimerization domains can interact in a "parallel" fashion and yield "head-to-head" or "tail-to-tail" dimers of fusion proteins that contain them. One potential dimerization strategy requires an array of identical ZFP-transcription factor fusions that bind in a "head-to-tail" orientation and thus this strategy requires dimerization domains that interact in an "anti-parallel" fashion. See, e.g., McClain et al. (2001) J Am. Chem. Soc. 123:3151-3152) and dimerizing zinc finger peptides (Giesecke et al. (2006), Molecular Systems Biology 2:2006.2011).
[0195] Dimerization contracts CC1 and CC2 were based on pairs of antiparallel coiled coils (McClain et al , ibid, Ghosh et al. (2000) J Am Chem Soc 122:5658-5659). Dimerization constructs CC3 and CC4 were truncated versions of CC2 that lack either 4 residues or 7 residues respectively. Dimerization constructs DZ1 , DZ2, DZ3, and DZ4 were based on pairs of dimerizing zinc finger domains (Giesecke et al, ibid). In each case, one member of the pair was fused to the N- terminus of the zinc finger DNA binding domain and the other member of the pair was fused to the C-terminus of the zinc finger DNA binding domain. Short linkers rich in glycine and serine residues were used to fuse the dimerization domains to the zinc finger binding domain. Additional embodiments of the invention utilize linkers with alternate lengths and/or amino acid composition. Linkers with one or more residues removed or with one or more glycine or serine residues changes to other amino acid residues will reduce the flexibility of these linkers and may result in improved discrimination between long and short CAG repeats.
[0196] To achieve selective repression of the mutant Htt allele, ZFPs were designed as illustrated in Figure ID and Figure 10A and 4B. Figure I OC and 10D show the sequences of the multimerization domains. Figure 11A and 1 IB depict the results that experiments designed to measure the ability of the ZFP-TFs comprising the CC and DZ domains, respectively to repress their targets. For these experiments, indicated ZFP constructs (50 ng) were co-transfected with pRL-Htt-CAG17 (200ng), pGL3-Htt-CAG47 (200ng) and pVax-SEAP (secreted alkaline phosphatase, 10 ng, used as normalization control) into HEK293 cells. Luciferase activity and secreted alkaline phosphatase activities were measured 24 hours after transfection. The Renilla luciferase (CAG17)/SEAP and firefly luciferase (CAG47)/SEAP ratios for each sample were normalized to those of the reporter-only samples. The pGL3-Htt- CAG47 reporter was constructed in the same way as the pRL-Htt-CAG47 reporter (see Example 3), except the pGL-promoter construct (Promega) was used instead of the pRL-TK construct.
[0197J As shown in Figure 1 1 A, 3 ZFPs, when tested asone or more CC domain-containing constructs, enhanced repression of one or both reporters when compared to constructs with the same ZFP but no CC domains. Figure 1 IB shows that DZ1 and DZ3 domains enhanced repression of 32220 on both reporters.
[0198] These results suggest that the CC and DZ domains can in general increase affinity of multimerized ZFPs and that design of the DNA binding domain and the dimerization domain may yield optimal CAG-repeat length discrimination. Example 11: Selective repression of mutant Htt with ZFP-ZFP-Kox designs
[0199] ZFP TFs were tested in HD fibroblasts that were of the ZFP-ZFP-KOX design. In these experiments, the two ZFP DNA binding domains were linked together with a flexible linker (LRQKDAARGSAAMAERP FQ, SEQ ID NO: 179) and fused to a KOX repression domain. The linker was placed between the conserved histidines and cysteines. The proteins were tested as described above using ZFP mPvNA at indicated doses. These results in the CAG18/45 (Figure 12A) and
CAG20/41 (Figure 12B) HD fibroblast lines demonstrated that linking less active ZFP DNA binding domains in this fashion can result in composite ZFPs that drive allele- specific repression.
Example 12: Activation of Htt in mouse cells
[0200] ZFPs as described herein were also evaluated for their ability to activate Htt expression. ZFPs targeted to the +200 to +467 bp region (relative to the transcription start site) of mouse Htt were fused to the transcriptional activation domain of NFKB p65 subunit. This targeting region was chosen because this fragment was replaced by the corresponding sequence (majority of exon 1 and some intron 1 sequence) from human Htt in various knock-in mouse models of HD
(Menalled et al. (2003) J Comp. Neurol 4651 :11-26; Wheeler et al. (2000) Hum Mol Genet 8:115-122), therefore ZFPs targeted to this region can selectively activate the wild type allele in those animals but not the knock-in allele.
[0201] ZFPs were transfected into Neuro2A cells (both Htt alleles are wild type in these cells), mouse Htt and ACTB mRNA levels were measured as described in Example 2 (duplicate transfections and multiple assays).
[0202] As shown in Figure 13, an increase in Htt mRNA levels as compared to a mock transfection was detected using both ZFP-TFs. See, Figure 13 A. Increased Htt protein levels were confirmed by Western blot. See, Figure 13B.
[0203] The generation of the knock-in Htt allele is illustrated in Figure 13C; sequence alignment (Figure 13D) shows divergence between the mouse sequence that was replaced and the corresponding human sequence. Figure 13E shows that when such ZFP activators were transfected into immortalized striatal cells derived from HdhQl 11/Q7 knock-in mice, only the wild type Htt was selectively activated. Example 13: Regulation of Htt expression in vivo
[0204] To test efficacy of the Htt-specific ZFP TFs in vivo, AAV2 vectors encoding the ZFPs are produced. These AAV2 based constructs are then delivered to the brains of mice. For human Htt-specific ZFP TFs, AAV vectors are delivered to R6.2 mice or BAC HD mice (C57B1/6 or FVB/N strains) to assess the repression of the human transgene, as well as change in HD-like phenotypes. For mouse Htt- specific ZFPs (activators or repressors), AAV vectors are delivered to wild-type mice (C57B1/6 or FVB/N) or human Htt knock-in mice (HdhQl 11/Q7, HdhQ140/Q7 or HdhQ175/Q7) to assess the activation or repression of the endogenous mouse Htt expression. For ZFPs that preferentially targeting the CAG-expanded allele, AAV vectors are delivered to R6.2 mice or human Htt knock-in mice (HdhQl 1 1/Q7, HdhQl 40/Q7 or HdhQl 75/Q7) to examine the selective repression of wt vs.
expanded Htt allele. Following sacrifice, brain tissues are analyzed for Htt expression by Taqman real-time RT-PCR, and demonstrate that the Htt genes are modulated by ZFP-TFs.
Example 14: Co-transfection of a neurotrophic factor and a HD Htt allele- specific ZFP TF
[0205] The Htt-specific ZFP TFs identified above are co-transfected with ZFP TFs-specific for a brain neurotrophic factor. The ZFP TF specific for brain neurotrophic factors used are specific for either GDNF or BDNF.
Example 15: Design and Construction of Htt-targeted zinc finger nucleases (ZFNs)
[0206] ZFNs targeting human Htt and mouse Htt were designed to target the sequences flanking the CAG repeats, sequences near the first coding ATG, the stop codon, as well as in early exons. ZFNs were designed and incorporated into plasmids or adenoviral vectors essentially as described in Urnov et al. (2005) Nature
435(7042):646-651, Perez et al (2008) Nature Biotechnology 26(7): 808-816, and U.S. Patent Publication 2008/0131962. Example 16: Cleavage activity of Htt-specific ZFNs
[0207] To test cleavage activity, plasmids encoding the pairs of human Htt- specific ZFNs described above were transfected into K562 cells. K562 cells were obtained from the American Type Culture Collection and grown as recommended in F-12 medium (Invitrogen) supplemented with 10% qualified fetal calf serum (FCS, Cyclone). Cells were disassociated from plastic ware using TrypLE Select™ protease (Invitrogen). For transfection, one million K562 cells were mixed with 2μg of the zinc-finger nuclease plasmid and ΙΟΟμΙ, Amaxa Solution T. Cells were transfected in an Amaxa Nucleofector II™ using program U-23 and recovered into 1.4mL warm F- 12 medium + 10% FCS.
[0208] Genomic DNA was harvested and a portion of the Hit locus encompassing the intended cleavage site was PCR amplified. PCR using the
Accuprime HiFi polymerase from InVitrogen was performed as follows: after an initial 3 minute denaturation at 94°C, 30 cycles of PCR are performed with a 30 second denaturation step at 94°C followed by a 30 second annealing step at 58°C followed by a 30 second extension step at 68°C. After the completion of 30 cycles, the reaction was incubated at 68°C for 7 minutes, then at 10°C indefinitely.
[0209] The genomic DNA from the K562 Htt-specific ZFN treated cells was examined by the Surveyor™ nuclease (Transgenomic) as described, for example, in U.S. Patent Publication Nos. 20080015164; 20080131962 and 20080159996.
[0210] Plasmids encoding the pairs of mouse Htt-specific ZFNs were tested in similar fashion in Neuro-2a cells.
[0211] Figure 14A and B show that the ZFNs were capable of targeting the
Htt genes with a gene modification efficiency of between 8-40%, assayed as described previously by the amount of indels observed.
Example 17: Targeted integration of varying lengths of trinucleotide repeats
[0212] The Htt-specific ZFNs with the greatest cleaving activity for sequences flanking the CAG repeat as described above are used in a targeted integration strategy to introduce varying lengths of CAG repeat into a wild-type copy of Htt. Donors are constructed that contain 50, 80, 109 and 180 repeat CAG units. These donors are then transfected into K562 cells with plasmids encoding the Htt-specific ZFNs as described above. Verification of donor integration is achieved by genomic DNA isolation, PCR amplification (as described above) followed by sequencing of the region of interest.
[0213] ZFNs identified in the K562 cells which result in targeted integration of the donor alleles into the Htt allele are used to insert the variable length donor nucleic acids into human embryonic stem cells (hESC). Successful donor integration is verified by genomic DNA isolation, PCR and sequencing as described above.
Example 18: Disruption/knock-out of wild-type and/or mutant Htt
[0214] ZFNs that cleave in early exons can result in small insertion or deletions (in-dels) as a result non-homologous end joining (NHEJ), this can generate cell models with one or both alleles of Htt disrupted,
[0215J Indicated ZFN pairs were prepared as described above and tested for cleavage activity using the Cel I mismatch as described for Example 8. These ZFN pairs target early exons of human Htt, and thus may be used to knock-out either the wild-type or a mutant Htt allele.
[0216] As shown in Figure 14A, ZFP pairs 29627/29628, 29631/29632 (exon
12) and 29637/29638 (exon 18) cleaved the Htt gene and can thus be utilized for generating knock-out cell lines. Example 19: Expression tagging of wild-type and HD Htt alleles.
[0217] ZFNs with the greatest cleaving activity for the first or last coding exon are used to tag the wild-type and mutant Htt allele with different reporter proteins. Donor DNAs for each reporter (A and B) are designed based on the cleavage site of the lead ZFN pair(s) to allow targeted integration of the reporter gene to produce an in-frame fusion to Htt. Donor DNAs are co-transfected with the lead ZFN pair(s) into K562 cells for selecting the donor DNA construct that gives the highest frequency of integration.
[0218] ZFN pairs were prepared as described above and tested for cleavage activity using the Cel I mismatch as described for Example 8. The ZFN pairs used target the 3' end of the Htt coding sequence, and thus may be used to target either a wild-type or a mutant Htt allele. As shown in Figure 14B, ZFP pairs 25917/25916, 25920/25921 and 25923/25922 were capable of cleaving the Htt gene and can thus be utilized for the introduction of a reporter tag. [0219] The selected donor DNA construct for reporter A along with corresponding ZFNs are delivered to cells derived from subjects carrying mutant Htt gene (e.g. fibroblasts, induced pluripotent cells) Clones are derived and screened for the target integration of the reporter A. Heterozygous events are desired and the targeted alleles are identified by PGR. Clones containing a single reporter-tagged Htt allele and unmodified ZFN target sequence on the other allele are selected; the donor construct for reporter B and corresponding ZFNs are transfected to tag the second allele with the reporter B.
[0220] The resulting mouse embryonic stem cell clone contains the wild-type Htt allele and mutant allele tagged with two different markers that allow tracking of expression from each allele; these cells are used to generate mouse models of trinucleotide repeat disorders using standard protocols.
Example 20: Construction of active TALE-TF proteins against Htt.
[0221] TALE DNA binding domains were linked to the KRAB repression domain from the Koxl protein (TALE TF) and used to test repression of the Htt gene in HD patient (CAG 20/41)-derived fibroblasts. The construction of the TALE proteins was done as described previously (see co-owned US Patent publication 20110301073 and co-owned US Patent application 13/679,684, both of which are incorporated herein by reference), and were constructed with three different C- terminal architectures: +63, +231 and +278 as described in US20110301073. To construct the TALE TF expression plasmids, the TALEN expression plasmids described previously (see US20110301073) were used except that the Fokl domain used for in the TALENs was replaced with the KRAB repression domain. The linkages of the C-terminus of the TALE protein and the KRAB domain are shown below, where the KRAB domain sequence is indicated by underline. The bold and italicized text indicates the triple flag tag, the bold text indicates the nuclear localization sequence, "[repeats]" indicates the location of the TALE repeat unit array (full repeats plus the C-terminal half repeat), and the wavy underlined portion shows the sequence of the KRAB domain:
TALE-C63-Koxl :
MD-^HDGDH¾PHDJgyKDDDDJ¾ ¾PKKKRKVGIHGVPMVDLRTLGYSQOQQEKIKPKVRSTVA
TH¾HIVALSQHPAALGTVAVKYQDMIAALPEATHEAIVGVGKQWSGARALEALLTV¾GELRGPPLQLDTGQLLKI
AERGGVTAVEAVHAWRNALTGAPLN [repeats ] GGRPALESIVAQLSRPDPALAALTNDHLVALACLGGRP LP AVKKGLPHAPALIKRTHRRIPERTSHRVaGSGMDAKSLTAWSRTLVTFKDVFVDFTREEWKLLDTAQQIVYRNVM
LENYKNLVSLGYQLTKPDVILRLERGEEPWLVEREIHQETHPDSETAFEIKSSV (SEQ ID NO:197)
TALE-C231-Koxl:
MDYKDHDGDYKDHDIDYKDDDDK^I^KKKKVGIEGVP^OLRTLGYSQQQQEKIK KVRSTVAQ}iBEA VGiGF
THAHIVALSQHPAALGTVAVKYQDMIAALPEATHEAIVGVGKQWSGARALEALLTVAGELRGPPLQLDTGQLLKI AKRGGVT VEAVHAWRNALTGAPLN [repeats] GGRPALESIVAQLSRPDPALAALTNDHLVALACLGGRPALD
AVKKGLPHAPALIKRTKRRIPERTSHRVADHAQVVRVLGFFQCHSHPAQAFDDAMTQFGMSRHGLLQLFRRVGVT ELEARSGTLPPASQRWDRILQASGMKRAKPSPTSTQTPDQASLHAFADSLERDLDAPSPTHEGDQRRASSRKRSR SDRAVTGPSAQQSFEVRAPEQRDALHLPLSWRVKRPRTSIGGGLPDPGSGMDARSLTAWSRTLVTFKDVFVDFTR EEWKLLDTAQQIVYRNVMLENYKNLVSLGYQLTKPDVILRLEKGEEPWLVEREIHQETHPDSETAFEIKSSV
(SEQ ID NO: 198)
TALE-C278-Koxl
MDXKDHDGDYlWHDIDYKDDDDmRPKKKRKVGIHGVP VDLRTLGYSQQQQEKIKPKVRSTVAQHHEALVGHGF
THAHIVALSQHPAALGTVAVKYQDMIAALPEATHEAIVGVGKQWSGARALEALLTVAGELRGPPLQLDTGQLLKI ARRGGVTAVEAVHAWRNALTGAPLN [ repeats ] GGRPALESIVAQLSRPDPALAALTNDHLVALACLGGRP LD
AVKKGLPHAPALIKRTNRRIPERTSHRVADRAQVVRVLGFFQCHSHPAQAFDDAMTQFGMSRHGLLQLFRRVGVT ELEARSGTLPPASQRWDRILQASGMKRARPSPTSTQTPDQASLHAFADSLERDLDAPSPTHEGDQRRASSRRRSR SDRAVTGPSAQQSFEVRAPEQRDALHLPLSWRVKRPRTSIGGGLPDPTPTAADLAASSTVMREQDEDPFAGAADD FPAFNEEELAWLMELLPQGSGMDAKSLTA SRTLVTFRDVFVDFTREEWKLLDTAQQIVYRNVMLENYRNLVSLG YQLTRPDVILRLERGEEPWLVEREIHQBTBPDSETAFEIKSSV (SEQ ID MO: 199)
[0222] Base recognition was achieved using the canonical VD-base correspondences (the "TALE code": NI for A, HD for C, NN for G (NK in half repeat), NG for T). In some of the TALE TFs, the protein is designed to bind the sense (5 '-3') strand of the DNA, while in others, the TALE TF is designed to bind to the anti-sense (3 '-5') strand. This set of TALE TFs was designed to target the CAG repeats of the Htt gene. TALE DNA binding proteins often preferentially interact with a 'T' nucleotide base at the 5' end of the target, and so since the targets are CAG repeat regions, it can be predicted that the proteins that bind to the anti-sense DNA strand, and thus CTG repeat sequences with the base 'T' at the 5' 3nd of the target, might have better binding affinity and specificity and thus repressor activity.
[0223] The targets and numeric identifiers for the TALE TFs tested are shown below in Table 4. Numeric identifiers are labeled "SBS#", specificity for the Sense or Antisense strand is indicated ("S/A"), as well as the target, the number of repeat units or RVDs and the type of C-terminus. Table 4: Htt specific TALE-TFs
Figure imgf000077_0001
[0224] The TALE TFs in the table were then tested for Htt repression in HD patient (CAG 20/41) derived fibroblasts, and the results are shown in Figure 15. In this experiment, the cells were transfected with either 1000, 100 or 10 ng of TALE-TF encoding mKNA. The results for each TALE TF assayed are shown in groups of three, representing the three transfected mRNA amounts. In each grouping, there are also three samples: the left bar indicates the total Htt expression, the middle bar indicates the expression from the CAG20 Htt allele, and the right bar indicates the expression from the CAG41 Htt allele. The data demonstrates that there are some TALE TFs that were able to repress both Htt alleles (see for example 102454), while other TALE TFs were able to selectively inhibit the mutant Htt with the extended CAG repeat (see for example 102451 and 102472). [0225] All patents, patent applications and publications mentioned herein are hereby incorporated by reference in their entirety.
[0226] Although disclosure has been provided in some detail by way of illustration and example for the purposes of clarity of understanding, it will be apparent to those skilled in the art that various changes and modifications can be practiced without departing from the spirit or scope of the disclosure. Accordingly, the foregoing descriptions and examples should not be construed as limiting.

Claims

CLAIMS What is claimed is:
1. A non-naturally occurring zinc finger protein that binds to an Htt gene, the zinc finger protein comprising 4, 5 or 6 zinc finger domains ordered Fl to F4, Fl to F5 and Fl to F6. wherein the zinc finger domains comprise the recognition helix regions sequences shown in a single row of Table IB.
2. The zinc finger protein of claim 1, wherein the zinc finger protein binds entirely or partially outside the CAG repeat region of the Htt gene.
3. The zinc finger protein of claim 1 , wherein the zinc finger protein binds to sequences within the CAG repeat region of the Htt gene.
4. The zinc finger protein of any of claims 1 to 3, further comprising a dimerization domain that allows multimerization of zinc finger proteins when bound to DNA.
5. A fusion protein comprising a zinc finger protein of any of claims 1 to 4 and a functional domain.
6. The fusion protein of claim 5, wherein the functional domain is selected from the group consisting of a transcriptional activation domain, a transcriptional repression domain, and a nuclease domain.
7. A polynucleotide encoding one or more zinc finger proteins of claims 1 to 4 or one or more fusion proteins of claims 5 or 6.
8. A host cell comprising one or more zinc finger proteins of claims 1 to 4, one or more fusion proteins of claims 5 or 6, or one or more polynucleotides according to claim 7.
9. A pharmaceutical composition comprising one or more zinc finger proteins of claims 1 to 4, one or more fusion proteins of claims 5 or 6, or one or more polynucleotides according to claim 7.
10. A method of modifying expression of an Htt gene in a cell, the method comprising administering to the cell one or more polynucleotides encoding one or more fusion proteins according to claim 5.
11. The method of claim 10, wherein the Htt gene comprises at least one mutant allele.
12. The method of claim 10, wherein the Htt gene is wild-type.
13. The method of any of claims 10 to 12, wherein the fusion protein comprises a nuclease domain and expression of the Htt gene is inactivated.
14. A method of modifying an Htt gene in a cell, the method comprising, administering to the cell one or more polynucleotides encoding one or more fusion proteins according to claim 5, wherein the one or more fusion proteins comprises a nuclease domain and wherein the sequence of the Htt gene is modified.
15. A method of treating Huntington's Disease, the method comprising administering to the cell one or more polynucleotides encoding one or more fusion proteins according to claim 5 to a subject in need thereof.
16. A method of generating a model system for the study of Huntington's Disease, the method comprising modifying an Htt gene according to the method of claim 14.
17. The method of claim 16, wherein the Htt gene is modified to comprise one or more mutant alleles.
18. The method of claim 17, wherein the mutant alleles comprise expanded trinucleotide repeats.
19. The method of any of claims 16 to 18, wherein the cell comprises an embryonic stem cell.
PCT/US2013/028348 2012-02-29 2013-02-28 Methods and compositions for treating huntington's disease WO2013130824A1 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
MX2014010455A MX359327B (en) 2012-02-29 2013-02-28 Methods and compositions for treating huntington's disease.
CA2865011A CA2865011C (en) 2012-02-29 2013-02-28 Methods and compositions for treating huntington's disease
NZ629427A NZ629427A (en) 2012-02-29 2013-02-28 Methods and compositions for treating huntington’s disease
CN201380016072.9A CN104204225A (en) 2012-02-29 2013-02-28 Methods and compositions for treating huntington's disease
AU2013225950A AU2013225950B2 (en) 2012-02-29 2013-02-28 Methods and compositions for treating huntington's disease
EP13755872.2A EP2820159B1 (en) 2012-02-29 2013-02-28 Methods and compositions for treating huntington's disease
KR1020147026364A KR102084539B1 (en) 2012-02-29 2013-02-28 Methods and compositions for treating huntington's disease
JP2014560044A JP6490426B2 (en) 2012-02-29 2013-02-28 Methods and compositions for treating Huntington's disease
RU2014138989A RU2639277C2 (en) 2012-02-29 2013-02-28 Methods and compositions for huntington disease treatment
BR112014021104-3A BR112014021104B1 (en) 2012-02-29 2013-02-28 NON-NATURALLY OCCURRING FUSION PROTEIN COMPRISING AN MANIPULATED ZINC FINGER DNA-BINDING DOMAIN WHICH BINDS TO AN HTT GENE, ITS USE, IN VITRO METHOD OF MODIFYING THE EXPRESSION OF AN HTT GENE IN A CELL, AND METHOD OF GENERATION OF A MODEL SYSTEM FOR THE STUDY OF HUNTINGTON'S DISEASE
ZA2014/06209A ZA201406209B (en) 2012-02-29 2014-08-22 Methods and compositions for treating huntington's disease
HK15103974.7A HK1203566A1 (en) 2012-02-29 2015-04-24 Methods and compositions for treating huntingtons disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261605028P 2012-02-29 2012-02-29
US61/605,028 2012-02-29

Publications (1)

Publication Number Publication Date
WO2013130824A1 true WO2013130824A1 (en) 2013-09-06

Family

ID=49083290

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/028348 WO2013130824A1 (en) 2012-02-29 2013-02-28 Methods and compositions for treating huntington's disease

Country Status (14)

Country Link
US (7) US8841260B2 (en)
EP (1) EP2820159B1 (en)
JP (3) JP6490426B2 (en)
KR (1) KR102084539B1 (en)
CN (2) CN104204225A (en)
AU (1) AU2013225950B2 (en)
BR (1) BR112014021104B1 (en)
CA (1) CA2865011C (en)
HK (1) HK1203566A1 (en)
MX (1) MX359327B (en)
NZ (1) NZ629427A (en)
RU (1) RU2639277C2 (en)
WO (1) WO2013130824A1 (en)
ZA (1) ZA201406209B (en)

Cited By (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015059265A1 (en) 2013-10-25 2015-04-30 Cellectis Design of rare-cutting endonucleases for efficient and specific targeting dna sequences comprising highly repetitive motives
WO2015070212A1 (en) 2013-11-11 2015-05-14 Sangamo Biosciences, Inc. Methods and compositions for treating huntington's disease
EP2878667A1 (en) * 2013-11-29 2015-06-03 Institut Pasteur TAL effector means useful for partial or full deletion of DNA tandem repeats
WO2015089354A1 (en) * 2013-12-12 2015-06-18 The Broad Institute Inc. Compositions and methods of use of crispr-cas systems in nucleotide repeat disorders
US9068179B1 (en) 2013-12-12 2015-06-30 President And Fellows Of Harvard College Methods for correcting presenilin point mutations
WO2015089419A3 (en) * 2013-12-12 2015-09-17 The Broad Institute Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
US9228207B2 (en) 2013-09-06 2016-01-05 President And Fellows Of Harvard College Switchable gRNAs comprising aptamers
EP2982758A1 (en) 2014-08-04 2016-02-10 Centre Hospitalier Universitaire Vaudois (CHUV) Genome editing for the treatment of huntington's disease
US9260752B1 (en) 2013-03-14 2016-02-16 Caribou Biosciences, Inc. Compositions and methods of nucleic acid-targeting nucleic acids
US9322006B2 (en) 2011-07-22 2016-04-26 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9499597B2 (en) 2012-02-29 2016-11-22 Sangamo Biosciences, Inc. Methods and compositions for treating Huntington's disease
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
CN106459894A (en) * 2014-03-18 2017-02-22 桑格摩生物科学股份有限公司 Methods and compositions for regulation of zinc finger protein expression
JP2017515819A (en) * 2014-05-08 2017-06-15 サンガモ セラピューティクス， インコーポレイテッド Methods and compositions for treating Huntington's disease
US9822372B2 (en) 2012-12-12 2017-11-21 The Broad Institute Inc. CRISPR-Cas component systems, methods and compositions for sequence manipulation
US9834791B2 (en) 2013-11-07 2017-12-05 Editas Medicine, Inc. CRISPR-related methods and compositions with governing gRNAS
WO2018013840A1 (en) 2016-07-13 2018-01-18 Vertex Pharmaceuticals Incorporated Methods, compositions and kits for increasing genome editing efficiency
US9885026B2 (en) 2011-12-30 2018-02-06 Caribou Biosciences, Inc. Modified cascade ribonucleoproteins and uses thereof
US10000772B2 (en) 2012-05-25 2018-06-19 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
WO2018127462A1 (en) * 2017-01-03 2018-07-12 Zain Luqman Rula Therapeutic method for huntington's disease
US10077453B2 (en) 2014-07-30 2018-09-18 President And Fellows Of Harvard College CAS9 proteins including ligand-dependent inteins
US10113163B2 (en) 2016-08-03 2018-10-30 President And Fellows Of Harvard College Adenosine nucleobase editors and uses thereof
US10150985B2 (en) 2014-02-13 2018-12-11 Takara Bio Usa, Inc. Methods of depleting a target molecule from an initial collection of nucleic acids, and compositions and kits for practicing the same
US10167457B2 (en) 2015-10-23 2019-01-01 President And Fellows Of Harvard College Nucleobase editors and uses thereof
EP3352776A4 (en) * 2015-09-23 2019-03-13 Sangamo Therapeutics, Inc. Htt repressors and uses thereof
WO2019143675A1 (en) 2018-01-17 2019-07-25 Vertex Pharmaceuticals Incorporated Dna-pk inhibitors
WO2019143677A1 (en) 2018-01-17 2019-07-25 Vertex Pharmaceuticals Incorporated Quinoxalinone compounds, compositions, methods, and kits for increasing genome editing efficiency
WO2019143678A1 (en) 2018-01-17 2019-07-25 Vertex Pharmaceuticals Incorporated Dna-pk inhibitors
US10377998B2 (en) 2013-12-12 2019-08-13 The Broad Institute, Inc. CRISPR-CAS systems and methods for altering expression of gene products, structural information and inducible modular CAS enzymes
US10494621B2 (en) 2015-06-18 2019-12-03 The Broad Institute, Inc. Crispr enzyme mutations reducing off-target effects
US10550372B2 (en) 2013-12-12 2020-02-04 The Broad Institute, Inc. Systems, methods and compositions for sequence manipulation with optimized functional CRISPR-Cas systems
US10577630B2 (en) 2013-06-17 2020-03-03 The Broad Institute, Inc. Delivery and use of the CRISPR-Cas systems, vectors and compositions for hepatic targeting and therapy
WO2020072684A1 (en) * 2018-10-02 2020-04-09 Sangamo Therapeutics, Inc. Engineered genetic modulators
WO2020131862A1 (en) 2018-12-17 2020-06-25 The Broad Institute, Inc. Crispr-associated transposase systems and methods of use thereof
US10696986B2 (en) 2014-12-12 2020-06-30 The Board Institute, Inc. Protected guide RNAS (PGRNAS)
US10711285B2 (en) 2013-06-17 2020-07-14 The Broad Institute, Inc. Optimized CRISPR-Cas double nickase systems, methods and compositions for sequence manipulation
US10731181B2 (en) 2012-12-06 2020-08-04 Sigma, Aldrich Co. LLC CRISPR-based genome modification and regulation
US10745677B2 (en) 2016-12-23 2020-08-18 President And Fellows Of Harvard College Editing of CCR5 receptor gene to protect against HIV infection
US10781444B2 (en) 2013-06-17 2020-09-22 The Broad Institute, Inc. Functional genomics using CRISPR-Cas systems, compositions, methods, screens and applications thereof
US10930367B2 (en) 2012-12-12 2021-02-23 The Broad Institute, Inc. Methods, models, systems, and apparatus for identifying target sequences for Cas enzymes or CRISPR-Cas systems for target sequences and conveying results thereof
US10946108B2 (en) 2013-06-17 2021-03-16 The Broad Institute, Inc. Delivery, use and therapeutic applications of the CRISPR-Cas systems and compositions for targeting disorders and diseases using viral components
US11008588B2 (en) 2013-06-17 2021-05-18 The Broad Institute, Inc. Delivery, engineering and optimization of tandem guide systems, methods and compositions for sequence manipulation
US11041173B2 (en) 2012-12-12 2021-06-22 The Broad Institute, Inc. Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications
US11149267B2 (en) 2013-10-28 2021-10-19 The Broad Institute, Inc. Functional genomics using CRISPR-Cas systems, compositions, methods, screens and applications thereof
US11155795B2 (en) 2013-12-12 2021-10-26 The Broad Institute, Inc. CRISPR-Cas systems, crystal structure and uses thereof
US11180751B2 (en) 2015-06-18 2021-11-23 The Broad Institute, Inc. CRISPR enzymes and systems
US11268082B2 (en) 2017-03-23 2022-03-08 President And Fellows Of Harvard College Nucleobase editors comprising nucleic acid programmable DNA binding proteins
US11306324B2 (en) 2016-10-14 2022-04-19 President And Fellows Of Harvard College AAV delivery of nucleobase editors
US11319532B2 (en) 2017-08-30 2022-05-03 President And Fellows Of Harvard College High efficiency base editors comprising Gam
US11407985B2 (en) 2013-12-12 2022-08-09 The Broad Institute, Inc. Delivery, use and therapeutic applications of the CRISPR-Cas systems and compositions for genome editing
US11447770B1 (en) 2019-03-19 2022-09-20 The Broad Institute, Inc. Methods and compositions for prime editing nucleotide sequences
US11504389B2 (en) 2016-12-01 2022-11-22 Sangamo Therapeutics, Inc. Tau modulators and methods and compositions for delivery thereof
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
US11542496B2 (en) 2017-03-10 2023-01-03 President And Fellows Of Harvard College Cytosine to guanine base editor
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
US11578312B2 (en) 2015-06-18 2023-02-14 The Broad Institute Inc. Engineering and optimization of systems, methods, enzymes and guide scaffolds of CAS9 orthologs and variants for sequence manipulation
US11661590B2 (en) 2016-08-09 2023-05-30 President And Fellows Of Harvard College Programmable CAS9-recombinase fusion proteins and uses thereof
US11732274B2 (en) 2017-07-28 2023-08-22 President And Fellows Of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE)
US11795443B2 (en) 2017-10-16 2023-10-24 The Broad Institute, Inc. Uses of adenosine base editors
US11898179B2 (en) 2017-03-09 2024-02-13 President And Fellows Of Harvard College Suppression of pain by gene editing
US11912985B2 (en) 2020-05-08 2024-02-27 The Broad Institute, Inc. Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
US12121524B2 (en) 2019-01-16 2024-10-22 Vertex Pharmaceuticals Incorporated DNA-PK inhibitors

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11021737B2 (en) 2011-12-22 2021-06-01 President And Fellows Of Harvard College Compositions and methods for analyte detection
RU2699523C2 (en) 2012-12-17 2019-09-05 Президент Энд Фэллоуз Оф Харвард Коллидж Rna-guided engineering of human genome
EP2971184B1 (en) 2013-03-12 2019-04-17 President and Fellows of Harvard College Method of generating a three-dimensional nucleic acid containing matrix
WO2014159247A1 (en) 2013-03-14 2014-10-02 University Of Florida Research Foundation, Inc. Di-amino acid repeat-containing proteins associated with als
US10760064B2 (en) 2013-03-15 2020-09-01 The General Hospital Corporation RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
US11332719B2 (en) * 2013-03-15 2022-05-17 The Broad Institute, Inc. Recombinant virus and preparations thereof
KR102210322B1 (en) 2013-03-15 2021-02-01 더 제너럴 하스피탈 코포레이션 Using rna-guided foki nucleases (rfns) to increase specificity for rna-guided genome editing
CN105518146B (en) 2013-04-04 2022-07-15 哈佛学院校长同事会 Therapeutic uses of genome editing with CRISPR/Cas systems
EP3003392B1 (en) 2013-06-04 2019-10-23 President and Fellows of Harvard College Rna-guideded transcriptional regulation
US20140356956A1 (en) 2013-06-04 2014-12-04 President And Fellows Of Harvard College RNA-Guided Transcriptional Regulation
ES2767318T3 (en) 2013-06-17 2020-06-17 Broad Inst Inc Supply, modification and optimization of systems, methods and compositions to generate models and act on postmitotic cell diseases and disorders
US10011850B2 (en) 2013-06-21 2018-07-03 The General Hospital Corporation Using RNA-guided FokI Nucleases (RFNs) to increase specificity for RNA-Guided Genome Editing
JP2016528890A (en) 2013-07-09 2016-09-23 プレジデント アンド フェローズ オブ ハーバード カレッジ Therapeutic use of genome editing using the CRISPR / Cas system
RU2748433C2 (en) 2013-07-10 2021-05-25 Президент Энд Фэллоуз Оф Харвард Коллидж ORTHOGONAL Cas9 PROTEINS FOR RNA-GUIDED REGULATION AND GENE EDITING
US10563225B2 (en) 2013-07-26 2020-02-18 President And Fellows Of Harvard College Genome engineering
US10787684B2 (en) 2013-11-19 2020-09-29 President And Fellows Of Harvard College Large gene excision and insertion
US9074199B1 (en) 2013-11-19 2015-07-07 President And Fellows Of Harvard College Mutant Cas9 proteins
US11028388B2 (en) 2014-03-05 2021-06-08 Editas Medicine, Inc. CRISPR/Cas-related methods and compositions for treating Usher syndrome and retinitis pigmentosa
US11141493B2 (en) 2014-03-10 2021-10-12 Editas Medicine, Inc. Compositions and methods for treating CEP290-associated disease
US11339437B2 (en) 2014-03-10 2022-05-24 Editas Medicine, Inc. Compositions and methods for treating CEP290-associated disease
ES2745769T3 (en) 2014-03-10 2020-03-03 Editas Medicine Inc CRISPR / CAS related procedures and compositions for treating Leber 10 congenital amaurosis (LCA10)
US11242525B2 (en) 2014-03-26 2022-02-08 Editas Medicine, Inc. CRISPR/CAS-related methods and compositions for treating sickle cell disease
AU2015259191B2 (en) 2014-05-13 2019-03-21 Sangamo Therapeutics, Inc. Methods and compositions for prevention or treatment of a disease
WO2015188056A1 (en) 2014-06-05 2015-12-10 Sangamo Biosciences, Inc. Methods and compositions for nuclease design
US9616090B2 (en) 2014-07-30 2017-04-11 Sangamo Biosciences, Inc. Gene correction of SCID-related genes in hematopoietic stem and progenitor cells
CA2959070C (en) 2014-08-27 2020-11-10 Caribou Biosciences, Inc. Methods for increasing cas9-mediated engineering efficiency
CA2963080A1 (en) 2014-10-01 2016-04-07 The General Hospital Corporation Methods for increasing efficiency of nuclease-induced homology-directed repair
ES2878451T3 (en) 2014-11-14 2021-11-18 Voyager Therapeutics Inc Modulating polynucleotides
WO2016094872A1 (en) 2014-12-12 2016-06-16 The Broad Institute Inc. Dead guides for crispr transcription factors
WO2016094874A1 (en) 2014-12-12 2016-06-16 The Broad Institute Inc. Escorted and functionalized guides for crispr-cas systems
AU2015369725A1 (en) 2014-12-24 2017-06-29 Massachusetts Institute Of Technology CRISPR having or associated with destabilization domains
MX2017010369A (en) 2015-02-10 2017-12-14 Genzyme Corp VARIANT RNAi.
EP3286571B1 (en) 2015-04-24 2021-08-18 Editas Medicine, Inc. Evaluation of cas9 molecule/guide rna molecule complexes
US10179918B2 (en) 2015-05-07 2019-01-15 Sangamo Therapeutics, Inc. Methods and compositions for increasing transgene activity
CA2988854A1 (en) 2015-05-08 2016-11-17 President And Fellows Of Harvard College Universal donor stem cells and related methods
WO2016196324A1 (en) * 2015-05-29 2016-12-08 University Of Floridia Research Foundation, Inc. Methods for diagnosing huntington's disease
US9580727B1 (en) 2015-08-07 2017-02-28 Caribou Biosciences, Inc. Compositions and methods of engineered CRISPR-Cas9 systems using split-nexus Cas9-associated polynucleotides
US9926546B2 (en) 2015-08-28 2018-03-27 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
US9512446B1 (en) 2015-08-28 2016-12-06 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
WO2017070598A1 (en) 2015-10-23 2017-04-27 Caribou Biosciences, Inc. Engineered crispr class 2 cross-type nucleic-acid targeting nucleic acids
AU2016349288A1 (en) 2015-11-03 2018-05-31 President And Fellows Of Harvard College Method and apparatus for volumetric imaging of a three-dimensional nucleic acid containing matrix
CN116763942A (en) 2016-02-18 2023-09-19 宾州研究基金会 Intra-brain generation of GABAergic neurons
WO2017165862A1 (en) 2016-03-25 2017-09-28 Editas Medicine, Inc. Systems and methods for treating alpha 1-antitrypsin (a1at) deficiency
CA3019847A1 (en) 2016-04-04 2017-10-12 University Of Florida Research Foundation, Incorporated Manipulation of eif3 to modulate repeat associated non-atg (ran) translation
CN116200465A (en) 2016-04-25 2023-06-02 哈佛学院董事及会员团体 Hybrid chain reaction method for in situ molecular detection
US11951121B2 (en) 2016-05-18 2024-04-09 Voyager Therapeutics, Inc. Compositions and methods for treating Huntington's disease
KR20240056729A (en) 2016-05-18 2024-04-30 보이저 테라퓨틱스, 인크. Modulatory polynucleotides
AU2017305404B2 (en) 2016-08-02 2023-11-30 Editas Medicine, Inc. Compositions and methods for treating CEP290 associated disease
US10960085B2 (en) 2016-09-07 2021-03-30 Sangamo Therapeutics, Inc. Modulation of liver genes
US9816093B1 (en) 2016-12-06 2017-11-14 Caribou Biosciences, Inc. Engineered nucleic acid-targeting nucleic acids
WO2018170184A1 (en) 2017-03-14 2018-09-20 Editas Medicine, Inc. Systems and methods for the treatment of hemoglobinopathies
CA3060250A1 (en) 2017-04-17 2018-10-25 University Of Florida Research Foundation, Incorporated Regulation of ran protein translation by pkr and eif2a-p pathways
EP3612023A4 (en) 2017-04-20 2021-05-12 Egenesis, Inc. Methods for generating genetically modified animals
CN111108198A (en) 2017-05-05 2020-05-05 沃雅戈治疗公司 Compositions and methods for treating huntington's disease
EP3622070A2 (en) 2017-05-10 2020-03-18 Editas Medicine, Inc. Crispr/rna-guided nuclease systems and methods
DK3645719T3 (en) 2017-06-30 2022-05-16 Inscripta Inc Automated cell processing methods, modules, instruments and systems
JP7248658B2 (en) * 2017-09-22 2023-03-29 ジェンザイム・コーポレーション Variant RNAi
JP7350337B2 (en) 2017-09-26 2023-09-26 ユニバーシティー オブ フロリダ リサーチ ファンデーション， インク． Use of metformin and its analogs to reduce RAN protein levels in the treatment of neurological disorders
CN111372650A (en) 2017-09-30 2020-07-03 因思科瑞普特公司 Flow-through electroporation apparatus
US20190233816A1 (en) 2018-01-26 2019-08-01 Massachusetts Institute Of Technology Structure-guided chemical modification of guide rna and its applications
AU2019236209A1 (en) 2018-03-14 2020-10-01 Editas Medicine, Inc. Systems and methods for the treatment of hemoglobinopathies
US11421007B2 (en) 2018-04-18 2022-08-23 Sangamo Therapeutics, Inc. Zinc finger protein compositions for modulation of huntingtin (Htt)
CN116144653A (en) * 2018-06-21 2023-05-23 陕西杆粒生物科技有限公司 Anti-apoptosis baculovirus expression vector
US20220306699A1 (en) * 2018-06-27 2022-09-29 Altius Institute For Biomedical Sciences Nucleic Acid Binding Domains and Methods of Use Thereof
WO2020077007A1 (en) 2018-10-09 2020-04-16 The University Of British Columbia Compositions and systems comprising transfection-competent vesicles free of organic-solvents and detergents and methods related thereto
WO2020076976A1 (en) 2018-10-10 2020-04-16 Readcoor, Inc. Three-dimensional spatial molecular indexing
EP3911349A4 (en) * 2019-01-15 2023-01-18 Sangamo Therapeutics, Inc. Htt repressors and uses thereof
AU2020262281A1 (en) 2019-04-23 2021-11-04 Sangamo Therapeutics, Inc. Modulators of chromosome 9 open reading frame 72 gene expression and uses thereof
WO2020263639A1 (en) * 2019-06-28 2020-12-30 The Penn State Research Foundation Methods and materials for treating huntington's disease
JP2022543112A (en) 2019-08-01 2022-10-07 サナ バイオテクノロジー，インコーポレイテッド DUX4-expressing cells and their uses
AU2020336302A1 (en) 2019-08-23 2022-03-03 Sana Biotechnology, Inc. CD24 expressing cells and uses thereof
EP4051787A1 (en) 2019-11-01 2022-09-07 Sangamo Therapeutics, Inc. Gin recombinase variants
CN114728018B (en) * 2019-11-01 2024-07-19 阿尔尼拉姆医药品有限公司 Huntington (HTT) iRNA pharmaceutical compositions and methods of use thereof
AU2020376048A1 (en) 2019-11-01 2022-06-02 Sangamo Therapeutics, Inc. Compositions and methods for genome engineering
CA3173096A1 (en) 2020-03-25 2021-09-30 Sonja SCHREPFER Hypoimmunogenic neural cells for the treatment of neurological disorders and conditions
US20230190871A1 (en) 2020-05-20 2023-06-22 Sana Biotechnology, Inc. Methods and compositions for treatment of viral infections
IL300516A (en) 2020-08-13 2023-04-01 Sana Biotechnology Inc Methods of treating sensitized patients with hypoimmunogenic cells, and associated methods and compositions
RU2748997C1 (en) * 2020-12-11 2021-06-02 Федеральное государственное автономное образовательное учреждение высшего образования "Российский национальный исследовательский медицинский университет имени Н.И. Пирогова" Министерства здравоохранения Российской Федерации (ФГАОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России) Universal epigenome repressor of transcription of target genes in human cells
AU2021412988A1 (en) 2020-12-31 2023-06-15 Sana Biotechnology, Inc. Methods and compositions for modulating car-t activity
KR20240013135A (en) 2021-05-27 2024-01-30 사나 바이오테크놀로지, 인크. Hypoimmunogenic cells containing engineered HLA-E or HLA-G
EP4370544A2 (en) 2021-07-14 2024-05-22 Sana Biotechnology, Inc. Altered expression of y chromosome-linked antigens in hypoimmunogenic cells
MX2024001443A (en) 2021-08-11 2024-05-15 Sana Biotechnology Inc Inducible systems for altering gene expression in hypoimmunogenic cells.
AU2022325232A1 (en) 2021-08-11 2024-02-08 Sana Biotechnology, Inc. Genetically modified primary cells for allogeneic cell therapy
AU2022325955A1 (en) 2021-08-11 2024-02-08 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions
WO2023019227A1 (en) 2021-08-11 2023-02-16 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions
JP2024534772A (en) 2021-08-11 2024-09-26 サナ バイオテクノロジー，インコーポレイテッド Genetically modified cells for allogeneic cell therapy
WO2023069790A1 (en) 2021-10-22 2023-04-27 Sana Biotechnology, Inc. Methods of engineering allogeneic t cells with a transgene in a tcr locus and associated compositions and methods
KR20240137574A (en) 2021-12-23 2024-09-20 사나 바이오테크놀로지, 인크. CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS FOR THERAPY OF AUTOIMMUNE DISEASES AND RELATED METHODS
WO2023154578A1 (en) 2022-02-14 2023-08-17 Sana Biotechnology, Inc. Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells
AU2023220128A1 (en) 2022-02-17 2024-08-22 Sana Biotechnology, Inc. Engineered cd47 proteins and uses thereof
WO2023173123A1 (en) 2022-03-11 2023-09-14 Sana Biotechnology, Inc. Genetically modified cells and compositions and uses thereof
WO2024151541A1 (en) 2023-01-09 2024-07-18 Sana Biotechnology, Inc. Type-1 diabetes autoimmune mouse

Citations (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US789538A (en) 1904-11-11 1905-05-09 Colin E Ham Dumb-bell.
US4186183A (en) 1978-03-29 1980-01-29 The United States Of America As Represented By The Secretary Of The Army Liposome carriers in chemotherapy of leishmaniasis
US4217344A (en) 1976-06-23 1980-08-12 L'oreal Compositions containing aqueous dispersions of lipid spheres
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4261975A (en) 1979-09-19 1981-04-14 Merck & Co., Inc. Viral liposome particle
US4485054A (en) 1982-10-04 1984-11-27 Lipoderm Pharmaceuticals Limited Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4774085A (en) 1985-07-09 1988-09-27 501 Board of Regents, Univ. of Texas Pharmaceutical administration systems containing a mixture of immunomodulators
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5049386A (en) 1985-01-07 1991-09-17 Syntex (U.S.A.) Inc. N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
WO1991016024A1 (en) 1990-04-19 1991-10-31 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
WO1991017424A1 (en) 1990-05-03 1991-11-14 Vical, Inc. Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US5176996A (en) 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
WO1993024641A2 (en) 1992-06-02 1993-12-09 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Adeno-associated virus with inverted terminal repeat sequences as promoter
US5356802A (en) 1992-04-03 1994-10-18 The Johns Hopkins University Functional domains in flavobacterium okeanokoites (FokI) restriction endonuclease
US5420032A (en) 1991-12-23 1995-05-30 Universitge Laval Homing endonuclease which originates from chlamydomonas eugametos and recognizes and cleaves a 15, 17 or 19 degenerate double stranded nucleotide sequence
US5422251A (en) 1986-11-26 1995-06-06 Princeton University Triple-stranded nucleic acids
WO1995019431A1 (en) 1994-01-18 1995-07-20 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
US5436150A (en) 1992-04-03 1995-07-25 The Johns Hopkins University Functional domains in flavobacterium okeanokoities (foki) restriction endonuclease
US5487994A (en) 1992-04-03 1996-01-30 The Johns Hopkins University Insertion and deletion mutants of FokI restriction endonuclease
WO1996006166A1 (en) 1994-08-20 1996-02-29 Medical Research Council Improvements in or relating to binding proteins for recognition of dna
US5585245A (en) 1994-04-22 1996-12-17 California Institute Of Technology Ubiquitin-based split protein sensor
US5789538A (en) 1995-02-03 1998-08-04 Massachusetts Institute Of Technology Zinc finger proteins with high affinity new DNA binding specificities
WO1998037186A1 (en) 1997-02-18 1998-08-27 Actinova Limited In vitro peptide or protein expression library
WO1998044350A1 (en) 1997-04-02 1998-10-08 The Board Of Trustees Of The Leland Stanford Junior University Detection of molecular interactions by reporter subunit complementation
WO1998053057A1 (en) 1997-05-23 1998-11-26 Gendaq Limited Nucleic acid binding polypeptide library
WO1998053059A1 (en) 1997-05-23 1998-11-26 Medical Research Council Nucleic acid binding proteins
WO1998054311A1 (en) 1997-05-27 1998-12-03 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
US5925523A (en) 1996-08-23 1999-07-20 President & Fellows Of Harvard College Intraction trap assay, reagents and uses thereof
US5928638A (en) 1996-06-17 1999-07-27 Systemix, Inc. Methods for gene transfer
GB2338237A (en) 1997-02-18 1999-12-15 Actinova Ltd In vitro peptide or protein expression library
US6008336A (en) 1994-03-23 1999-12-28 Case Western Reserve University Compacted nucleic acids and their delivery to cells
WO2000027878A1 (en) 1998-11-09 2000-05-18 Gendaq Limited Screening system for zinc finger polypeptides for a desired binding ability
WO2000042219A1 (en) 1999-01-12 2000-07-20 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
US6140081A (en) 1998-10-16 2000-10-31 The Scripps Research Institute Zinc finger binding domains for GNN
US6242568B1 (en) 1994-01-18 2001-06-05 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
WO2001060970A2 (en) 2000-02-18 2001-08-23 Toolgen, Inc. Zinc finger domains and methods of identifying same
WO2001083793A2 (en) 2000-04-28 2001-11-08 Sangamo Biosciences, Inc. Targeted modification of chromatin structure
WO2001083732A2 (en) 2000-04-28 2001-11-08 Sangamo Biosciences, Inc. Databases of regulatory sequences; methods of making and using same
WO2001088197A2 (en) 2000-05-16 2001-11-22 Massachusetts Institute Of Technology Methods and compositions for interaction trap assays
WO2002016536A1 (en) 2000-08-23 2002-02-28 Kao Corporation Bactericidal antifouling detergent for hard surface
WO2002044376A2 (en) 2000-11-28 2002-06-06 Sangamo Biosciences, Inc. Modulation of gene expression using insulator binding proteins
US6410248B1 (en) 1998-01-30 2002-06-25 Massachusetts Institute Of Technology General strategy for selecting high-affinity zinc finger proteins for diverse DNA target sites
WO2002077227A2 (en) 2000-11-20 2002-10-03 Sangamo Biosciences, Inc. Iterative optimization in the design of binding proteins
US20020160940A1 (en) 1999-01-12 2002-10-31 Case Casey C. Modulation of endogenous gene expression in cells
US6479626B1 (en) 1998-03-02 2002-11-12 Massachusetts Institute Of Technology Poly zinc finger proteins with improved linkers
WO2002099084A2 (en) 2001-04-04 2002-12-12 Gendaq Limited Composite binding polypeptides
US6503717B2 (en) 1999-12-06 2003-01-07 Sangamo Biosciences, Inc. Methods of using randomized libraries of zinc finger proteins for the identification of gene function
WO2003016496A2 (en) 2001-08-20 2003-02-27 The Scripps Research Institute Zinc finger binding domains for cnn
US20030082552A1 (en) 2000-09-29 2003-05-01 Wolffe Alan P. Modulation of gene expression using localization domains
US6599692B1 (en) 1999-09-14 2003-07-29 Sangamo Bioscience, Inc. Functional genomics using zinc finger proteins
US20030232410A1 (en) 2002-03-21 2003-12-18 Monika Liljedahl Methods and compositions for using zinc finger endonucleases to enhance homologous recombination
US20040002092A1 (en) 2002-03-15 2004-01-01 Sylvain Arnould Hybrid and single chain meganucleases and use thereof
US6689558B2 (en) 2000-02-08 2004-02-10 Sangamo Biosciences, Inc. Cells for drug discovery
US6833252B1 (en) 1992-05-05 2004-12-21 Institut Pasteur Nucleotide sequence encoding the enzyme I-SecI and the uses thereof
US20050026157A1 (en) 2002-09-05 2005-02-03 David Baltimore Use of chimeric nucleases to stimulate gene targeting
US20050064474A1 (en) 2003-08-08 2005-03-24 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US20050208489A1 (en) 2002-01-23 2005-09-22 Dana Carroll Targeted chromosomal mutagenasis using zinc finger nucleases
US20050267061A1 (en) 2004-04-08 2005-12-01 Sangamo Biosciences, Inc. Methods and compositions for treating neuropathic and neurodegenerative conditions
US7013219B2 (en) 1999-01-12 2006-03-14 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US20060063231A1 (en) 2004-09-16 2006-03-23 Sangamo Biosciences, Inc. Compositions and methods for protein production
US7030215B2 (en) 1999-03-24 2006-04-18 Sangamo Biosciences, Inc. Position dependent recognition of GNN nucleotide triplets by zinc fingers
US7067317B2 (en) 2000-12-07 2006-06-27 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
US7070934B2 (en) 1999-01-12 2006-07-04 Sangamo Biosciences, Inc. Ligand-controlled regulation of endogenous gene expression
US7074596B2 (en) 2002-03-25 2006-07-11 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Synthesis and use of anti-reverse mRNA cap analogues
US20060153826A1 (en) 2003-01-28 2006-07-13 Sylvain Arnould Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereof
US20060188987A1 (en) 2003-08-08 2006-08-24 Dmitry Guschin Targeted deletion of cellular DNA sequences
WO2007014275A2 (en) 2005-07-26 2007-02-01 Sangamo Biosciences, Inc. Targeted integration and expression of exogenous nucleic acid sequences
US20070117128A1 (en) 2005-10-18 2007-05-24 Smith James J Rationally-designed meganucleases with altered sequence specificity and DNA-binding affinity
US7253273B2 (en) 2004-04-08 2007-08-07 Sangamo Biosciences, Inc. Treatment of neuropathic pain with zinc finger proteins
US7262054B2 (en) 2002-01-22 2007-08-28 Sangamo Biosciences, Inc. Zinc finger proteins for DNA binding and gene regulation in plants
US20070218528A1 (en) 2004-02-05 2007-09-20 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US20080015164A1 (en) 2006-05-19 2008-01-17 Sangamo Biosciences, Inc. Methods and compositions for inactivation of dihydrofolate reductase
US7361635B2 (en) 2002-08-29 2008-04-22 Sangamo Biosciences, Inc. Simultaneous modulation of multiple genes
US20080131962A1 (en) 2006-05-25 2008-06-05 Sangamo Biosciences, Inc. Engineered cleavage half-domains
US20080159996A1 (en) 2006-05-25 2008-07-03 Dale Ando Methods and compositions for gene inactivation
US20090068164A1 (en) 2005-05-05 2009-03-12 The Ariz Bd Of Regents On Behald Of The Univ Of Az Sequence enabled reassembly (seer) - a novel method for visualizing specific dna sequences
WO2009042163A2 (en) 2007-09-27 2009-04-02 Sangamo Biosciences, Inc. Rapid in vivo identification of biologically active nucleases
US20090136465A1 (en) 2007-09-28 2009-05-28 Intrexon Corporation Therapeutic Gene-Switch Constructs and Bioreactors for the Expression of Biotherapeutic Molecules, and Uses Thereof
WO2009068164A1 (en) 2007-11-27 2009-06-04 Peter Moosbauer Circuit and method for controlling the power supply of a consumer with current pulses having steep flanks
US20100003756A1 (en) 2008-06-10 2010-01-07 Sangamo BioSciences ,Inc. Methods and compositions for generation of Bax-and Bak-deficient cell lines
WO2010079430A1 (en) 2009-01-12 2010-07-15 Ulla Bonas Modular dna-binding domains and methods of use
WO2011016840A2 (en) 2009-07-28 2011-02-10 Sangamo Biosciences, Inc. Methods and compositions for treating trinucleotide repeat disorders
US20110201055A1 (en) 2010-02-08 2011-08-18 Yannick Doyon Engineered cleavage half-domains
US20110287512A1 (en) 2010-05-03 2011-11-24 Sangamo Biosciences, Inc. Compositions for linking zinc finger modules
WO2011146121A1 (en) 2010-05-17 2011-11-24 Sangamo Biosciences, Inc. Novel dna-binding proteins and uses thereof
US8153773B2 (en) 2007-06-19 2012-04-10 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Synthesis and use of anti-reverse phosphorothioate analogs of the messenger RNA cap
US9405700B2 (en) 2010-11-04 2016-08-02 Sonics, Inc. Methods and apparatus for virtualization in an integrated circuit

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070060606A1 (en) 1999-10-07 2007-03-15 Robertson Harold A Compounds and methods for modulating phosphodiesterase 10A
EP1303608A2 (en) * 2000-07-21 2003-04-23 Syngenta Participations AG Zinc finger domain recognition code and uses thereof
KR100535326B1 (en) * 2004-01-20 2005-12-09 한국생명공학연구원 Differentiation regulating agent containing gene which regulating differentiation from stem cell to natural killer cell as effective ingradient
EP2314614B1 (en) * 2005-02-28 2015-11-25 Sangamo BioSciences, Inc. Anti-angiogenic methods and compositions
CN101365801B (en) * 2005-10-28 2013-03-27 阿尔尼拉姆医药品有限公司 Compositions and methods for inhibiting expression of huntingtin gene
PT2415872T (en) 2006-12-14 2016-07-07 Sangamo Biosciences Inc Optimized non-canonical zinc finger proteins
UA100505C2 (en) * 2006-12-14 2013-01-10 ДАУ АГРОСАЙЕНСИЗ ЕлЕлСи Protein with zinc fingers
ATE462787T1 (en) 2007-06-18 2010-04-15 Commissariat Energie Atomique REVERSIBLE SIRNA-SILENCING OF A MUTATED AND ENDOGENOUS HUNTINGTON WILD-TYPE AND ITS APPLICATION TO THE TREATMENT OF HUNTINGTON'S DISEASE
ES2713560T3 (en) * 2010-10-15 2019-05-22 Fund Centre De Regulacio Genòmica Peptides that have zinc finger domains and uses of these
KR102084539B1 (en) 2012-02-29 2020-03-04 상가모 테라퓨틱스, 인코포레이티드 Methods and compositions for treating huntington's disease

Patent Citations (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US789538A (en) 1904-11-11 1905-05-09 Colin E Ham Dumb-bell.
US4217344A (en) 1976-06-23 1980-08-12 L'oreal Compositions containing aqueous dispersions of lipid spheres
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4186183A (en) 1978-03-29 1980-01-29 The United States Of America As Represented By The Secretary Of The Army Liposome carriers in chemotherapy of leishmaniasis
US4261975A (en) 1979-09-19 1981-04-14 Merck & Co., Inc. Viral liposome particle
US4485054A (en) 1982-10-04 1984-11-27 Lipoderm Pharmaceuticals Limited Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5049386A (en) 1985-01-07 1991-09-17 Syntex (U.S.A.) Inc. N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US4774085A (en) 1985-07-09 1988-09-27 501 Board of Regents, Univ. of Texas Pharmaceutical administration systems containing a mixture of immunomodulators
US5422251A (en) 1986-11-26 1995-06-06 Princeton University Triple-stranded nucleic acids
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5176996A (en) 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
WO1991016024A1 (en) 1990-04-19 1991-10-31 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
WO1991017424A1 (en) 1990-05-03 1991-11-14 Vical, Inc. Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US5420032A (en) 1991-12-23 1995-05-30 Universitge Laval Homing endonuclease which originates from chlamydomonas eugametos and recognizes and cleaves a 15, 17 or 19 degenerate double stranded nucleotide sequence
US5356802A (en) 1992-04-03 1994-10-18 The Johns Hopkins University Functional domains in flavobacterium okeanokoites (FokI) restriction endonuclease
US5436150A (en) 1992-04-03 1995-07-25 The Johns Hopkins University Functional domains in flavobacterium okeanokoities (foki) restriction endonuclease
US5487994A (en) 1992-04-03 1996-01-30 The Johns Hopkins University Insertion and deletion mutants of FokI restriction endonuclease
US6833252B1 (en) 1992-05-05 2004-12-21 Institut Pasteur Nucleotide sequence encoding the enzyme I-SecI and the uses thereof
WO1993024641A2 (en) 1992-06-02 1993-12-09 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Adeno-associated virus with inverted terminal repeat sequences as promoter
WO1995019431A1 (en) 1994-01-18 1995-07-20 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
US6242568B1 (en) 1994-01-18 2001-06-05 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
US6140466A (en) 1994-01-18 2000-10-31 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
US6008336A (en) 1994-03-23 1999-12-28 Case Western Reserve University Compacted nucleic acids and their delivery to cells
US5585245A (en) 1994-04-22 1996-12-17 California Institute Of Technology Ubiquitin-based split protein sensor
WO1996006166A1 (en) 1994-08-20 1996-02-29 Medical Research Council Improvements in or relating to binding proteins for recognition of dna
US6013453A (en) 1994-08-20 2000-01-11 Medical Research Council Binding proteins for recognition of DNA
US6007988A (en) 1994-08-20 1999-12-28 Medical Research Council Binding proteins for recognition of DNA
US5789538A (en) 1995-02-03 1998-08-04 Massachusetts Institute Of Technology Zinc finger proteins with high affinity new DNA binding specificities
US5928638A (en) 1996-06-17 1999-07-27 Systemix, Inc. Methods for gene transfer
US5925523A (en) 1996-08-23 1999-07-20 President & Fellows Of Harvard College Intraction trap assay, reagents and uses thereof
US6200759B1 (en) 1996-08-23 2001-03-13 President And Fellows Of Harvard College Interaction trap assay, reagents and uses thereof
WO1998037186A1 (en) 1997-02-18 1998-08-27 Actinova Limited In vitro peptide or protein expression library
GB2338237A (en) 1997-02-18 1999-12-15 Actinova Ltd In vitro peptide or protein expression library
WO1998044350A1 (en) 1997-04-02 1998-10-08 The Board Of Trustees Of The Leland Stanford Junior University Detection of molecular interactions by reporter subunit complementation
WO1998053057A1 (en) 1997-05-23 1998-11-26 Gendaq Limited Nucleic acid binding polypeptide library
WO1998053059A1 (en) 1997-05-23 1998-11-26 Medical Research Council Nucleic acid binding proteins
WO1998053058A1 (en) 1997-05-23 1998-11-26 Gendaq Limited Nucleic acid binding proteins
WO1998053060A1 (en) 1997-05-23 1998-11-26 Gendaq Limited Nucleic acid binding proteins
WO1998054311A1 (en) 1997-05-27 1998-12-03 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
US6410248B1 (en) 1998-01-30 2002-06-25 Massachusetts Institute Of Technology General strategy for selecting high-affinity zinc finger proteins for diverse DNA target sites
US7153949B2 (en) 1998-03-02 2006-12-26 Massachusetts Institute Of Technology Nucleic acid encoding poly-zinc finger proteins with improved linkers
US6903185B2 (en) 1998-03-02 2005-06-07 Massachusetts Institute Of Technology Poly zinc finger proteins with improved linkers
US6479626B1 (en) 1998-03-02 2002-11-12 Massachusetts Institute Of Technology Poly zinc finger proteins with improved linkers
US6140081A (en) 1998-10-16 2000-10-31 The Scripps Research Institute Zinc finger binding domains for GNN
WO2000027878A1 (en) 1998-11-09 2000-05-18 Gendaq Limited Screening system for zinc finger polypeptides for a desired binding ability
US20020160940A1 (en) 1999-01-12 2002-10-31 Case Casey C. Modulation of endogenous gene expression in cells
US7070934B2 (en) 1999-01-12 2006-07-04 Sangamo Biosciences, Inc. Ligand-controlled regulation of endogenous gene expression
US6979539B2 (en) 1999-01-12 2005-12-27 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6933113B2 (en) 1999-01-12 2005-08-23 Sangamo Biosciences, Inc. Modulation of endogenous gene expression in cells
US6453242B1 (en) 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
WO2000042219A1 (en) 1999-01-12 2000-07-20 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
US7163824B2 (en) 1999-01-12 2007-01-16 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6824978B1 (en) 1999-01-12 2004-11-30 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US7013219B2 (en) 1999-01-12 2006-03-14 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6607882B1 (en) 1999-01-12 2003-08-19 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US7030215B2 (en) 1999-03-24 2006-04-18 Sangamo Biosciences, Inc. Position dependent recognition of GNN nucleotide triplets by zinc fingers
US6599692B1 (en) 1999-09-14 2003-07-29 Sangamo Bioscience, Inc. Functional genomics using zinc finger proteins
US6503717B2 (en) 1999-12-06 2003-01-07 Sangamo Biosciences, Inc. Methods of using randomized libraries of zinc finger proteins for the identification of gene function
US6689558B2 (en) 2000-02-08 2004-02-10 Sangamo Biosciences, Inc. Cells for drug discovery
WO2001060970A2 (en) 2000-02-18 2001-08-23 Toolgen, Inc. Zinc finger domains and methods of identifying same
US20020115215A1 (en) 2000-04-28 2002-08-22 Wolffe Alan P. Targeted modification of chromatin structure
WO2001083732A2 (en) 2000-04-28 2001-11-08 Sangamo Biosciences, Inc. Databases of regulatory sequences; methods of making and using same
WO2001083793A2 (en) 2000-04-28 2001-11-08 Sangamo Biosciences, Inc. Targeted modification of chromatin structure
WO2001088197A2 (en) 2000-05-16 2001-11-22 Massachusetts Institute Of Technology Methods and compositions for interaction trap assays
WO2002016536A1 (en) 2000-08-23 2002-02-28 Kao Corporation Bactericidal antifouling detergent for hard surface
US20030082552A1 (en) 2000-09-29 2003-05-01 Wolffe Alan P. Modulation of gene expression using localization domains
WO2002077227A2 (en) 2000-11-20 2002-10-03 Sangamo Biosciences, Inc. Iterative optimization in the design of binding proteins
US6794136B1 (en) 2000-11-20 2004-09-21 Sangamo Biosciences, Inc. Iterative optimization in the design of binding proteins
WO2002044376A2 (en) 2000-11-28 2002-06-06 Sangamo Biosciences, Inc. Modulation of gene expression using insulator binding proteins
US7067317B2 (en) 2000-12-07 2006-06-27 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
WO2002099084A2 (en) 2001-04-04 2002-12-12 Gendaq Limited Composite binding polypeptides
WO2003016496A2 (en) 2001-08-20 2003-02-27 The Scripps Research Institute Zinc finger binding domains for cnn
US7262054B2 (en) 2002-01-22 2007-08-28 Sangamo Biosciences, Inc. Zinc finger proteins for DNA binding and gene regulation in plants
US20050208489A1 (en) 2002-01-23 2005-09-22 Dana Carroll Targeted chromosomal mutagenasis using zinc finger nucleases
US20040002092A1 (en) 2002-03-15 2004-01-01 Sylvain Arnould Hybrid and single chain meganucleases and use thereof
US20060078552A1 (en) 2002-03-15 2006-04-13 Sylvain Arnould Hybrid and single chain meganucleases and use thereof
US20030232410A1 (en) 2002-03-21 2003-12-18 Monika Liljedahl Methods and compositions for using zinc finger endonucleases to enhance homologous recombination
US7074596B2 (en) 2002-03-25 2006-07-11 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Synthesis and use of anti-reverse mRNA cap analogues
US7361635B2 (en) 2002-08-29 2008-04-22 Sangamo Biosciences, Inc. Simultaneous modulation of multiple genes
US20050026157A1 (en) 2002-09-05 2005-02-03 David Baltimore Use of chimeric nucleases to stimulate gene targeting
US20060206949A1 (en) 2003-01-28 2006-09-14 Sylvain Arnould Custom-made meganuclease and use thereof
US20060153826A1 (en) 2003-01-28 2006-07-13 Sylvain Arnould Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereof
US20060188987A1 (en) 2003-08-08 2006-08-24 Dmitry Guschin Targeted deletion of cellular DNA sequences
US20050064474A1 (en) 2003-08-08 2005-03-24 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US20070218528A1 (en) 2004-02-05 2007-09-20 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US7253273B2 (en) 2004-04-08 2007-08-07 Sangamo Biosciences, Inc. Treatment of neuropathic pain with zinc finger proteins
US20050267061A1 (en) 2004-04-08 2005-12-01 Sangamo Biosciences, Inc. Methods and compositions for treating neuropathic and neurodegenerative conditions
US20060063231A1 (en) 2004-09-16 2006-03-23 Sangamo Biosciences, Inc. Compositions and methods for protein production
US20090068164A1 (en) 2005-05-05 2009-03-12 The Ariz Bd Of Regents On Behald Of The Univ Of Az Sequence enabled reassembly (seer) - a novel method for visualizing specific dna sequences
WO2007014275A2 (en) 2005-07-26 2007-02-01 Sangamo Biosciences, Inc. Targeted integration and expression of exogenous nucleic acid sequences
US20070117128A1 (en) 2005-10-18 2007-05-24 Smith James J Rationally-designed meganucleases with altered sequence specificity and DNA-binding affinity
US20080015164A1 (en) 2006-05-19 2008-01-17 Sangamo Biosciences, Inc. Methods and compositions for inactivation of dihydrofolate reductase
US20080131962A1 (en) 2006-05-25 2008-06-05 Sangamo Biosciences, Inc. Engineered cleavage half-domains
US20080159996A1 (en) 2006-05-25 2008-07-03 Dale Ando Methods and compositions for gene inactivation
US8153773B2 (en) 2007-06-19 2012-04-10 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Synthesis and use of anti-reverse phosphorothioate analogs of the messenger RNA cap
WO2009042163A2 (en) 2007-09-27 2009-04-02 Sangamo Biosciences, Inc. Rapid in vivo identification of biologically active nucleases
US20090136465A1 (en) 2007-09-28 2009-05-28 Intrexon Corporation Therapeutic Gene-Switch Constructs and Bioreactors for the Expression of Biotherapeutic Molecules, and Uses Thereof
WO2009068164A1 (en) 2007-11-27 2009-06-04 Peter Moosbauer Circuit and method for controlling the power supply of a consumer with current pulses having steep flanks
US20100003756A1 (en) 2008-06-10 2010-01-07 Sangamo BioSciences ,Inc. Methods and compositions for generation of Bax-and Bak-deficient cell lines
WO2010079430A1 (en) 2009-01-12 2010-07-15 Ulla Bonas Modular dna-binding domains and methods of use
WO2011016840A2 (en) 2009-07-28 2011-02-10 Sangamo Biosciences, Inc. Methods and compositions for treating trinucleotide repeat disorders
US20110082093A1 (en) 2009-07-28 2011-04-07 Sangamo Biosciences, Inc. Methods and compositions for treating trinucleotide repeat disorders
US20110201055A1 (en) 2010-02-08 2011-08-18 Yannick Doyon Engineered cleavage half-domains
US20110287512A1 (en) 2010-05-03 2011-11-24 Sangamo Biosciences, Inc. Compositions for linking zinc finger modules
WO2011146121A1 (en) 2010-05-17 2011-11-24 Sangamo Biosciences, Inc. Novel dna-binding proteins and uses thereof
US20110301073A1 (en) 2010-05-17 2011-12-08 Sangamo Biosciences, Inc. Novel DNA-binding proteins and uses thereof
US9405700B2 (en) 2010-11-04 2016-08-02 Sonics, Inc. Methods and apparatus for virtualization in an integrated circuit

Non-Patent Citations (162)

* Cited by examiner, † Cited by third party
Title
"METHODS IN ENZYMOLOGY", ACADEMIC PRESS
"METHODS IN ENZYMOLOGY", vol. 304, 1999, ACADEMIC PRESS, article "Chromatin"
"METHODS IN MOLECULAR BIOLOGY", vol. 119, 1999, HUMANA PRESS, article "Chromatin Protocols"
"Nucleases", 1993, COLD SPRING HARBOR LABORATORY PRESS
"Remington's Pharmaceutical Sciences", 1985
"Remington's Pharmaceutical Sciences", 1989
AHMAD ET AL., CANCER RES., vol. 52, 1992, pages 4817 - 4820
ALVAREZ ET AL., HUM. GENE THER., vol. 5, 1997, pages 597 - 613
ANDERSON, SCIENCE, vol. 256, 1992, pages 808 - 813
ARGAST ET AL., J. MOL. BIOL., vol. 280, 1998, pages 345 - 353
ARNOULD ET AL., J. MOL. BIOL., vol. 355, 2006, pages 443 - 458
ASHWORTH ET AL., NATURE, vol. 441, 2006, pages 656 - 659
AUSUBEL ET AL.: "CURRENT PROTOCOLS IN MOLECULAR BIOLOGY", 1987, JOHN WILEY & SONS
BEERLI ET AL., NATURE BIOTECHNOL., vol. 20, 2002, pages 135 - 141
BEERLI ET AL., PROC. NATL. ACAD. SCI. USA, vol. 95, 1998, pages 14623 - 33
BEHR ET AL., BIOCONJUGATE CHEM., vol. 5, 1994, pages 382 - 389
BELFORT ET AL., NUCLEIC ACIDS RES., vol. 25, 1997, pages 3379 - 3388
BENN ET AL., MOLECULAR NEURODEGENERATION, vol. 3, 2008, pages 17
BIRD ET AL., CELL, vol. 99, 1999, pages 451 - 454
BITINAITE ET AL., PROC. NATL. ACAD. SCI. USA, vol. 95, 1998, pages 10,570 - 10,575
BITKO; BARIK, J. VIROL., vol. 72, 1998, pages 5610 - 5618
BLAESE ET AL., CANCER GENE THER, vol. 2, 1995, pages 291 - 297
BLAESE ET AL., SCIENCE, vol. 270, 1995, pages 475 - 480
BOCH ET AL., SCIENCE, vol. 326, 2009, pages 1509 - 1512
BONAS ET AL., MOL GEN GENET, vol. 218, 1989, pages 127 - 136
BUCHSCHER ET AL., J. VIROL., vol. 66, 1992, pages 2731 - 2739
CARROLL ET AL., MOL THER., vol. 19, 2011, pages 2178 - 85
CHAMES ET AL., NUCLEIC ACIDS RES, vol. 33, no. 20, 2005, pages e178
CHEM ET AL., PLANT CELL, vol. 8, 1996, pages 305 - 321
CHEVALIER ET AL., MOLEC. CELL, vol. 10, 2002, pages 895 - 905
CHILTON ET AL., PLANT PHYSIOLOGY, vol. 133, 2003, pages 956 - 65
CHO ET AL., PLANT MOL. BIOL., vol. 40, 1999, pages 419 - 429
CHOO ET AL., CURR. OPIN. STRUCT. BIOL., vol. 10, 2000, pages 411 - 416
CHRISTIAN ET AL., GENETICS, 2010
CIRILLO ET AL., EMBO J., vol. 17, 1998, pages 244 - 254
COLLINGWOOD ET AL., J. MOL. ENDOCRINOL., vol. 23, 1999, pages 255 - 275
CORDINGLEY ET AL., CELL, vol. 48, 1987, pages 261 - 270
CRYSTAL, SCIENCE, vol. 270, 1995, pages 404 - 410
DAVID SEGAL, ELIFE, vol. 2, 2013, pages e00563
DAVIES; RUBINSZTEIN, JOURNAL OF MEDICAL GENETICS, vol. 43, 2006, pages 893 - 896
DI PROSPERO; FISCHBECK, NATURE REVIEWS GENETICS, vol. 6, 2005, pages 756 - 765
DILLON, TIBTECH, vol. 11, 1993, pages 167 - 175
DOYLE; HUNT, NEUROREPORT, vol. 8, 1997, pages 2937 - 2942
DRANOFF ET AL., HUM. GENE THER., vol. 1, 1997, pages 111 - 2
DUJON ET AL., GENE, vol. 82, 1989, pages 115 - 118
DULL ET AL., J. VIROL., vol. 72, 1998, pages 8463 - 8471
DUNBAR ET AL., BLOOD, vol. 85, 1995, pages 3048 - 305
ELLEM ET AL., IMMUNOL IMMUNOTHER., vol. 44, no. 1, 1997, pages 10 - 20
EPINAT ET AL., NUCLEIC ACIDS RES., vol. 31, 2003, pages 2952 - 2962
EPINAT ET AL., NUCLEIC ACIDS RES., vol. 31, 2003, pages 2952 - 62
FIELDS ET AL., NATURE, vol. 340, 1989, pages 245 - 246
FOLLENZI ET AL., NATURE GENETICS, vol. 25, 2000, pages 217 - 222
FRESHNEY ET AL.: "Culture of Animal Cells, A Manual of Basic Technique", 1994
GAO ET AL., GENE THERAPY, vol. 2, 1995, pages 710 - 722
GHOSH ET AL., JAM CHEM SOC, vol. 122, 2000, pages 5658 - 5659
GIESECKE ET AL., MOLECULAR SYSTEMS BIOLOGY, vol. 2, 2006
GIMBLE ET AL., J. MOL. BIOL., vol. 263, 1996, pages 163 - 180
GOFF ET AL., GENES DEV, vol. 5, 1991, pages 298 - 309
GONG ET AL., PLANT MOL. BIOL., vol. 41, 1999, pages 33 - 44
GOUBLE ET AL., J. GENE MED., vol. 8, no. 5, 2006, pages 616 - 622
GRAHAM ET AL., CELL, vol. 125, 2006, pages 1179 - 1191
GRAHAM ET AL., J GEN VIROL, vol. 36, 1977, pages 59 - 74
HADDADA ET AL.: "Current Topics in Microbiology and Immunology", 1995
HAGMANN ET AL., J. VIROL., vol. 71, 1997, pages 5952 - 5962
HAN ET AL., PROC. NATL. ACAD. SCI. USA, vol. 92, 1995, pages 9747 - 9751
HERMONAT; MUZYCZKA, PNAS, vol. 81, 1984, pages 6466 - 6470
HEUER ET AL., APPL AND ENVIR MICRO, vol. 73, no. 13, 2007, pages 4379 - 4384
HEUER ET AL., APPLIED AND ENVIRONMENTAL MICROBIOLOGY, vol. 73, no. 13, 2007, pages 4379 - 4384
HOBO ET AL., PROC. NATL. ACAD. SCI. USA, vol. 96, 1999, pages 15,348 - 15,353
INABA ET AL., J. EXP. MED., vol. 176, 1992, pages 1693 - 1702
ISALAN ET AL., NATURE BIOTECHNOL., vol. 19, 2001, pages 656 - 660
J. AM. CHEM. SOC., vol. 122, 2000, pages 5658 - 5659
J. AM. CHEM. SOC., vol. 123, 2001, pages 3151 - 3152
JASIN, TRENDS GENET, vol. 12, 1996, pages 224 - 228
JINEKET, ELIFE, vol. 2, 2013, pages e00471
JINEKET, SCIENCE, vol. 337, 2012, pages 816 - 821
JOHANN ET AL., J. VIROL., vol. 66, 1992, pages 1635 - 1640
KAY ET AL., SCIENCE, vol. 318, 2007, pages 648 - 651
KEARNS ET AL., GENE THER., vol. 9, 1996, pages 748 - 55
KELLS ET AL., MOLECULAR THERAPY, vol. 9, no. 5, 2004, pages 682 - 688
KIM ET AL., J. BIOL. CHEM., vol. 269, 1994, pages 31,978 - 31,982
KIM ET AL., PROC NATL ACAD SCI USA, vol. 93, no. 3, 1996, pages 1156 - 1160
KIM ET AL., PROC. NATL. ACAD. SCI. USA, vol. 91, 1994, pages 883 - 887
KLEBE; RUDDLE, J. CELL BIOL., vol. 43, 1969, pages 69A
KNOEPFLER ET AL., CELL, vol. 99, 1999, pages 447 - 450
KOHN ET AL., NAT. MED., vol. 1, 1995, pages 1017 - 102
KOTIN, HUMAN GENE THERAPY, vol. 5, 1994, pages 793 - 801
KREMER; PERRICAUDET, BRITISH MEDICAL BULLETIN, vol. 51, no. 1, 1995, pages 31 - 44
LEMON ET AL., CURR. OPIN. GENET. DEV., vol. 9, 1999, pages 499 - 504
LEO ET AL., GENE, vol. 245, 2000, pages 1 - 11
LI ET AL., PROC. NATL. ACAD. SCI. USA, vol. 89, 1992, pages 4275 - 4279
LI ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 2764 - 2768
LIU ET AL., CANCER GENE THER., vol. 5, 1998, pages 3 - 28
MACDIARMID ET AL., NATURE BIOTECHNOLOGY, vol. 27, no. 7, 2009, pages 643
MALECH ET AL., PNAS, vol. 94, no. 22, 1997, pages 12133 - 12138
MALIK ET AL., TRENDS BIOCHEM. SCI., vol. 25, 2000, pages 277 - 283
MANGIARINI ET AL., CELL, vol. 15, 1996, pages 197
MANTEUFFEL-CYMBOROWSKA, ACTA BIOCHIM. POL., vol. 46, 1999, pages 77 - 89
MAPP ET AL., PROC. NATL. ACAD. SCI. USA, vol. 97, 2000, pages 3930 - 3935
MCCLAIN ET AL., J. AM. CHEM. SOC., vol. 123, 2001, pages 3151 - 3152
MCKENNA ET AL., J. STEROID BIOCHEM. MOL. BIOL., vol. 69, 1999, pages 3 - 12
MENALLED ET AL., J. COMP. NEUROL, vol. 4651, 2003, pages 11 - 26
MILLER ET AL., J. VIROL., vol. 65, 1991, pages 2220 - 2224
MILLER, NATURE, vol. 357, 1992, pages 455 - 460
MITANI; CASKEY, TIBTECH, vol. 11, 1993, pages 162 - 166
MITTELMAN, D. ET AL.: "Zinc-finger directed double-strand breaks within CAG repeat tracts promote repeat instability in human cells.", PROC. NATL. ACAD. SCI. USA., vol. 106, no. 24, 16 June 2009 (2009-06-16), pages 9607 - 9612, XP002660316 *
MOL. SYST. BIOL., vol. 2, 2006
MOLINARI ET AL., EMBO J., vol. 18, 1999, pages 6439 - 6447
MONET ET AL., BIOCHEM. BIOPHYSICS. RES. COMMON., vol. 255, 1999, pages 88 - 93
MOSCOU; BOGDANOVE, SCIENCE, vol. 326, 2009, pages 1501
MUZYCZKA, J. CLIN. INVEST., vol. 94, 1994, pages 1351
NABEL; FELGNER, TIBTECH, vol. 11, 1993, pages 211 - 217
OGAWA ET AL., GENE, vol. 245, 2000, pages 21 - 29
OKANAMI ET AL., GENES CELLS, vol. 1, 1996, pages 87 - 99
ORY ET AL., PROC. NATL. ACAD. SCI. USA, vol. 93, 1996, pages 11382 - 11388
PABO ET AL., ANN. REV. BIOCHEM., vol. 70, 2001, pages 313 - 340
PAQUES ET AL., CURRENT GENE THERAPY, vol. 7, 2007, pages 49 - 66
PEREZ ET AL., NATURE BIOTECHNOLOGY, vol. 26, no. 7, 2008, pages 808 - 816
PERLER ET AL., NUCLEIC ACIDS RES., vol. 22, 1994, pages 1125 - 1127
PINA ET AL., CELL, vol. 60, 1990, pages 719 - 731
PORTEUS ET AL., NAT. BIOTECHNOL., vol. 23, 2005, pages 967 - 73
PUCHTA ET AL., PROC. NATL. ACAD. SCI. USA, vol. 93, 1996, pages 5055 - 60
REMACLE ET AL., EMBO JOURNAL, vol. 18, no. 18, 1999, pages 5073 - 5084
REMY ET AL., BIOCONJUGATE CHEM., vol. 5, 1994, pages 647 - 654
ROBERTS ET AL., NUCLEIC ACIDS RES., vol. 31, 2003, pages 418 - 420
ROBERTSON ET AL., NATURE GENET, vol. 25, 2000, pages 338 - 342
ROBYR ET AL., MOL. ENDOCRINOL., vol. 14, 2000, pages 329 - 347
RONG ET AL., GENES DEV., vol. 16, 2002, pages 1568 - 81
ROSENECKER ET AL., INFECTION, vol. 24, no. 1, 1996, pages 5 - 10
ROUTE ET AL., MOL. CELL. BIOL., vol. 14, 1994, pages 8096 - 106
SAMBROOK ET AL.: "MOLECULAR CLONING: A LABORATORY MANUAL", 1989, COLD SPRING HARBOR LABORATORY PRESS
SAMULSKI ET AL., J. VIROL., vol. 63, 1989, pages 03822 - 3828
SCHORNACK S ET AL., J PLANT PHYSIOL, vol. 163, no. 3, 2006, pages 256 - 272
SEGAL ET AL., CURR. OPIN. BIOTECHNOL., vol. 12, 2001, pages 632 - 637
SEIPEL ET AL., EMBO J., vol. 11, 1992, pages 4961 - 4968
SOMMERFELT ET AL., VIROL., vol. 176, 1990, pages 58 - 59
SPRENGER-HAUSSELS ET AL., PLANT J., vol. 22, 2000, pages 1 - 8
STERMAN ET AL., HUM. GENE THER., vol. 7, 1998, pages 1083 - 1089
STERMAN ET AL., HUM. GENE THER., vol. 7, 1998, pages 1083 - 9
STERMAN ET AL., HUM. GENE THER., vol. 9, no. 7, 1998, pages 1083 - 1089
SUSSMAN ET AL., J. MOL. BIOL., vol. 342, 2004, pages 31 - 41
TOPF ET AL., GENE THER., vol. 5, 1998, pages 507 - 513
TORCHIA ET AL., CURR. OPIN. CELL. BIOL., vol. 10, 1998, pages 373 - 383
TRATSCHIN ET AL., MOL. CELL. BIOL., vol. 4, 1984, pages 2072 - 2081
TRATSCHIN ET AL., MOL. CELL. BIOL., vol. 5, 1985, pages 3251 - 3260
TRETTEL ET AL., HUM. MOL. GENET, vol. 9, 2000, pages 2799 - 2809
TYLER ET AL., CELL, vol. 99, 1999, pages 443 - 446
ULMASON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 96, 1999, pages 5844 - 5849
URNOV ET AL., NATURE, vol. 435, no. 7042, 2005, pages 646 - 651
VAN BRUNT, BIOTECHNOLOGY, vol. 6, no. 10, 1988, pages 1149 - 1154
VIGNE, RESTORATIVE NEUROLOGY AND NEUROSCIENCE, vol. 8, 1995, pages 35 - 36
WAGNER ET AL., LANCET, vol. 351, 1998, pages 9117 1702 - 3
WALKER, LANCET, vol. 369, 2007, pages 218 - 228
WELSH ET AL., HUM. GENE THER., vol. 2, 1995, pages 205 - 18
WEST ET AL., VIROLOGY, vol. 160, 1987, pages 38 - 47
WHEELER ET AL., HUM MOL GENET, vol. 8, 2000, pages 115 - 122
WILSON ET AL., J. VIROL., vol. 63, 1989, pages 2374 - 2378
WOLFFE: "CHROMATIN STRUCTURE AND FUNCTION", 1998, ACADEMIC PRESS
WU ET AL., PLANT J, vol. 22, 2000, pages 19 - 27
YU ET AL., GENE THERAPY, vol. 1, 1994, pages 13 - 26
ZUCCATO ET AL., PHARMACOLOGICAL RESEARCH, vol. 52, no. 2, 2005, pages 133 - 139
ZUFFERY ET AL., J. VIROL., vol. 72, 1998, pages 9873 - 9880

Cited By (223)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9322006B2 (en) 2011-07-22 2016-04-26 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
US10323236B2 (en) 2011-07-22 2019-06-18 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
US12006520B2 (en) 2011-07-22 2024-06-11 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
US10435678B2 (en) 2011-12-30 2019-10-08 Caribou Biosciences, Inc. Modified cascade ribonucleoproteins and uses thereof
US11939604B2 (en) 2011-12-30 2024-03-26 Caribou Biosciences, Inc. Modified cascade ribonucleoproteins and uses thereof
US10711257B2 (en) 2011-12-30 2020-07-14 Caribou Biosciences, Inc. Modified cascade ribonucleoproteins and uses thereof
US9885026B2 (en) 2011-12-30 2018-02-06 Caribou Biosciences, Inc. Modified cascade ribonucleoproteins and uses thereof
US10954498B2 (en) 2011-12-30 2021-03-23 Caribou Biosciences, Inc. Modified cascade ribonucleoproteins and uses thereof
US10471123B2 (en) 2012-02-29 2019-11-12 Sangamo Therapeutics, Inc. Methods and compositions for treating Huntington's disease
US11723952B2 (en) 2012-02-29 2023-08-15 Sangamo Therapeutics, Inc. Methods and compositions for treating Huntington's Disease
US10265377B2 (en) 2012-02-29 2019-04-23 Sangamo Therapeutics, Inc. Methods and compositions for treating Huntington's Disease
US10857203B2 (en) 2012-02-29 2020-12-08 Sangamo Therapeutics, Inc. Methods and compositions for treating Huntington's disease
US9499597B2 (en) 2012-02-29 2016-11-22 Sangamo Biosciences, Inc. Methods and compositions for treating Huntington's disease
US10676759B2 (en) 2012-05-25 2020-06-09 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10415061B2 (en) 2012-05-25 2019-09-17 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US11479794B2 (en) 2012-05-25 2022-10-25 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US11473108B2 (en) 2012-05-25 2022-10-18 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10577631B2 (en) 2012-05-25 2020-03-03 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US11401532B2 (en) 2012-05-25 2022-08-02 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US11332761B2 (en) 2012-05-25 2022-05-17 The Regenis of Wie University of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10570419B2 (en) 2012-05-25 2020-02-25 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10597680B2 (en) 2012-05-25 2020-03-24 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US11293034B2 (en) 2012-05-25 2022-04-05 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US11274318B2 (en) 2012-05-25 2022-03-15 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US11242543B2 (en) 2012-05-25 2022-02-08 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US11186849B2 (en) 2012-05-25 2021-11-30 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10563227B2 (en) 2012-05-25 2020-02-18 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10612045B2 (en) 2012-05-25 2020-04-07 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10550407B2 (en) 2012-05-25 2020-02-04 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US11028412B2 (en) 2012-05-25 2021-06-08 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US11008590B2 (en) 2012-05-25 2021-05-18 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US11008589B2 (en) 2012-05-25 2021-05-18 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10533190B2 (en) 2012-05-25 2020-01-14 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US11001863B2 (en) 2012-05-25 2021-05-11 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10526619B2 (en) 2012-05-25 2020-01-07 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10988780B2 (en) 2012-05-25 2021-04-27 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10988782B2 (en) 2012-05-25 2021-04-27 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10519467B2 (en) 2012-05-25 2019-12-31 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10513712B2 (en) 2012-05-25 2019-12-24 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10626419B2 (en) 2012-05-25 2020-04-21 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10982230B2 (en) 2012-05-25 2021-04-20 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10487341B2 (en) 2012-05-25 2019-11-26 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10982231B2 (en) 2012-05-25 2021-04-20 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10640791B2 (en) 2012-05-25 2020-05-05 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US11634730B2 (en) 2012-05-25 2023-04-25 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10443076B2 (en) 2012-05-25 2019-10-15 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US11970711B2 (en) 2012-05-25 2024-04-30 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10000772B2 (en) 2012-05-25 2018-06-19 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10669560B2 (en) 2012-05-25 2020-06-02 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10428352B2 (en) 2012-05-25 2019-10-01 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10113167B2 (en) 2012-05-25 2018-10-30 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10900054B2 (en) 2012-05-25 2021-01-26 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10421980B2 (en) 2012-05-25 2019-09-24 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US11674159B2 (en) 2012-05-25 2023-06-13 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10793878B1 (en) 2012-05-25 2020-10-06 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US11549127B2 (en) 2012-05-25 2023-01-10 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10407697B2 (en) 2012-05-25 2019-09-10 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10227611B2 (en) 2012-05-25 2019-03-12 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10774344B1 (en) 2012-05-25 2020-09-15 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10400253B2 (en) 2012-05-25 2019-09-03 The Regents Of The University Of California Methods and compositions or RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10266850B2 (en) 2012-05-25 2019-04-23 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10301651B2 (en) 2012-05-25 2019-05-28 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10308961B2 (en) 2012-05-25 2019-06-04 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US11814645B2 (en) 2012-05-25 2023-11-14 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10337029B2 (en) 2012-05-25 2019-07-02 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10752920B2 (en) 2012-05-25 2020-08-25 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10351878B2 (en) 2012-05-25 2019-07-16 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10358659B2 (en) 2012-05-25 2019-07-23 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10358658B2 (en) 2012-05-25 2019-07-23 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10385360B2 (en) 2012-05-25 2019-08-20 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US10731181B2 (en) 2012-12-06 2020-08-04 Sigma, Aldrich Co. LLC CRISPR-based genome modification and regulation
US10745716B2 (en) 2012-12-06 2020-08-18 Sigma-Aldrich Co. Llc CRISPR-based genome modification and regulation
US10930367B2 (en) 2012-12-12 2021-02-23 The Broad Institute, Inc. Methods, models, systems, and apparatus for identifying target sequences for Cas enzymes or CRISPR-Cas systems for target sequences and conveying results thereof
US9840713B2 (en) 2012-12-12 2017-12-12 The Broad Institute Inc. CRISPR-Cas component systems, methods and compositions for sequence manipulation
US9822372B2 (en) 2012-12-12 2017-11-21 The Broad Institute Inc. CRISPR-Cas component systems, methods and compositions for sequence manipulation
US11041173B2 (en) 2012-12-12 2021-06-22 The Broad Institute, Inc. Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications
US9260752B1 (en) 2013-03-14 2016-02-16 Caribou Biosciences, Inc. Compositions and methods of nucleic acid-targeting nucleic acids
US9803194B2 (en) 2013-03-14 2017-10-31 Caribou Biosciences, Inc. Compositions and methods of nucleic acid-targeting nucleic acids
US10125361B2 (en) 2013-03-14 2018-11-13 Caribou Biosciences, Inc. Compositions and methods of nucleic acid-targeting nucleic acids
US9725714B2 (en) 2013-03-14 2017-08-08 Caribou Biosciences, Inc. Compositions and methods of nucleic acid-targeting nucleic acids
US9809814B1 (en) 2013-03-14 2017-11-07 Caribou Biosciences, Inc. Compositions and methods of nucleic acid-targeting nucleic acids
US9410198B2 (en) 2013-03-14 2016-08-09 Caribou Biosciences, Inc. Compostions and methods of nucleic acid-targeting nucleic acids
US9909122B2 (en) 2013-03-14 2018-03-06 Caribou Biosciences, Inc. Compositions and methods of nucleic acid-targeting nucleic acids
US11312953B2 (en) 2013-03-14 2022-04-26 Caribou Biosciences, Inc. Compositions and methods of nucleic acid-targeting nucleic acids
US12018275B2 (en) 2013-06-17 2024-06-25 The Broad Institute, Inc. Delivery and use of the CRISPR-CAS systems, vectors and compositions for hepatic targeting and therapy
US11008588B2 (en) 2013-06-17 2021-05-18 The Broad Institute, Inc. Delivery, engineering and optimization of tandem guide systems, methods and compositions for sequence manipulation
US10711285B2 (en) 2013-06-17 2020-07-14 The Broad Institute, Inc. Optimized CRISPR-Cas double nickase systems, methods and compositions for sequence manipulation
US10577630B2 (en) 2013-06-17 2020-03-03 The Broad Institute, Inc. Delivery and use of the CRISPR-Cas systems, vectors and compositions for hepatic targeting and therapy
US10946108B2 (en) 2013-06-17 2021-03-16 The Broad Institute, Inc. Delivery, use and therapeutic applications of the CRISPR-Cas systems and compositions for targeting disorders and diseases using viral components
US10781444B2 (en) 2013-06-17 2020-09-22 The Broad Institute, Inc. Functional genomics using CRISPR-Cas systems, compositions, methods, screens and applications thereof
US11597949B2 (en) 2013-06-17 2023-03-07 The Broad Institute, Inc. Optimized CRISPR-Cas double nickase systems, methods and compositions for sequence manipulation
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
US10508298B2 (en) 2013-08-09 2019-12-17 President And Fellows Of Harvard College Methods for identifying a target site of a CAS9 nuclease
US10954548B2 (en) 2013-08-09 2021-03-23 President And Fellows Of Harvard College Nuclease profiling system
US11920181B2 (en) 2013-08-09 2024-03-05 President And Fellows Of Harvard College Nuclease profiling system
US10227581B2 (en) 2013-08-22 2019-03-12 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US11046948B2 (en) 2013-08-22 2021-06-29 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US10682410B2 (en) 2013-09-06 2020-06-16 President And Fellows Of Harvard College Delivery system for functional nucleases
US9737604B2 (en) 2013-09-06 2017-08-22 President And Fellows Of Harvard College Use of cationic lipids to deliver CAS9
US10597679B2 (en) 2013-09-06 2020-03-24 President And Fellows Of Harvard College Switchable Cas9 nucleases and uses thereof
US9228207B2 (en) 2013-09-06 2016-01-05 President And Fellows Of Harvard College Switchable gRNAs comprising aptamers
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US9999671B2 (en) 2013-09-06 2018-06-19 President And Fellows Of Harvard College Delivery of negatively charged proteins using cationic lipids
US10912833B2 (en) 2013-09-06 2021-02-09 President And Fellows Of Harvard College Delivery of negatively charged proteins using cationic lipids
US11299755B2 (en) 2013-09-06 2022-04-12 President And Fellows Of Harvard College Switchable CAS9 nucleases and uses thereof
US9388430B2 (en) 2013-09-06 2016-07-12 President And Fellows Of Harvard College Cas9-recombinase fusion proteins and uses thereof
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
US9340800B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College Extended DNA-sensing GRNAS
US10858639B2 (en) 2013-09-06 2020-12-08 President And Fellows Of Harvard College CAS9 variants and uses thereof
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
JP7083595B2 (en) 2013-10-25 2022-06-13 セレクティス Design of rare cut endonucleases that efficiently and specifically target DNA sequences with highly repetitive motifs
JP2016535594A (en) * 2013-10-25 2016-11-17 セレクティス Design of rare-cutting endonucleases that efficiently and specifically target DNA sequences with highly repetitive motifs
KR102251168B1 (en) * 2013-10-25 2021-05-13 셀렉티스 Design of rare-cutting endonucleases for efficient and specific targeting dna sequences comprising highly repetitive motives
WO2015059265A1 (en) 2013-10-25 2015-04-30 Cellectis Design of rare-cutting endonucleases for efficient and specific targeting dna sequences comprising highly repetitive motives
KR20160068971A (en) * 2013-10-25 2016-06-15 셀렉티스 Design of rare-cutting endonucleases for efficient and specific targeting dna sequences comprising highly repetitive motives
CN105916983A (en) * 2013-10-25 2016-08-31 塞勒克提斯公司 Design of rare-cutting endonucleases for efficient and specific targeting DNA sequences comprising highly repetitive motives
US11149267B2 (en) 2013-10-28 2021-10-19 The Broad Institute, Inc. Functional genomics using CRISPR-Cas systems, compositions, methods, screens and applications thereof
US10190137B2 (en) 2013-11-07 2019-01-29 Editas Medicine, Inc. CRISPR-related methods and compositions with governing gRNAS
US11390887B2 (en) 2013-11-07 2022-07-19 Editas Medicine, Inc. CRISPR-related methods and compositions with governing gRNAS
US10640788B2 (en) 2013-11-07 2020-05-05 Editas Medicine, Inc. CRISPR-related methods and compositions with governing gRNAs
US9834791B2 (en) 2013-11-07 2017-12-05 Editas Medicine, Inc. CRISPR-related methods and compositions with governing gRNAS
JP2016537341A (en) * 2013-11-11 2016-12-01 サンガモ バイオサイエンシーズ， インコーポレイテッド Methods and compositions for treating Huntington's disease
AU2014346424B2 (en) * 2013-11-11 2020-09-17 Sangamo Therapeutics, Inc. Methods and compositions for treating Huntington's Disease
CN105934524A (en) * 2013-11-11 2016-09-07 桑格摩生物科学股份有限公司 Methods and compositions for treating huntington's disease
EP3068905A4 (en) * 2013-11-11 2017-07-05 Sangamo BioSciences, Inc. Methods and compositions for treating huntington's disease
KR20160077208A (en) * 2013-11-11 2016-07-01 상가모 바이오사이언스 인코포레이티드 Methods and compositions for treating huntington's disease
US10369201B2 (en) 2013-11-11 2019-08-06 Sangamo Therapeutics, Inc. Methods and compositions for treating Huntington's disease
KR102431079B1 (en) * 2013-11-11 2022-08-11 상가모 테라퓨틱스, 인코포레이티드 Methods and compositions for treating huntington's disease
RU2693891C1 (en) * 2013-11-11 2019-07-05 Сангамо Байосайенсиз, Инк. Methods and compositions for treating huntington's disease
WO2015070212A1 (en) 2013-11-11 2015-05-14 Sangamo Biosciences, Inc. Methods and compositions for treating huntington's disease
WO2015078935A1 (en) * 2013-11-29 2015-06-04 Institut Pasteur Tal effector means useful for partial or full deletion of dna tandem repeats
US11384346B2 (en) 2013-11-29 2022-07-12 Institut Pasteur TAL effector means useful for partial or full deletion of DNA tandem repeats
EP2878667A1 (en) * 2013-11-29 2015-06-03 Institut Pasteur TAL effector means useful for partial or full deletion of DNA tandem repeats
US9068179B1 (en) 2013-12-12 2015-06-30 President And Fellows Of Harvard College Methods for correcting presenilin point mutations
WO2015089351A1 (en) * 2013-12-12 2015-06-18 The Broad Institute Inc. Compositions and methods of use of crispr-cas systems in nucleotide repeat disorders
US10550372B2 (en) 2013-12-12 2020-02-04 The Broad Institute, Inc. Systems, methods and compositions for sequence manipulation with optimized functional CRISPR-Cas systems
US9840699B2 (en) 2013-12-12 2017-12-12 President And Fellows Of Harvard College Methods for nucleic acid editing
CN106029880A (en) * 2013-12-12 2016-10-12 布罗德研究所有限公司 Compositions and methods of use of CRISPR-Cas systems in nucleotide repeat disorders
US10851357B2 (en) 2013-12-12 2020-12-01 The Broad Institute, Inc. Compositions and methods of use of CRISPR-Cas systems in nucleotide repeat disorders
US10465176B2 (en) 2013-12-12 2019-11-05 President And Fellows Of Harvard College Cas variants for gene editing
CN106103705A (en) * 2013-12-12 2016-11-09 布罗德研究所有限公司 Nucleotide repeats compositions and the using method of CRISPR cas system in obstacle
US11591581B2 (en) 2013-12-12 2023-02-28 The Broad Institute, Inc. Compositions and methods of use of CRISPR-Cas systems in nucleotide repeat disorders
US11597919B2 (en) 2013-12-12 2023-03-07 The Broad Institute Inc. Systems, methods and compositions for sequence manipulation with optimized functional CRISPR-Cas systems
EP3653703A1 (en) * 2013-12-12 2020-05-20 The Broad Institute, Inc. Compositions and methods of use of crispr-cas systems in nucleotide repeat disorders
CN106536729A (en) * 2013-12-12 2017-03-22 布罗德研究所有限公司 Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components
US11155795B2 (en) 2013-12-12 2021-10-26 The Broad Institute, Inc. CRISPR-Cas systems, crystal structure and uses thereof
WO2015089419A3 (en) * 2013-12-12 2015-09-17 The Broad Institute Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components
US11149259B2 (en) 2013-12-12 2021-10-19 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products, structural information and inducible modular Cas enzymes
US11407985B2 (en) 2013-12-12 2022-08-09 The Broad Institute, Inc. Delivery, use and therapeutic applications of the CRISPR-Cas systems and compositions for genome editing
US11053481B2 (en) 2013-12-12 2021-07-06 President And Fellows Of Harvard College Fusions of Cas9 domains and nucleic acid-editing domains
WO2015089354A1 (en) * 2013-12-12 2015-06-18 The Broad Institute Inc. Compositions and methods of use of crispr-cas systems in nucleotide repeat disorders
EP3653704A1 (en) * 2013-12-12 2020-05-20 The Broad Institute, Inc. Compositions and methods of use of crispr-cas systems in nucleotide repeat disorders
US10377998B2 (en) 2013-12-12 2019-08-13 The Broad Institute, Inc. CRISPR-CAS systems and methods for altering expression of gene products, structural information and inducible modular CAS enzymes
US11124782B2 (en) 2013-12-12 2021-09-21 President And Fellows Of Harvard College Cas variants for gene editing
US11884963B2 (en) 2014-02-13 2024-01-30 Takara Bio Usa, Inc. Methods of depleting a target molecule from an initial collection of nucleic acids, and compositions and kits for practicing the same
US10988796B2 (en) 2014-02-13 2021-04-27 Takara Bio Usa, Inc. Methods of depleting a target molecule from an initial collection of nucleic acids, and compositions and kits for practicing the same
US10150985B2 (en) 2014-02-13 2018-12-11 Takara Bio Usa, Inc. Methods of depleting a target molecule from an initial collection of nucleic acids, and compositions and kits for practicing the same
CN106459894A (en) * 2014-03-18 2017-02-22 桑格摩生物科学股份有限公司 Methods and compositions for regulation of zinc finger protein expression
EP3119878A4 (en) * 2014-03-18 2017-08-16 Sangamo BioSciences, Inc. Methods and compositions for regulation of zinc finger protein expression
EP3929279A1 (en) * 2014-03-18 2021-12-29 Sangamo Therapeutics, Inc. Methods and compositions for regulation of zinc finger protein expression
CN106459894B (en) * 2014-03-18 2020-02-18 桑格摩生物科学股份有限公司 Methods and compositions for modulating zinc finger protein expression
US11110154B2 (en) 2014-05-08 2021-09-07 Sangamo Therapeutics, Inc. Methods and compositions for treating Huntington's Disease
JP2017515819A (en) * 2014-05-08 2017-06-15 サンガモ セラピューティクス， インコーポレイテッド Methods and compositions for treating Huntington's disease
US10077453B2 (en) 2014-07-30 2018-09-18 President And Fellows Of Harvard College CAS9 proteins including ligand-dependent inteins
US11578343B2 (en) 2014-07-30 2023-02-14 President And Fellows Of Harvard College CAS9 proteins including ligand-dependent inteins
US10704062B2 (en) 2014-07-30 2020-07-07 President And Fellows Of Harvard College CAS9 proteins including ligand-dependent inteins
WO2016020399A1 (en) 2014-08-04 2016-02-11 Centre Hospitalier Universitaire Vaudois (Chuv) GENOME EDITING FOR THE TREATMENT OF HUNTINGTON's DISEASE
EP2982758A1 (en) 2014-08-04 2016-02-10 Centre Hospitalier Universitaire Vaudois (CHUV) Genome editing for the treatment of huntington's disease
US10696986B2 (en) 2014-12-12 2020-06-30 The Board Institute, Inc. Protected guide RNAS (PGRNAS)
US11624078B2 (en) 2014-12-12 2023-04-11 The Broad Institute, Inc. Protected guide RNAS (pgRNAS)
US10876100B2 (en) 2015-06-18 2020-12-29 The Broad Institute, Inc. Crispr enzyme mutations reducing off-target effects
US10494621B2 (en) 2015-06-18 2019-12-03 The Broad Institute, Inc. Crispr enzyme mutations reducing off-target effects
US11180751B2 (en) 2015-06-18 2021-11-23 The Broad Institute, Inc. CRISPR enzymes and systems
US11578312B2 (en) 2015-06-18 2023-02-14 The Broad Institute Inc. Engineering and optimization of systems, methods, enzymes and guide scaffolds of CAS9 orthologs and variants for sequence manipulation
IL258030B (en) * 2015-09-23 2022-08-01 Sangamo Therapeutics Inc Htt repressors and uses thereof
US11123443B2 (en) 2015-09-23 2021-09-21 Sangamo Therapeutics, Inc. Htt repressors and uses thereof
AU2020204035B2 (en) * 2015-09-23 2021-03-11 Sangamo Therapeutics, Inc. HTT Repressors And Uses Thereof
US10435441B2 (en) 2015-09-23 2019-10-08 Sangamo Therapeutics, Inc. HTT repressors and uses thereof
AU2016325613B2 (en) * 2015-09-23 2020-06-25 Sangamo Therapeutics, Inc. Htt repressors and uses thereof
EP3352776A4 (en) * 2015-09-23 2019-03-13 Sangamo Therapeutics, Inc. Htt repressors and uses thereof
US10167457B2 (en) 2015-10-23 2019-01-01 President And Fellows Of Harvard College Nucleobase editors and uses thereof
US11214780B2 (en) 2015-10-23 2022-01-04 President And Fellows Of Harvard College Nucleobase editors and uses thereof
US12043852B2 (en) 2015-10-23 2024-07-23 President And Fellows Of Harvard College Evolved Cas9 proteins for gene editing
EP4219462A1 (en) 2016-07-13 2023-08-02 Vertex Pharmaceuticals Incorporated Methods, compositions and kits for increasing genome editing efficiency
WO2018013840A1 (en) 2016-07-13 2018-01-18 Vertex Pharmaceuticals Incorporated Methods, compositions and kits for increasing genome editing efficiency
US12031150B2 (en) 2016-07-13 2024-07-09 Vertex Pharmaceuticals Incorporated Methods, compositions and kits for increasing genome editing efficiency
US10113163B2 (en) 2016-08-03 2018-10-30 President And Fellows Of Harvard College Adenosine nucleobase editors and uses thereof
US11702651B2 (en) 2016-08-03 2023-07-18 President And Fellows Of Harvard College Adenosine nucleobase editors and uses thereof
US11999947B2 (en) 2016-08-03 2024-06-04 President And Fellows Of Harvard College Adenosine nucleobase editors and uses thereof
US10947530B2 (en) 2016-08-03 2021-03-16 President And Fellows Of Harvard College Adenosine nucleobase editors and uses thereof
US11661590B2 (en) 2016-08-09 2023-05-30 President And Fellows Of Harvard College Programmable CAS9-recombinase fusion proteins and uses thereof
US12084663B2 (en) 2016-08-24 2024-09-10 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
US11306324B2 (en) 2016-10-14 2022-04-19 President And Fellows Of Harvard College AAV delivery of nucleobase editors
US11504389B2 (en) 2016-12-01 2022-11-22 Sangamo Therapeutics, Inc. Tau modulators and methods and compositions for delivery thereof
US11820969B2 (en) 2016-12-23 2023-11-21 President And Fellows Of Harvard College Editing of CCR2 receptor gene to protect against HIV infection
US10745677B2 (en) 2016-12-23 2020-08-18 President And Fellows Of Harvard College Editing of CCR5 receptor gene to protect against HIV infection
US11268093B2 (en) 2017-01-03 2022-03-08 Rula Zain-Luqman Therapeutic method for huntington's disease
WO2018127462A1 (en) * 2017-01-03 2018-07-12 Zain Luqman Rula Therapeutic method for huntington's disease
US11898179B2 (en) 2017-03-09 2024-02-13 President And Fellows Of Harvard College Suppression of pain by gene editing
US11542496B2 (en) 2017-03-10 2023-01-03 President And Fellows Of Harvard College Cytosine to guanine base editor
US11268082B2 (en) 2017-03-23 2022-03-08 President And Fellows Of Harvard College Nucleobase editors comprising nucleic acid programmable DNA binding proteins
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
US11732274B2 (en) 2017-07-28 2023-08-22 President And Fellows Of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE)
US11932884B2 (en) 2017-08-30 2024-03-19 President And Fellows Of Harvard College High efficiency base editors comprising Gam
US11319532B2 (en) 2017-08-30 2022-05-03 President And Fellows Of Harvard College High efficiency base editors comprising Gam
US11795443B2 (en) 2017-10-16 2023-10-24 The Broad Institute, Inc. Uses of adenosine base editors
WO2019143675A1 (en) 2018-01-17 2019-07-25 Vertex Pharmaceuticals Incorporated Dna-pk inhibitors
WO2019143677A1 (en) 2018-01-17 2019-07-25 Vertex Pharmaceuticals Incorporated Quinoxalinone compounds, compositions, methods, and kits for increasing genome editing efficiency
WO2019143678A1 (en) 2018-01-17 2019-07-25 Vertex Pharmaceuticals Incorporated Dna-pk inhibitors
US12005127B2 (en) 2018-01-17 2024-06-11 Vertex Pharmaceuticals Incorporated DNA-PK inhibitors
WO2020072684A1 (en) * 2018-10-02 2020-04-09 Sangamo Therapeutics, Inc. Engineered genetic modulators
CN113195002A (en) * 2018-10-02 2021-07-30 桑格摩生物治疗股份有限公司 Engineered genetic modulators
WO2020131862A1 (en) 2018-12-17 2020-06-25 The Broad Institute, Inc. Crispr-associated transposase systems and methods of use thereof
US12121524B2 (en) 2019-01-16 2024-10-22 Vertex Pharmaceuticals Incorporated DNA-PK inhibitors
US11795452B2 (en) 2019-03-19 2023-10-24 The Broad Institute, Inc. Methods and compositions for prime editing nucleotide sequences
US11643652B2 (en) 2019-03-19 2023-05-09 The Broad Institute, Inc. Methods and compositions for prime editing nucleotide sequences
US11447770B1 (en) 2019-03-19 2022-09-20 The Broad Institute, Inc. Methods and compositions for prime editing nucleotide sequences
US12123032B2 (en) 2019-11-26 2024-10-22 The Broad Institute, Inc. CRISPR enzyme mutations reducing off-target effects
US11912985B2 (en) 2020-05-08 2024-02-27 The Broad Institute, Inc. Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
US12031126B2 (en) 2020-05-08 2024-07-09 The Broad Institute, Inc. Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
US12123015B2 (en) 2021-09-21 2024-10-22 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

Also Published As

Publication number Publication date
BR112014021104B1 (en) 2023-03-28
CN108285491A (en) 2018-07-17
NZ629427A (en) 2016-04-29
US20210060124A1 (en) 2021-03-04
ZA201406209B (en) 2016-01-27
MX359327B (en) 2018-09-25
JP6490426B2 (en) 2019-03-27
CN108285491B (en) 2021-08-10
US11723952B2 (en) 2023-08-15
RU2639277C2 (en) 2017-12-20
US20140336133A1 (en) 2014-11-13
KR102084539B1 (en) 2020-03-04
CA2865011A1 (en) 2013-09-06
US20190183970A1 (en) 2019-06-20
JP2019022531A (en) 2019-02-14
US10857203B2 (en) 2020-12-08
US20130253040A1 (en) 2013-09-26
US10471123B2 (en) 2019-11-12
US20230414710A1 (en) 2023-12-28
BR112014021104A2 (en) 2017-07-04
CN104204225A (en) 2014-12-10
EP2820159A4 (en) 2015-08-26
CA2865011C (en) 2021-06-15
AU2013225950B2 (en) 2018-02-15
US9499597B2 (en) 2016-11-22
JP2017143835A (en) 2017-08-24
US20200030408A1 (en) 2020-01-30
HK1203566A1 (en) 2015-10-30
RU2014138989A (en) 2016-04-20
JP2015509958A (en) 2015-04-02
MX2014010455A (en) 2015-02-10
EP2820159B1 (en) 2019-10-23
US20170035839A1 (en) 2017-02-09
KR20140131973A (en) 2014-11-14
US10265377B2 (en) 2019-04-23
US8841260B2 (en) 2014-09-23
EP2820159A1 (en) 2015-01-07
AU2013225950A1 (en) 2014-09-18

Similar Documents

Publication Publication Date Title
US11723952B2 (en) Methods and compositions for treating Huntington&#39;s Disease
AU2014346424B2 (en) Methods and compositions for treating Huntington&#39;s Disease
US10646543B2 (en) Methods and compositions for treating trinucleotide repeat disorders
AU2015231353B2 (en) Methods and compositions for regulation of zinc finger protein expression

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13755872

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2865011

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2014560044

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: MX/A/2014/010455

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2013225950

Country of ref document: AU

Date of ref document: 20130228

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20147026364

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2014138989

Country of ref document: RU

Ref document number: 2013755872

Country of ref document: EP

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112014021104

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112014021104

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20140827